Alteration	Alteration type	Assay type	Association	Biomarker	Curator	Drug	Drug family	Drug full name	Drug status	Evidence level	Gene	Metastatic Tumor Type	Primary Tumor type	Source	Targeting	individual_mutation	transcript	gene	strand	region	info	cDNA	gDNA
ABL1:T315I	MUT		Responsive	ABL1 (T315I)	DTamborero	Axitinib	VEGFR inhibitor	Axitinib (VEGFR inhibitor)		Pre-clinical	ABL1		CANCER	PMID:25686603		ABL1:p.T315I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	c.944C>T	chr9:g.133748283C>T
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		ABL1:p.V299L	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.895G>C	chr9:g.133747588G>C
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		ABL1:p.V299L	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.895G>C	chr9:g.133747588G>C
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Foretinib 	MET inhibitor	Foretinib  (MET inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		ABL1:p.V299L	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.895G>C	chr9:g.133747588G>C
ABL1:V299L	MUT		Responsive	ABL1 (V299L)	DTamborero	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Pre-clinical	ABL1		CANCER	PMID:26924578		ABL1:p.V299L	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.895G>C	chr9:g.133747588G>C
ABL1:T315I	MUT		Resistant	ABL1 (T315I)	CRubio-Perez	[Nilotinib,Dasatinib]	[BCR-ABL inhibitor 2nd gen]	BCR-ABL inhibitor 2nd gens (Nilotinib,Dasatinib,etc)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.T315I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	c.944C>T	chr9:g.133748283C>T
ABL1:T315I	MUT		Resistant	ABL1 (T315I)	CRubio-Perez	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.T315I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	c.944C>T	chr9:g.133748283C>T
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.V299L	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.895G>C	chr9:g.133747588G>C
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.T315A	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	c.943A>G	chr9:g.133748282A>G
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317L	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	c.949T>C	chr9:g.133748288T>C
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.949T>G	chr9:g.133748288T>G
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.949T>A	chr9:g.133748288T>A
ABL1:V299L,T315A,F317L,F317V,F317I,F317C	MUT		Resistant	ABL1 (V299L,T315A,F317L,F317V,F317I,F317C)	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.950T>G	chr9:g.133748289T>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.I242T	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133738325_133738326delTCinsCA,chr9:g.133738325_133738326delTCinsCG,chr9:g.133738325_133738326delTCinsCT;aliases=ENSP00000323315;source=Ensembl	c.725T>C	chr9:g.133738325T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.M244V	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=ATG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738330_133738332delATGinsGTA,chr9:g.133738330_133738332delATGinsGTC,chr9:g.133738330_133738332delATGinsGTT;aliases=ENSP00000323315;source=Ensembl	c.730A>G	chr9:g.133738330A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.K247R	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=AAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133738340_133738341delAGinsGA,chr9:g.133738339_133738340delAAinsCG,chr9:g.133738339_133738341delAAGinsCGA,chr9:g.133738339_133738341delAAGinsCGC,chr9:g.133738339_133738341delAAGinsCGT;aliases=ENSP00000323315;source=Ensembl	c.740A>G	chr9:g.133738340A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L248V	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738342_133738344delCTGinsGTA,chr9:g.133738342_133738344delCTGinsGTC,chr9:g.133738342_133738344delCTGinsGTT;aliases=ENSP00000323315;source=Ensembl	c.742C>G	chr9:g.133738342C>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.G250E	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GGG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr9:g.133738349_133738350delGGinsAA;aliases=ENSP00000323315;source=Ensembl	c.749G>A	chr9:g.133738349G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.G250R	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr9:g.133738348G>C;candidate_mnv_variants=chr9:g.133738348_133738350delGGGinsAGA,chr9:g.133738348_133738350delGGGinsCGA,chr9:g.133738348_133738350delGGGinsCGC,chr9:g.133738348_133738350delGGGinsCGT;aliases=ENSP00000323315;source=Ensembl	c.748G>A	chr9:g.133738348G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Q252R	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133738354_133738355delCAinsAG,chr9:g.133738355_133738356delAGinsGA,chr9:g.133738355_133738356delAGinsGC,chr9:g.133738355_133738356delAGinsGT,chr9:g.133738354_133738356delCAGinsAGA;aliases=ENSP00000323315;source=Ensembl	c.755A>G	chr9:g.133738355A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Q252H	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=CAG;candidate_codons=CAT,CAC;candidate_snv_variants=chr9:g.133738356G>C;aliases=ENSP00000323315;source=Ensembl	c.756G>T	chr9:g.133738356G>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y253F	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TAC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.133738358_133738359delACinsTT;aliases=ENSP00000323315;source=Ensembl	c.758A>T	chr9:g.133738358A>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y253H	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	c.757T>C	chr9:g.133738357T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255K	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.763G>A	chr9:g.133738363G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255V	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.764A>T	chr9:g.133738364A>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.M237V	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=ATG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738309_133738311delATGinsGTA,chr9:g.133738309_133738311delATGinsGTC,chr9:g.133738309_133738311delATGinsGTT;aliases=ENSP00000323315;source=Ensembl	c.709A>G	chr9:g.133738309A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E258D	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=GAC,GAT;candidate_snv_variants=chr9:g.133738374G>T;aliases=ENSP00000323315;source=Ensembl	c.774G>C	chr9:g.133738374G>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.W261L	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TGG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr9:g.133738381_133738382delTGinsCT,chr9:g.133738382_133738383delGGinsTA,chr9:g.133738381_133738383delTGGinsCTT,chr9:g.133738381_133738383delTGGinsCTA,chr9:g.133738381_133738383delTGGinsCTC;aliases=ENSP00000323315;source=Ensembl	c.782G>T	chr9:g.133738382G>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L273M	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	c.817T>A	chr9:g.133738417T>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E275K	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133747516_133747518delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.823G>A	chr9:g.133747516G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E275Q	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GAG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133747516_133747518delGAGinsCAA;aliases=ENSP00000323315;source=Ensembl	c.823G>C	chr9:g.133747516G>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.D276G	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133747520_133747521delACinsGT,chr9:g.133747520_133747521delACinsGG,chr9:g.133747520_133747521delACinsGA;aliases=ENSP00000323315;source=Ensembl	c.827A>G	chr9:g.133747520A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.T277A	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=ACC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747522_133747524delACCinsGCA,chr9:g.133747522_133747524delACCinsGCG,chr9:g.133747522_133747524delACCinsGCT;aliases=ENSP00000323315;source=Ensembl	c.829A>G	chr9:g.133747522A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E279K	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133747528_133747530delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.835G>A	chr9:g.133747528G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.V280A	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747532_133747533delTGinsCA,chr9:g.133747532_133747533delTGinsCC,chr9:g.133747532_133747533delTGinsCT;aliases=ENSP00000323315;source=Ensembl	c.839T>C	chr9:g.133747532T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.V289A	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133747559_133747560delTCinsCA,chr9:g.133747559_133747560delTCinsCG,chr9:g.133747559_133747560delTCinsCT;aliases=ENSP00000323315;source=Ensembl	c.866T>C	chr9:g.133747559T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.V289I	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133747558_133747560delGTCinsATA,chr9:g.133747558_133747560delGTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.865G>A	chr9:g.133747558G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E292V	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747568_133747569delAGinsTA,chr9:g.133747568_133747569delAGinsTC,chr9:g.133747568_133747569delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.875A>T	chr9:g.133747568A>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E292Q	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GAG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133747567_133747569delGAGinsCAA;aliases=ENSP00000323315;source=Ensembl	c.874G>C	chr9:g.133747567G>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.I293V	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747570_133747572delATCinsGTA,chr9:g.133747570_133747572delATCinsGTG,chr9:g.133747570_133747572delATCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.877A>G	chr9:g.133747570A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L298V	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133747585_133747587delCTGinsGTA,chr9:g.133747585_133747587delCTGinsGTC,chr9:g.133747585_133747587delCTGinsGTT;aliases=ENSP00000323315;source=Ensembl	c.892C>G	chr9:g.133747585C>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.V299L	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.895G>C	chr9:g.133747588G>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F311L	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748272C>A,chr9:g.133748272C>G;candidate_mnv_variants=chr9:g.133748270_133748272delTTCinsCTT,chr9:g.133748270_133748272delTTCinsCTG,chr9:g.133748270_133748272delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	c.931T>C	chr9:g.133748270T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F311I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748270_133748272delTTCinsATA,chr9:g.133748270_133748272delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.931T>A	chr9:g.133748270T>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.T315I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	c.944C>T	chr9:g.133748283C>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317L	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	c.949T>C	chr9:g.133748288T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.949T>G	chr9:g.133748288T>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.949T>A	chr9:g.133748288T>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.950T>G	chr9:g.133748289T>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y320C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748298_133748299delACinsGT;aliases=ENSP00000323315;source=Ensembl	c.959A>G	chr9:g.133748298A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L324Q	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr9:g.133748310_133748311delTGinsAA;aliases=ENSP00000323315;source=Ensembl	c.971T>A	chr9:g.133748310T>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y342H	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133748363_133748365delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	c.1024T>C	chr9:g.133748363T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.M343T	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133748367_133748368delTGinsCA,chr9:g.133748367_133748368delTGinsCT,chr9:g.133748367_133748368delTGinsCC;aliases=ENSP00000323315;source=Ensembl	c.1028T>C	chr9:g.133748367T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.A344V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748370_133748371delCCinsTA,chr9:g.133748370_133748371delCCinsTG,chr9:g.133748370_133748371delCCinsTT;aliases=ENSP00000323315;source=Ensembl	c.1031C>T	chr9:g.133748370C>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.A350V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748388_133748389delCCinsTA,chr9:g.133748388_133748389delCCinsTG,chr9:g.133748388_133748389delCCinsTT;aliases=ENSP00000323315;source=Ensembl	c.1049C>T	chr9:g.133748388C>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.M351T	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133748391_133748392delTGinsCA,chr9:g.133748391_133748392delTGinsCT,chr9:g.133748391_133748392delTGinsCC;aliases=ENSP00000323315;source=Ensembl	c.1052T>C	chr9:g.133748391T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E355D	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GAG;candidate_codons=GAC,GAT;candidate_snv_variants=chr9:g.133748404G>T;aliases=ENSP00000323315;source=Ensembl	c.1065G>C	chr9:g.133748404G>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E355G	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133748403_133748404delAGinsGT,chr9:g.133748403_133748404delAGinsGA,chr9:g.133748403_133748404delAGinsGC;aliases=ENSP00000323315;source=Ensembl	c.1064A>G	chr9:g.133748403A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E355A	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748403_133748404delAGinsCA,chr9:g.133748403_133748404delAGinsCC,chr9:g.133748403_133748404delAGinsCT;aliases=ENSP00000323315;source=Ensembl	c.1064A>C	chr9:g.133748403A>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.1075T>G	chr9:g.133748414T>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.1075T>A	chr9:g.133748414T>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.1076T>G	chr9:g.133748415T>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359L	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748416C>A,chr9:g.133748416C>G;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsCTT,chr9:g.133748414_133748416delTTCinsCTG,chr9:g.133748414_133748416delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	c.1075T>C	chr9:g.133748414T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.D363Y	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr9:g.133750256_133750258delGATinsTAC;aliases=ENSP00000323315;source=Ensembl	c.1087G>T	chr9:g.133750256G>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L364I	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133750259_133750261delCTTinsATC,chr9:g.133750259_133750261delCTTinsATA;aliases=ENSP00000323315;source=Ensembl	c.1090C>A	chr9:g.133750259C>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.A365V	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750263_133750264delCTinsTA,chr9:g.133750263_133750264delCTinsTC,chr9:g.133750263_133750264delCTinsTG;aliases=ENSP00000323315;source=Ensembl	c.1094C>T	chr9:g.133750263C>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.A366G	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133750266_133750267delCCinsGT,chr9:g.133750266_133750267delCCinsGG,chr9:g.133750266_133750267delCCinsGA;aliases=ENSP00000323315;source=Ensembl	c.1097C>G	chr9:g.133750266C>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L370P	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750278_133750279delTGinsCT,chr9:g.133750278_133750279delTGinsCA,chr9:g.133750278_133750279delTGinsCC;aliases=ENSP00000323315;source=Ensembl	c.1109T>C	chr9:g.133750278T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.V371A	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GTA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133750281_133750282delTAinsCC,chr9:g.133750281_133750282delTAinsCG,chr9:g.133750281_133750282delTAinsCT;aliases=ENSP00000323315;source=Ensembl	c.1112T>C	chr9:g.133750281T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E373K	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133750286_133750288delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.1117G>A	chr9:g.133750286G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.V379I	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133750304_133750306delGTAinsATC,chr9:g.133750304_133750306delGTAinsATT;aliases=ENSP00000323315;source=Ensembl	c.1135G>A	chr9:g.133750304G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.A380T	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133750307_133750309delGCTinsACA,chr9:g.133750307_133750309delGCTinsACG,chr9:g.133750307_133750309delGCTinsACC;aliases=ENSP00000323315;source=Ensembl	c.1138G>A	chr9:g.133750307G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F382L	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TTT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133750315T>A,chr9:g.133750315T>G;candidate_mnv_variants=chr9:g.133750313_133750315delTTTinsCTG,chr9:g.133750313_133750315delTTTinsCTA,chr9:g.133750313_133750315delTTTinsCTC;aliases=ENSP00000323315;source=Ensembl	c.1144T>C	chr9:g.133750313T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L384M	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	c.1150C>A	chr9:g.133750319C>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L387M	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000323315;source=Ensembl	c.1159T>A	chr9:g.133750328T>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L387F	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TTG;candidate_codons=TTT,TTC;candidate_snv_variants=chr9:g.133750330G>C;aliases=ENSP00000323315;source=Ensembl	c.1161G>T	chr9:g.133750330G>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.L387V	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750328_133750330delTTGinsGTA,chr9:g.133750328_133750330delTTGinsGTC,chr9:g.133750328_133750330delTTGinsGTT;aliases=ENSP00000323315;source=Ensembl	c.1159T>G	chr9:g.133750328T>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.M388L	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=ATG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133750331A>T;candidate_mnv_variants=chr9:g.133750331_133750333delATGinsCTT,chr9:g.133750331_133750333delATGinsCTA,chr9:g.133750331_133750333delATGinsCTC,chr9:g.133750331_133750333delATGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.1162A>C	chr9:g.133750331A>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y393C	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133750347_133750348delACinsGT;aliases=ENSP00000323315;source=Ensembl	c.1178A>G	chr9:g.133750347A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.H396P	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CAT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750356_133750357delATinsCG,chr9:g.133750356_133750357delATinsCA,chr9:g.133750356_133750357delATinsCC;aliases=ENSP00000323315;source=Ensembl	c.1187A>C	chr9:g.133750356A>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.H396R	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr9:g.133750356_133750357delATinsGA,chr9:g.133750356_133750357delATinsGC,chr9:g.133750356_133750357delATinsGG,chr9:g.133750355_133750357delCATinsAGG,chr9:g.133750355_133750357delCATinsAGA;aliases=ENSP00000323315;source=Ensembl	c.1187A>G	chr9:g.133750356A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.H396A	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CAT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133750355_133750357delCATinsGCA,chr9:g.133750355_133750357delCATinsGCC,chr9:g.133750355_133750357delCATinsGCG;aliases=ENSP00000323315;source=Ensembl	c.1186_1187delCAinsGC	chr9:g.133750355_133750356delCAinsGC
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.A397P	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr9:g.133750358_133750360delGCTinsCCG,chr9:g.133750358_133750360delGCTinsCCA,chr9:g.133750358_133750360delGCTinsCCC;aliases=ENSP00000323315;source=Ensembl	c.1189G>C	chr9:g.133750358G>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.S417F	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.133750419_133750420delCCinsTT;aliases=ENSP00000323315;source=Ensembl	c.1250C>T	chr9:g.133750419C>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.S417Y	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr9:g.133750419_133750420delCCinsAT;aliases=ENSP00000323315;source=Ensembl	c.1250C>A	chr9:g.133750419C>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.I418S	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=ATC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr9:g.133750422_133750423delTCinsGT,chr9:g.133750421_133750422delATinsTC,chr9:g.133750421_133750423delATCinsTCT,chr9:g.133750421_133750423delATCinsTCG,chr9:g.133750421_133750423delATCinsTCA;aliases=ENSP00000323315;source=Ensembl	c.1253T>G	chr9:g.133750422T>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.I418V	ENST00000318560	ABL1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133750421_133750423delATCinsGTA,chr9:g.133750421_133750423delATCinsGTG,chr9:g.133750421_133750423delATCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.1252A>G	chr9:g.133750421A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.A433T	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr9:g.133753828_133753830delGCTinsACA,chr9:g.133753828_133753830delGCTinsACG,chr9:g.133753828_133753830delGCTinsACC;aliases=ENSP00000323315;source=Ensembl	c.1297G>A	chr9:g.133753828G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.S438C	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133753844_133753845delCCinsGT;aliases=ENSP00000323315;source=Ensembl	c.1313C>G	chr9:g.133753844C>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E450K	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753879_133753881delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.1348G>A	chr9:g.133753879G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E450G	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsGT,chr9:g.133753880_133753881delAGinsGA,chr9:g.133753880_133753881delAGinsGC;aliases=ENSP00000323315;source=Ensembl	c.1349A>G	chr9:g.133753880A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E450A	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsCA,chr9:g.133753880_133753881delAGinsCC,chr9:g.133753880_133753881delAGinsCT;aliases=ENSP00000323315;source=Ensembl	c.1349A>C	chr9:g.133753880A>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E450V	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753880_133753881delAGinsTA,chr9:g.133753880_133753881delAGinsTC,chr9:g.133753880_133753881delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.1349A>T	chr9:g.133753880A>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E453K	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753888_133753890delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.1357G>A	chr9:g.133753888G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E453G	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsGT,chr9:g.133753889_133753890delAGinsGA,chr9:g.133753889_133753890delAGinsGC;aliases=ENSP00000323315;source=Ensembl	c.1358A>G	chr9:g.133753889A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E453A	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsCA,chr9:g.133753889_133753890delAGinsCC,chr9:g.133753889_133753890delAGinsCT;aliases=ENSP00000323315;source=Ensembl	c.1358A>C	chr9:g.133753889A>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E453V	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753889_133753890delAGinsTA,chr9:g.133753889_133753890delAGinsTC,chr9:g.133753889_133753890delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.1358A>T	chr9:g.133753889A>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E459K	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133753906_133753908delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.1375G>A	chr9:g.133753906G>A
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E459G	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsGT,chr9:g.133753907_133753908delAGinsGA,chr9:g.133753907_133753908delAGinsGC;aliases=ENSP00000323315;source=Ensembl	c.1376A>G	chr9:g.133753907A>G
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E459A	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsCA,chr9:g.133753907_133753908delAGinsCC,chr9:g.133753907_133753908delAGinsCT;aliases=ENSP00000323315;source=Ensembl	c.1376A>C	chr9:g.133753907A>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E459V	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133753907_133753908delAGinsTA,chr9:g.133753907_133753908delAGinsTC,chr9:g.133753907_133753908delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.1376A>T	chr9:g.133753907A>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.M472I	ENST00000318560	ABL1	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=ATG;candidate_codons=ATC,ATA,ATT;candidate_snv_variants=chr9:g.133753947G>A,chr9:g.133753947G>T;aliases=ENSP00000323315;source=Ensembl	c.1416G>C	chr9:g.133753947G>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.P480L	ENST00000318560	ABL1	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=CCC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr9:g.133755470_133755471delCCinsTT,chr9:g.133755470_133755471delCCinsTG,chr9:g.133755470_133755471delCCinsTA,chr9:g.133755469_133755471delCCCinsTTA,chr9:g.133755469_133755471delCCCinsTTG;aliases=ENSP00000323315;source=Ensembl	c.1439C>T	chr9:g.133755470C>T
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F486S	ENST00000318560	ABL1	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=TTT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr9:g.133755487_133755488delTTinsAG,chr9:g.133755488_133755489delTTinsCG,chr9:g.133755488_133755489delTTinsCC,chr9:g.133755488_133755489delTTinsCA,chr9:g.133755487_133755489delTTTinsAGC;aliases=ENSP00000323315;source=Ensembl	c.1457T>C	chr9:g.133755488T>C
ABL1:I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G	MUT		Resistant	ABL1 (I242T,M244V,K247R,L248V,G250E,G250R,Q252R,Q252H,Y253F,Y253H,E255K,E255V,M237V,E258D,W261L,L273M,E275K,E275Q,D276G,T277A,E279K,V280A,V289A,V289I,E292V,E292Q,I293V,L298V,V299L,F311L,F311I,T315I,F317L,F317V,F317I,F317C,Y320C,L324Q,Y342H,M343T,A344V,A350V,M351T,E355D,E355G,E355A,F359V,F359I,F359C,F359L,D363Y,L364I,A365V,A366G,L370P,V371A,E373K,V379I,A380T,F382L,L384M,L387M,L387F,L387V,M388L,Y393C,H396P,H396R,H396A,A397P,S417F,S417Y,I418S,I418V,A433T,S438C,E450K,E450G,E450A,E450V,E453K,E453G,E453A,E453V,E459K,E459G,E459A,E459V,M472I,P480L,F486S,E507G)	CRubio-Perez	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E507G	ENST00000318560	ABL1	+	inside_[cds_in_exon_10]	CSQN=Missense;reference_codon=GAA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr9:g.133755893_133755894delAAinsGT,chr9:g.133755893_133755894delAAinsGG,chr9:g.133755893_133755894delAAinsGC;aliases=ENSP00000323315;source=Ensembl	c.1520A>G	chr9:g.133755893A>G
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255K	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.763G>A	chr9:g.133738363G>A
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255V	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.764A>T	chr9:g.133738364A>T
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y253H	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	c.757T>C	chr9:g.133738357T>C
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.1075T>G	chr9:g.133748414T>G
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.1076T>G	chr9:g.133748415T>G
ABL1:E255K,E255V,Y253H,F359V,F359C,F359I	MUT		Resistant	ABL1 (E255K,E255V,Y253H,F359V,F359C,F359I)	CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	European LeukemiaNet guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.1075T>A	chr9:g.133748414T>A
ABL1:T315I	MUT		Responsive	ABL1 (T315I)	CRubio-Perez;DTamborero;RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	FDA		ABL1:p.T315I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	c.944C>T	chr9:g.133748283C>T
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	FDA guidelines	ABL1		CML	FDA									
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.T315A	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	c.943A>G	chr9:g.133748282A>G
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317L	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	c.949T>C	chr9:g.133748288T>C
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.949T>G	chr9:g.133748288T>G
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.949T>A	chr9:g.133748288T>A
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.950T>G	chr9:g.133748289T>G
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.949T>A	chr9:g.133748288T>A
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y253H	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	c.757T>C	chr9:g.133738357T>C
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255K	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.763G>A	chr9:g.133738363G>A
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255V	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.764A>T	chr9:g.133738364A>T
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.1075T>G	chr9:g.133748414T>G
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.1076T>G	chr9:g.133748415T>G
ABL1:T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,F317I,Y253H,E255K,E255V,F359V,F359C,F359I)	RDientsmann	Bosutinib	BCR-ABL inhibitor  3rd gen	Bosutinib (BCR-ABL inhibitor  3rd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.1075T>A	chr9:g.133748414T>A
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	ABL1		CML;ALL	FDA									
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsGTA,chr9:g.133748414_133748416delTTCinsGTG,chr9:g.133748414_133748416delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.1075T>G	chr9:g.133748414T>G
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748415_133748416delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.1076T>G	chr9:g.133748415T>G
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F359I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748414_133748416delTTCinsATA,chr9:g.133748414_133748416delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.1075T>A	chr9:g.133748414T>A
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.Y253H	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr9:g.133738357_133738359delTACinsCAT;aliases=ENSP00000323315;source=Ensembl	c.757T>C	chr9:g.133738357T>C
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255K	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr9:g.133738363_133738365delGAGinsAAA;aliases=ENSP00000323315;source=Ensembl	c.763G>A	chr9:g.133738363G>A
ABL1:F359V,F359C,F359I,Y253H,E255K,E255V	MUT		Responsive	ABL1 (F359V,F359C,F359I,Y253H,E255K,E255V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.E255V	ENST00000318560	ABL1	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133738364_133738365delAGinsTA,chr9:g.133738364_133738365delAGinsTC,chr9:g.133738364_133738365delAGinsTT;aliases=ENSP00000323315;source=Ensembl	c.764A>T	chr9:g.133738364A>T
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	EMA									
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	ABL1		CML	FDA									
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.T315A	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr9:g.133748282_133748284delACTinsGCA,chr9:g.133748282_133748284delACTinsGCC,chr9:g.133748282_133748284delACTinsGCG;aliases=ENSP00000323315;source=Ensembl	c.943A>G	chr9:g.133748282A>G
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317L	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133748290C>A,chr9:g.133748290C>G;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsCTT,chr9:g.133748288_133748290delTTCinsCTG,chr9:g.133748288_133748290delTTCinsCTA;aliases=ENSP00000323315;source=Ensembl	c.949T>C	chr9:g.133748288T>C
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317V	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsGTA,chr9:g.133748288_133748290delTTCinsGTG,chr9:g.133748288_133748290delTTCinsGTT;aliases=ENSP00000323315;source=Ensembl	c.949T>G	chr9:g.133748288T>G
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748288_133748290delTTCinsATA,chr9:g.133748288_133748290delTTCinsATT;aliases=ENSP00000323315;source=Ensembl	c.949T>A	chr9:g.133748288T>A
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.F317C	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr9:g.133748289_133748290delTCinsGT;aliases=ENSP00000323315;source=Ensembl	c.950T>G	chr9:g.133748289T>G
ABL1:T315A,F317L,F317V,F317I,F317C,V299L	MUT		Responsive	ABL1 (T315A,F317L,F317V,F317I,F317C,V299L)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.V299L	ENST00000318560	ABL1	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr9:g.133747588G>T;candidate_mnv_variants=chr9:g.133747588_133747590delGTGinsCTT,chr9:g.133747588_133747590delGTGinsCTA,chr9:g.133747588_133747590delGTGinsCTC,chr9:g.133747588_133747590delGTGinsTTA;aliases=ENSP00000323315;source=Ensembl	c.895G>C	chr9:g.133747588G>C
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	CRubio-Perez;DTamborero;RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	FDA guidelines	ABL1		CML;ALL	FDA									
ABL1:T315I	MUT		Responsive	ABL1 (T315I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)	Approved	NCCN guidelines	ABL1		CML	PMID:21562040		ABL1:p.T315I	ENST00000318560	ABL1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr9:g.133748283_133748284delCTinsTC,chr9:g.133748283_133748284delCTinsTA;aliases=ENSP00000323315;source=Ensembl	c.944C>T	chr9:g.133748283C>T
ABL1__BCR	FUS		Responsive	ABL1-BCR fusion	RDientsmann	Dasatinib;Venetoclax	BCR-ABL inhibitor 2nd gen;BCL2 inhibitor	Dasatinib + Venetoclax (BCR-ABL inhibitor 2nd gen + BCL2 inhibitor)		Pre-clinical	ABL1		ALL	PMID:27582059									
AKT1:Q79K,E17K	MUT		Resistant	AKT1 (Q79K,E17K)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	AKT1		CM	PMID:24265152		AKT1:p.Q79K	ENST00000554581	AKT1	-	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105243046_105243048delCTGinsTTT;aliases=ENSP00000451828;source=Ensembl	c.235C>A	chr14:g.105243048G>T
AKT1:Q79K,E17K	MUT		Resistant	AKT1 (Q79K,E17K)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	AKT1		CM	PMID:24265152		AKT1:p.E17K	ENST00000554581	AKT1	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	c.49G>A	chr14:g.105246551C>T
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	AKT1		HNSC	PMID:26763254		AKT1:p.E17K	ENST00000554581	AKT1	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	c.49G>A	chr14:g.105246551C>T
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Early trials	AKT1		ED	PMID:27016228		AKT1:p.E17K	ENST00000554581	AKT1	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	c.49G>A	chr14:g.105246551C>T
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors	Clinical Trials	Pre-clinical	AKT1		CANCER	PMID:21464312;PMID:17611497;PMID:23134728; ENA 2015 (abstr B109)		AKT1:p.E17K	ENST00000554581	AKT1	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	c.49G>A	chr14:g.105246551C>T
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[non-allosteric AKT inhibitor]	non-allosteric AKT inhibitors	Clinical Trials	Early trials	AKT1		CANCER	ENA 2015 (abstract B109)		AKT1:p.E17K	ENST00000554581	AKT1	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	c.49G>A	chr14:g.105246551C>T
AKT1:E17K	MUT		Responsive	AKT1 (E17K)	RDientsmann	[]	[allosteric AKT inhibitor]	allosteric AKT inhibitors	Clinical Trials	Pre-clinical	AKT1		BRCA	PMID:21464312;PMID:17611497		AKT1:p.E17K	ENST00000554581	AKT1	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr14:g.105246549_105246551delCTCinsTTT;aliases=ENSP00000451828;source=Ensembl	c.49G>A	chr14:g.105246551C>T
AKT1:H238Y	MUT		Responsive	AKT1 (H238Y)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	AKT1		FH	ASCO 2015 (abstr 11010)		AKT1:p.H238Y	ENST00000554581	AKT1	-	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=CAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr14:g.105239906_105239908delGTGinsATA;aliases=ENSP00000451828;source=Ensembl	c.712C>T	chr14:g.105239908G>A
AKT2:amp	CNA		Responsive	AKT2 amplification	RDientsmann	MK2206	Allosteric AKT inhibitor	MK2206 (Allosteric AKT inhibitor)	Clinical Trials	Pre-clinical	AKT2		CANCER	ENA 2014 (abstr 373)									
AKT3__.	FUS	Cell line	Responsive	AKT3 fusion	JAlbanell;ARovira;RDientsmann	[AZD5363,GSK2141795]	[ATP competitive AKT inhibitor]	ATP competitive AKT inhibitors (AZD5363,GSK2141795,etc)	Clinical Trials;Clinical Trials	Pre-clinical	AKT3		BRCA	PMID:22722202	Direct								
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	ALK		LUAD	PMID:23553849									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[novel ALK inhibitor]	novel ALK inhibitors		Early trials	ALK		LUAD	PMID:23639470									
ALK:F1174L	MUT		Responsive	ALK (F1174L)	RDientsmann	[]	[novel ALK inhibitor]	novel ALK inhibitors		Pre-clinical	ALK		LUAD	PMID:24327273		ALK:p.F1174L	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	c.3520T>C	chr2:g.29443697A>G
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor;IGF1R inhibitor]	ALK inhibitor + IGF1R inhibitors		Pre-clinical	ALK		LUAD	PMID:25173427									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor;SRC inhibitor]	ALK inhibitor + SRC inhibitors		Pre-clinical	ALK		LUAD	PMID:25394791									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor;MEK inhibitor]	ALK inhibitor + MEK inhibitors		Pre-clinical	ALK		LUAD	PMID:26301689									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	[]	[ALK inhibitor]	ALK inhibitors		Case report	ALK		COREAD	PMID:26633560									
ALK:I1171T	MUT		Resistant	ALK (I1171T)	RDientsmann	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:25228534		ALK:p.I1171T	ENST00000389048	ALK	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	c.3512T>C	chr2:g.29445213A>G
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		ALK:p.L1196M	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	c.3586C>A	chr2:g.29443631G>T
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		ALK:p.S1206Y	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29443599_29443600delGGinsAT;aliases=ENSP00000373700;source=Ensembl	c.3617C>A	chr2:g.29443600G>T
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		ALK:p.G1269A	ENST00000389048	ALK	-	inside_[cds_in_exon_25]	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29432681_29432682delTCinsGG,chr2:g.29432681_29432682delTCinsCG,chr2:g.29432681_29432682delTCinsAG;aliases=ENSP00000373700;source=Ensembl	c.3806G>C	chr2:g.29432682C>G
ALK:L1196M,S1206Y,G1269A,I1171T	MUT		Responsive	ALK (L1196M,S1206Y,G1269A,I1171T)	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	PMID:24670165;PMID:24327273		ALK:p.I1171T	ENST00000389048	ALK	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	c.3512T>C	chr2:g.29445213A>G
ALK:F856S,A348D	MUT		Responsive	ALK (F856S,A348D)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		AML	PMID:26032424		ALK:p.F856S	ENST00000389048	ALK	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=TTC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr2:g.29455235_29455236delAAinsCT,chr2:g.29455234_29455235delGAinsAG,chr2:g.29455234_29455235delGAinsCG,chr2:g.29455234_29455235delGAinsTG,chr2:g.29455234_29455236delGAAinsACT;aliases=ENSP00000373700;source=Ensembl	c.2567T>C	chr2:g.29455235A>G
ALK:F856S,A348D	MUT		Responsive	ALK (F856S,A348D)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		AML	PMID:26032424		ALK:p.A348D	ENST00000389048	ALK	-	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GCC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr2:g.29754891_29754892delGGinsAT;aliases=ENSP00000373700;source=Ensembl	c.1043C>A	chr2:g.29754892G>T
ALK:L1198F	MUT		Responsive	ALK (L1198F)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:26698910		ALK:p.L1198F	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=CTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr2:g.29443623_29443625delGAGinsAAA;aliases=ENSP00000373700;source=Ensembl	c.3592C>T	chr2:g.29443625G>A
ALK:G1123S	MUT		Resistant	ALK (G1123S)	EArriola	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:26134233		ALK:p.G1123S	ENST00000389048	ALK	-	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr2:g.29445464_29445466delGCCinsACT,chr2:g.29445465_29445466delCCinsGA,chr2:g.29445464_29445466delGCCinsAGA,chr2:g.29445464_29445466delGCCinsCGA,chr2:g.29445464_29445466delGCCinsTGA;aliases=ENSP00000373700;source=Ensembl	c.3367G>A	chr2:g.29445466C>T
ALK:C1156Y,L1196M	MUT		Resistant	ALK (C1156Y,L1196M)	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ALK		NSCLC	PMID:20979473		ALK:p.C1156Y	ENST00000389048	ALK	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	c.3467G>A	chr2:g.29445258C>T
ALK:C1156Y,L1196M	MUT		Resistant	ALK (C1156Y,L1196M)	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ALK		NSCLC	PMID:20979473		ALK:p.L1196M	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	c.3586C>A	chr2:g.29443631G>T
ALK:.	MUT		Resistant	ALK oncogenic mutation	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Clinical trial	ALK		NSCLC	PMID:22235099									
ALK:amp	CNA		Resistant	ALK amplification	EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Clinical trial	ALK		NSCLC	PMID:22235099									
ALK__.	FUS		Responsive	ALK fusion	MMartínez;RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	ALK		LY;GB	PMID:24491302;NCT02270034									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)		FDA guidelines	ALK		LUAD	FDA									
ALK__.	FUS		Responsive	ALK fusion	CRubio-Perez;DTamborero;RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)	Approved	FDA guidelines	ALK		NSCLC;LUAD	FDA									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)		Case report	ALK		COREAD;IM	PMID:26633560;PMID:26933125;PMID:27742657									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Entrictinib	Pan-TK inhibitor	Entrictinib (Pan-TK inhibitor)		Case report	ALK		COREAD	PMID:26633560;PMID:26933125									
ALK__.	FUS		Responsive	ALK fusion	EArriola;CRubio-Perez	Alectinib	ALK inhibitor	Alectinib (ALK inhibitor)	Clinical_Trials	FDA guidelines	ALK		NSCLC	FDA									
ALK__.	FUS		Responsive	ALK fusion	ECampo	Ceritinib	ALK inhibitor	Ceritinib (ALK inhibitor)	Clinical Trials	Early trials	ALK		HEMATO	NCT02186821	Direct								
ALK__.	FUS		Responsive	ALK fusion	CRubio-Perez;DTamborero;RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	FDA guidelines	ALK		NSCLC;LUAD	FDA									
ALK__.	FUS		Responsive	ALK fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		IM;THCA	PMID:20979472;PMID:24687827									
ALK:F1174L	MUT		Resistant	ALK (F1174L)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		ALK:p.F1174L	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	c.3520T>C	chr2:g.29443697A>G
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		ALK:p.R1275Q	ENST00000389048	ALK	-	inside_[cds_in_exon_25]	CSQN=Missense;reference_codon=CGA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.29432663_29432664delTCinsCT;aliases=ENSP00000373700;source=Ensembl	c.3824G>A	chr2:g.29432664C>T
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		ALK:p.G1128A	ENST00000389048	ALK	-	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=GGG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29445449_29445450delCCinsTG,chr2:g.29445449_29445450delCCinsGG,chr2:g.29445449_29445450delCCinsAG;aliases=ENSP00000373700;source=Ensembl	c.3383G>C	chr2:g.29445450C>G
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		ALK:p.I1171N	ENST00000389048	ALK	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsAT;aliases=ENSP00000373700;source=Ensembl	c.3512T>A	chr2:g.29445213A>T
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		ALK:p.R1192P	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=CGG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr2:g.29443641_29443642delCCinsAG,chr2:g.29443641_29443642delCCinsTG,chr2:g.29443641_29443642delCCinsGG;aliases=ENSP00000373700;source=Ensembl	c.3575G>C	chr2:g.29443642C>G
ALK:R1275Q,G1128A,I1171N,R1192P,F1245C	MUT		Responsive	ALK (R1275Q,G1128A,I1171N,R1192P,F1245C)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	ALK		G	PMID:22072639		ALK:p.F1245C	ENST00000389048	ALK	-	inside_[cds_in_exon_24]	CSQN=Missense;reference_codon=TTC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr2:g.29436858_29436859delGAinsAC;aliases=ENSP00000373700;source=Ensembl	c.3734T>G	chr2:g.29436859A>C
ALK:amp	CNA		Resistant	ALK amplification	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784									
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.L1196M	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=CTG;candidate_codons=ATG;aliases=ENSP00000373700;source=Ensembl	c.3586C>A	chr2:g.29443631G>T
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.L1152R	ENST00000389048	ALK	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr2:g.29445270_29445271delAGinsCT,chr2:g.29445269_29445270delCAinsTC,chr2:g.29445269_29445270delCAinsGC,chr2:g.29445269_29445270delCAinsAC,chr2:g.29445269_29445271delCAGinsTCT;aliases=ENSP00000373700;source=Ensembl	c.3455T>G	chr2:g.29445270A>C
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.C1156Y	ENST00000389048	ALK	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=TGC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29445257_29445258delGCinsAT;aliases=ENSP00000373700;source=Ensembl	c.3467G>A	chr2:g.29445258C>T
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.F1174L	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr2:g.29443695G>T,chr2:g.29443695G>C;candidate_mnv_variants=chr2:g.29443695_29443697delGAAinsAAG,chr2:g.29443695_29443697delGAAinsCAG,chr2:g.29443695_29443697delGAAinsTAG;aliases=ENSP00000373700;source=Ensembl	c.3520T>C	chr2:g.29443697A>G
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.G1202R	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.29443613C>G;candidate_mnv_variants=chr2:g.29443611_29443613delTCCinsCCT,chr2:g.29443611_29443613delTCCinsGCG,chr2:g.29443611_29443613delTCCinsCCG,chr2:g.29443611_29443613delTCCinsACG;aliases=ENSP00000373700;source=Ensembl	c.3604G>A	chr2:g.29443613C>T
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.S1206Y	ENST00000389048	ALK	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr2:g.29443599_29443600delGGinsAT;aliases=ENSP00000373700;source=Ensembl	c.3617C>A	chr2:g.29443600G>T
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.G1269A	ENST00000389048	ALK	-	inside_[cds_in_exon_25]	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr2:g.29432681_29432682delTCinsGG,chr2:g.29432681_29432682delTCinsCG,chr2:g.29432681_29432682delTCinsAG;aliases=ENSP00000373700;source=Ensembl	c.3806G>C	chr2:g.29432682C>G
ALK:L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T	MUT		Resistant	ALK (L1196M,L1152R,C1156Y,F1174L,G1202R,S1206Y,G1269A,I1171T)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ALK		LUAD	PMID:22277784;PMID:25228534		ALK:p.I1171T	ENST00000389048	ALK	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr2:g.29445212_29445213delGAinsTG,chr2:g.29445212_29445213delGAinsCG,chr2:g.29445212_29445213delGAinsAG;aliases=ENSP00000373700;source=Ensembl	c.3512T>C	chr2:g.29445213A>G
APC:.	MUT		Responsive	APC oncogenic mutation	RDientsmann	[]	[Tankyrase inhibitor]	Tankyrase inhibitors		Pre-clinical	APC		COREAD	PMID:22440753;PMID:23539443									
AR:W741.,T878A	MUT		Responsive	AR (W741,T878A)	RDientsmann	Arn-509	AR inhibitor	Arn-509 (AR inhibitor)		Pre-clinical	AR		PRAD	PMID:23779130									
AR:W741.,T878A	MUT		Responsive	AR (W741,T878A)	RDientsmann	Arn-509	AR inhibitor	Arn-509 (AR inhibitor)		Pre-clinical	AR		PRAD	PMID:23779130		AR:p.T878A	ENST00000374690	AR	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	c.2632A>G	chrX:g.66943552A>G
AR:W741.,T878A	MUT		Responsive	AR (W741,T878A)	RDientsmann	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Pre-clinical	AR		PRAD	PMID:23779130									
AR:W741.,T878A	MUT		Responsive	AR (W741,T878A)	RDientsmann	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Pre-clinical	AR		PRAD	PMID:23779130		AR:p.T878A	ENST00000374690	AR	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	c.2632A>G	chrX:g.66943552A>G
AR:over	EXPR		Responsive	AR overexpression	JAlbanell;ARovira	[Bicalutamide,Enzalutamide,Orterone,4OHtestosterone]	[AR inhibitor]	AR inhibitors (Bicalutamide,Enzalutamide,Orterone,4OHtestosterone,etc)	Clinical Trials	Early trials	AR		BRCA	ASCO 2015 (abstr 1003)	Direct								
AR:F877L	MUT		Resistant	AR (F877L)	RDientsmann;ARodriguez-Vida	Arn-509	AR inhibitor	Arn-509 (AR inhibitor)		Case report	AR	PRAD	PRAD	PMID:23779130		AR:p.F877L	ENST00000374690	AR	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chrX:g.66943551C>A,chrX:g.66943551C>G;candidate_mnv_variants=chrX:g.66943549_66943551delTTCinsCTT,chrX:g.66943549_66943551delTTCinsCTG,chrX:g.66943549_66943551delTTCinsCTA;aliases=ENSP00000363822;source=Ensembl	c.2629T>C	chrX:g.66943549T>C
AR:over	EXPR		Responsive	AR overexpression	ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)	Approved	Early trials	AR	PRAD	PRAD	PMID:24882673	Direct								
AR:F877L	MUT		Resistant	AR (F877L)	RDientsmann;ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Case report	AR	PRAD	PRAD	PMID:23779130		AR:p.F877L	ENST00000374690	AR	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chrX:g.66943551C>A,chrX:g.66943551C>G;candidate_mnv_variants=chrX:g.66943549_66943551delTTCinsCTT,chrX:g.66943549_66943551delTTCinsCTG,chrX:g.66943549_66943551delTTCinsCTA;aliases=ENSP00000363822;source=Ensembl	c.2629T>C	chrX:g.66943549T>C
AR:T878A	MUT		Resistant	AR (T878A)	RDientsmann;ARodriguez-Vida	Flutamide	AR inhibitor	Flutamide (AR inhibitor)		Case report	AR	PRAD	PRAD	PMID:2260966		AR:p.T878A	ENST00000374690	AR	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	c.2632A>G	chrX:g.66943552A>G
AR:L702H,T878A	MUT		Resistant	AR (L702H,T878A)	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	PMID:26537258		AR:p.L702H	ENST00000374690	AR	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=CTC;candidate_codons=CAT,CAC;candidate_mnv_variants=chrX:g.66931463_66931464delTCinsAT;aliases=ENSP00000363822;source=Ensembl	c.2105T>A	chrX:g.66931463T>A
AR:L702H,T878A	MUT		Resistant	AR (L702H,T878A)	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	PMID:26537258		AR:p.T878A	ENST00000374690	AR	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=ACT;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chrX:g.66943552_66943554delACTinsGCA,chrX:g.66943552_66943554delACTinsGCC,chrX:g.66943552_66943554delACTinsGCG;aliases=ENSP00000363822;source=Ensembl	c.2632A>G	chrX:g.66943552A>G
AR:amp	CNA		Resistant	AR amplification	RDientsmann	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	AR		PRAD	PMID:26537258									
AR:amp	CNA		Responsive	AR amplification	RDientsmann	[]	[AR inhibitor next gen]	AR inhibitor next gens		Pre-clinical	AR		PRAD	PMID:23589709;PMID:21859989									
AR:F877L;AR:T878A	MUT;MUT		Responsive	AR (F877L) + AR (T878A)	RDientsmann	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)		Pre-clinical	AR;AR		PRAD	PMID:27196756									
ARAF:S214C	MUT		Responsive	ARAF (S214C)	JAlbanell;ARovira;RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)	FDA approved	Case report	ARAF		LUAD	http://www.jci.org/articles/view/72763;PMID:24569458	Direct:primary target	ARAF:p.S214C	ENST00000377045	ARAF	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chrX:g.47426121_47426122delCCinsGT;aliases=ENSP00000366244;source=Ensembl	c.641C>G	chrX:g.47426121C>G
ARAF:.	MUT		Resistant	ARAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor]	BRAF inhibitor + EGFR mAb inhibitors		Case report	ARAF		COREAD	ENA 2014 (abstr 428)									
ARAF:.	MUT		Resistant	ARAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	ARAF		COREAD	ENA 2014 (abstr 428)									
AREG:amp	CNA		Responsive	AREG amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	AREG		COREAD	PMID:19738126;PMID:26341080									
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	ARID1A		OV	PMID:25686104									
ARID1A:.	MUT		Responsive	ARID1A oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ARID1A		CANCER	PMID:26069190									
ARID1A:amp;ANXA1:over	CNA;EXPR		Resistant	ARID1A amplification + ANXA1 overexpression	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	FDA approved	Early trials	ARID1A;ANXA1		BRCA	PMID:27172896									
ARID1A:.;ANXA1:over	MUT;EXPR		Resistant	ARID1A oncogenic mutation + ANXA1 overexpression	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	FDA approved	Early trials	ARID1A;ANXA1		BRCA	PMID:27172896									
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	ATM		ST;PRAD	ENA 2014 (abstr 8LBA);PMID:26510020									
ATM:del	CNA		Responsive	ATM deletion	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	ATM	BLCA	BLCA	PMID:26238431	Indirect								
ATM:.	MUT		Responsive	ATM oncogenic mutation	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	ATM	BLCA	BLCA	PMID:26238431	Indirect								
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	[]	[ATR inhibitor]	ATR inhibitors		Case report	ATM		COREAD	ENA 2015 (abstr A48)									
ATM:del	CNA		Responsive	ATM deletion	RDientsmann	[]	[ATR inhibitor]	ATR inhibitors		Case report	ATM		COREAD	ENA 2015 (abstr A48)									
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	ATM		LY	PMID:23761041									
ATM:del	CNA		Responsive	ATM deletion	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	ATM		LY	PMID:23761041									
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	ATM		ST	ENA 2014 (abstr 8LBA)									
ATM:del	CNA		Responsive	ATM deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	ATM		ST	ENA 2014 (abstr 8LBA)									
ATM:.	BIA		Responsive	ATM biallelic inactivation	ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	ATM		BCL	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Indirect								
ATM:.	MUT		Responsive	ATM oncogenic mutation	RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	ATM		G	PMID:23960094									
ATR:.	MUT	Cell line	Responsive	ATR oncogenic mutation	CRubio-Perez;ECampo;RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Pre-clinical	ATR		OV;CANCER	PMID:23548269	Indirect								
ATR:del	CNA	Cell line	Responsive	ATR deletion	CRubio-Perez;ECampo;RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Pre-clinical	ATR		OV;CANCER	PMID:23548269	Indirect								
ATR:.	MUT		Responsive	ATR oncogenic mutation	RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	ATR		G	PMID:23960094									
AURKA:amp	CNA		Responsive	AURKA amplification	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	AURKA		PRAD;CANCER	PMID:22302096;PMID:22389870									
B2M:.	MUT		Resistant	B2M oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	B2M		CM	PMID:27433843									
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	BAP1		MESO	PMID:26437366									
BAP1:del	CNA		Responsive	BAP1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	BAP1		MESO	PMID:26437366									
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	BAP1		CM	PMID:22038994									
BAP1:del	CNA		Responsive	BAP1 deletion	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	BAP1		CM	PMID:22038994									
BAP1:.	MUT		Responsive	BAP1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BAP1		R;CANCER	PMID:22683710									
BAP1:del	CNA		Responsive	BAP1 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BAP1		R;CANCER	PMID:22683710									
BCL2:amp	CNA		Responsive	BCL2 amplification	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	BCL2		LY	PMID:22649144									
BCL2:over	EXPR		Responsive	BCL overexpression	CRubio-Perez	Venetoclax;Bortezomib	BCL2 inhibitor;Proteasome inhibitor	Venetoclax + Bortezomib (BCL2 inhibitor + Proteasome inhibitor)		Early trials	BCL		MM	ASH 2015 (Blood 2015 126:2975)									
BCL6:over	EXPR		Responsive	BCL6 overexpression	CRubio-Perez	Onalespib	HSP90 inhibitor	Onalespib (HSP90 inhibitor)		Early trials	BCL6		LY	NCT02572453									
BCOR:.	MUT		Responsive	BCOR oncogenic mutation	RDientsmann	Enzastaurin	PKCb inhibitor	Enzastaurin (PKCb inhibitor)		Pre-clinical	BCOR		ST	PMID:27397505									
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		BRAF:p.V600D	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAT;aliases=ENSP00000288602;source=Ensembl	c.1799_1800delTGinsAC	chr7:g.140453135_140453136delCAinsGT
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		BRAF:p.V600K	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		BRAF:p.V600M	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000288602;source=Ensembl	c.1798G>A	chr7:g.140453137C>T
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		BRAF:p.V600G	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAC,chr7:g.140453135_140453136delCAinsTC,chr7:g.140453135_140453136delCAinsGC;aliases=ENSP00000288602;source=Ensembl	c.1799T>G	chr7:g.140453136A>C
BRAF:V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600D,V600K,V600M,V600G,V600R)	CRubio-Perez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		CM	NCCN		BRAF:p.V600R	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Early trials	BRAF		TH	ASCO 2013 (abstr 9029)		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Early trials	BRAF		TH	PMID:22241789		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;HSP90 inhibitor]	BRAF inhibitor + HSP90 inhibitors		Pre-clinical	BRAF		CM	PMID:22351686		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;PI3K pathway inhibitor]	BRAF inhibitor + PI3K pathway inhibitors		Pre-clinical	BRAF		CM	PMID:22389471;PMID:21156289		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor;CDK2/4 inhibitor]	BRAF inhibitor + CDK2/4 inhibitors		Pre-clinical	BRAF		CM	PMID:22997239		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	BRAF		CM	PMID:23614898;PMID:22997239		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:L597R	MUT		Responsive	BRAF (L597R)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	BRAF		CM	PMID:23715574		BRAF:p.L597R	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=CTA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453145_140453146delAGinsCT,chr7:g.140453144_140453145delTAinsGC,chr7:g.140453144_140453145delTAinsCC,chr7:g.140453144_140453145delTAinsAC,chr7:g.140453144_140453146delTAGinsCCT;aliases=ENSP00000288602;source=Ensembl	c.1790T>G	chr7:g.140453145A>C
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		Early trials	BRAF		COREAD	PMID:26392102;ASCO 2015 (abstr 8006)		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600.	MUT		Responsive	BRAF (V600)	RDientsmann	Panitumumab;Dabrafenib;BYL719	EGFR mAb inhibitor;BRAF inhibitor;PI3K inhibitor	Panitumumab + Dabrafenib + BYL719 (EGFR mAb inhibitor + BRAF inhibitor + PI3K inhibitor)	Approved; Approved;Clinical Trials	Early trials	BRAF		COREAD	ENA 2014 (abstr 11LBA)	Indirect								
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Panitumumab;Dabrafenib;Trametinib	EGFR mAb inhibitor;BRAF inhibitor;MEK inhibitor	Panitumumab + Dabrafenib + Trametinib (EGFR mAb inhibitor + BRAF inhibitor + MEK inhibitor)	Approved; Approved;Clinical Trials	Early trials	BRAF		COREAD	ASCO 2014 (abstr 3515);ASCO 2015 (abstr 103)	Indirect	BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF__.	FUS		Responsive	BRAF fusion	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	BRAF		OV	PMID:26324360									
BRAF:V600E,G469A	MUT		Resistant	BRAF (V600E,G469A)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Case report	BRAF		LUAD	PMID:22773810		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E,G469A	MUT		Resistant	BRAF (V600E,G469A)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Case report	BRAF		LUAD	PMID:22773810		BRAF:p.G469A	ENST00000288602	BRAF	-	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsGG,chr7:g.140481401_140481402delTCinsCG,chr7:g.140481401_140481402delTCinsAG;aliases=ENSP00000288602;source=Ensembl	c.1406G>C	chr7:g.140481402C>G
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Early trials	BRAF		LUAD;TH	PMID:23524406;PMID:22608338;ASCO 2013 (abstr 8009);ESMO 2014 (abstr LBA38_PR);PMID:20818844;PMID:23489023;PMID:27080216		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Case report	BRAF		LUAD;HCL;MYMA	PMID:22743296;PMID:22621641;PMID:23612012		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Early trials	BRAF		CM;TH	ESMO 2015 (abstract 300);AACR 2016 (abstr CT005)		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		NCCN guidelines	BRAF		NSCLC	NCCN		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		Case report	BRAF		NEU	PMID:27048246		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT	Cell line	Responsive	BRAF (V600E)	MMartínez	PLX4720	BRAF inhibitor	PLX4720 (BRAF inhibitor)		Pre-clinical	BRAF		MA	PMC3638050		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	MMartínez	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)	Clinical Trials	Early trials	BRAF		PG	NCT01089101		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	MMartínez	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		MA	PMID:22586120		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Vemurafenib;Cobimetinib	BRAF inhibitor;MEK inhibitor	Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Vemurafenib;Cobimetinib	BRAF inhibitor;MEK inhibitor	Vemurafenib + Cobimetinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600K	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	BRAF		OV	PMID:19018267		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	BRAF		G	PMID:22038996;PMID:22586120		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	BRAF		OV	PMID:22608338		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	PMID:23248257;PMID:22805292;PMID:23248257		BRAF:p.K601R	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=AAA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453132_140453133delTTinsCC,chr7:g.140453133_140453134delTTinsCG,chr7:g.140453132_140453134delTTTinsGCG,chr7:g.140453132_140453134delTTTinsCCG,chr7:g.140453132_140453134delTTTinsACG;aliases=ENSP00000288602;source=Ensembl	c.1802A>G	chr7:g.140453133T>C
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	PMID:23248257;PMID:22805292;PMID:23248257		BRAF:p.L597R	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=CTA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453145_140453146delAGinsCT,chr7:g.140453144_140453145delTAinsGC,chr7:g.140453144_140453145delTAinsCC,chr7:g.140453144_140453145delTAinsAC,chr7:g.140453144_140453146delTAGinsCCT;aliases=ENSP00000288602;source=Ensembl	c.1790T>G	chr7:g.140453145A>C
BRAF:K601R,L597R,V600R	MUT		Responsive	BRAF (K601R,L597R,V600R)	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Case report	BRAF		CM	PMID:23248257;PMID:22805292;PMID:23248257		BRAF:p.V600R	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT
BRAF__.	FUS		Responsive	BRAF fusion	RDientsmann	[Trametinib]	[MEK inhibitor]	MEK inhibitors (Trametinib,etc)		Pre-clinical	BRAF		LUAD;CM;PRAD	PMID:24727320;PMID:24345920;PMID:20526349									
BRAF:V600E	MUT		Resistant	BRAF (V600E)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	BRAF		COREAD	PMID:20619739;PMID:21163703;PMID:23325582		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	CRubio-Perez;DTamborero;RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600R	MUT		Responsive	BRAF (V600R)	RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Early trials	BRAF		CM	PMID:23237741		BRAF:p.V600R	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)		Case report	BRAF		GIST	PMID:23470635;PMID:22608338		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600K	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT
BRAF:Y472C	MUT		Responsive	BRAF (Y472C)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	BRAF		LUAD	PMID:22649091		BRAF:p.Y472C	ENST00000288602	BRAF	-	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=TAC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.140481392_140481393delGTinsAC;aliases=ENSP00000288602;source=Ensembl	c.1415A>G	chr7:g.140481393T>C
BRAF:G466V	MUT		Responsive	BRAF (G466V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	BRAF		LUAD	PMID:22649091		BRAF:p.G466V	ENST00000288602	BRAF	-	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=GGA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.140481410_140481411delTCinsGA,chr7:g.140481410_140481411delTCinsCA,chr7:g.140481410_140481411delTCinsAA;aliases=ENSP00000288602;source=Ensembl	c.1397G>T	chr7:g.140481411C>A
BRAF:V600E	MUT		Resistant	BRAF (V600E)	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Late trials	BRAF		COREAD	PMID:20619739;PMID:21163703;PMID:23325582		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:D594G,G469E	MUT		Responsive	BRAF (D594G,G469E)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM	PMID:18794803		BRAF:p.D594G	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GAT;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453153_140453154delATinsCC,chr7:g.140453153_140453154delATinsTC,chr7:g.140453153_140453154delATinsGC;aliases=ENSP00000288602;source=Ensembl	c.1781A>G	chr7:g.140453154T>C
BRAF:D594G,G469E	MUT		Responsive	BRAF (D594G,G469E)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM	PMID:18794803		BRAF:p.G469E	ENST00000288602	BRAF	-	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140481401_140481402delTCinsCT;aliases=ENSP00000288602;source=Ensembl	c.1406G>A	chr7:g.140481402C>T
BRAF__.	FUS		Responsive	BRAF fusion	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	BRAF		CM;LUAD;PRAD	PMID:238900088;PMID:20526349;PMID:24727320									
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	CRubio-Perez;DTamborero;RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E,V600K	MUT		Responsive	BRAF (V600E,V600K)	CRubio-Perez;DTamborero;RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600K	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT
BRAF:V600E	MUT		Responsive	BRAF (V600E)	CRubio-Perez;DTamborero;RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	FDA guidelines	BRAF		CM	FDA		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600.	MUT		No Responsive	BRAF (V600)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		COREAD	PMID:26287849									
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	BRAF:p.V600D	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAT;aliases=ENSP00000288602;source=Ensembl	c.1799_1800delTGinsAC	chr7:g.140453135_140453136delCAinsGT
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	BRAF:p.V600K	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.140453135_140453137delCACinsTTT;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAA	chr7:g.140453136_140453137delACinsTT
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	BRAF:p.V600M	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000288602;source=Ensembl	c.1798G>A	chr7:g.140453137C>T
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	BRAF:p.V600G	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsAC,chr7:g.140453135_140453136delCAinsTC,chr7:g.140453135_140453136delCAinsGC;aliases=ENSP00000288602;source=Ensembl	c.1799T>G	chr7:g.140453136A>C
BRAF:V600E,V600D,V600K,V600M,V600G,V600R	MUT		Responsive	BRAF (V600E,V600D,V600K,V600M,V600G,V600R)	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	NCCN guidelines	BRAF		NSCLC;HISLC;HISEC	PMID:26287849	Indirect	BRAF:p.V600R	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.140453136_140453137delACinsCG,chr7:g.140453135_140453137delCACinsTCT,chr7:g.140453135_140453137delCACinsTCG,chr7:g.140453135_140453137delCACinsGCG,chr7:g.140453135_140453137delCACinsACG;aliases=ENSP00000288602;source=Ensembl	c.1798_1799delGTinsAG	chr7:g.140453136_140453137delACinsCT
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)	Approved	Early trials	BRAF		THCA	PMID:22608338;PMID:20818844;PMID:23489023		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:V600E	MUT		Responsive	BRAF (V600E)	RDientsmann	Dabrafenib;Trametinib	BRAF inhibitor;MEK inhibitor	Dabrafenib + Trametinib (BRAF inhibitor + MEK inhibitor)		FDA guidelines	BRAF		LUAD	PMID:27283860		BRAF:p.V600E	ENST00000288602	BRAF	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GTG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.140453135_140453136delCAinsTT;aliases=ENSP00000288602;source=Ensembl	c.1799T>A	chr7:g.140453136A>T
BRAF:G469A;EGFR:.	MUT;MUT		Responsive	BRAF (G469A) + EGFR oncogenic mutation	RDientsmann	[]	[EGFR TK inhibitor;MEK inhibitor]	EGFR TK inhibitor + MEK inhibitors		Pre-clinical	BRAF;EGFR		LUAD	PMID:22773810									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	BRCA1		PRAD	PMID:26510020									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Early trials	BRCA1		BRCA	PMID:25847936									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor;Chemotherapy]	PARP inhibitor + Chemotherapys		Early trials	BRCA1		OV	PMID:22307137;ASCO 2012 (abstr 1009)									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	FDA guidelines	BRCA1		OV	FDA									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Late trials	BRCA1		OV	PMID:22406760;PMID:22711857									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Rucaparib	PARP inhibitor	Rucaparib (PARP inhibitor)		FDA guidelines	BRCA1		OV	FDA									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	Veliparib;Cisplatin	PARP inhibitor;Chemotherapy	Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)		Early trials	BRCA1		BRCA	PMID:26801247									
BRCA1:del	CNA		Responsive	BRCA1 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	BRCA1		OV	PMID:22392482									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	BRCA1		PA	PMID:25366685;PMID:25719666;PMID:19553641;PMID:25366685									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Case report	BRCA1		CANCER	PMID:25964244									
BRCA1:.	MUT		Responsive	BRCA1 oncogenic mutation	RDientsmann;JAlbanell	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)		Early trials	BRCA1		BRCA	PMID:20609467;PMID:25366685									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann;ARodriguez-Vida	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	Early trials	BRCA2		PRAD	PMID:26510020;NCT01682772;http://cancerres.aacrjournals.org/content/75/15_Supplement/CT322	Indirect								
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Early trials	BRCA2		BRCA	PMID:25847936									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor;Chemotherapy]	PARP inhibitor + Chemotherapys		Early trials	BRCA2		OV	PMID:22307137;ASCO 2012 (abstr 1009)									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Case report	BRCA2		CM	PMID:26997480									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Late trials	BRCA2		OV	PMID:22406760;PMID:22711857									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Rucaparib	PARP inhibitor	Rucaparib (PARP inhibitor)		FDA guidelines	BRCA2		OV	FDA									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Veliparib;Cisplatin	PARP inhibitor;Chemotherapy	Veliparib + Cisplatin (PARP inhibitor + Chemotherapy)		Early trials	BRCA2		BRCA	PMID:26801247									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	JAlbanell;ARovira;RDientsmann	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)	Approved	Early trials	BRCA2		BRCA	PMID:20609467	Indirect								
BRCA2:del	CNA		Responsive	BRCA2 deletion	RDientsmann	[Olaparib]	[PARP inhibitor]	PARP inhibitors (Olaparib,etc)		Pre-clinical	BRCA2		OV	PMID:22392482									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)	Approved	FDA guidelines	BRCA2		OV	FDA									
BRCA2:.	MUT		Responsive	BRCA2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	BRCA2		PA	PMID:25719666									
BTK:C481S	MUT		Resistant	BTK (C481S)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		Early trials	BTK		CLL	PMID:24869598;PMID:27199251		BTK:p.C481S	ENST00000308731	BTK	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chrX:g.100611164C>G;candidate_mnv_variants=chrX:g.100611163_100611165delGCAinsACT,chrX:g.100611163_100611164delGCinsAG,chrX:g.100611163_100611164delGCinsCG,chrX:g.100611163_100611164delGCinsTG;aliases=ENSP00000308176;source=Ensembl	c.1441T>A	chrX:g.100611165A>T
BTK:C481.	MUT		Resistant	BTK (C481)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)		Case report	BTK		MCL	PMID:25082755									
BRD4__C15orf55	FUS		Responsive	BRD4-C15orf55 fusion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Case report	C15orf55		NMC	ENA 2015 (abstr A49)									
CA9:over	EXPR	Cell line	Responsive	CA9 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	CA9		R	PMID:24086736	Indirect								
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	CBL		MDPS	PMID:23696637		CBL:p.Y371H	ENST00000264033	CBL	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr11:g.119148891_119148893delTACinsCAT;aliases=ENSP00000264033;source=Ensembl	c.1111T>C	chr11:g.119148891T>C
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	CBL		MDPS	PMID:23696637		CBL:p.C384R	ENST00000264033	CBL	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.119148930_119148932delTGTinsAGG,chr11:g.119148930_119148932delTGTinsAGA,chr11:g.119148930_119148932delTGTinsCGA,chr11:g.119148930_119148932delTGTinsCGC,chr11:g.119148930_119148932delTGTinsCGG;aliases=ENSP00000264033;source=Ensembl	c.1150T>C	chr11:g.119148930T>C
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CBL		MDPS	PMID:23696637		CBL:p.Y371H	ENST00000264033	CBL	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr11:g.119148891_119148893delTACinsCAT;aliases=ENSP00000264033;source=Ensembl	c.1111T>C	chr11:g.119148891T>C
CBL:Y371H,C384R	MUT		Responsive	CBL (Y371H,C384R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CBL		MDPS	PMID:23696637		CBL:p.C384R	ENST00000264033	CBL	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.119148930_119148932delTGTinsAGG,chr11:g.119148930_119148932delTGTinsAGA,chr11:g.119148930_119148932delTGTinsCGA,chr11:g.119148930_119148932delTGTinsCGC,chr11:g.119148930_119148932delTGTinsCGG;aliases=ENSP00000264033;source=Ensembl	c.1150T>C	chr11:g.119148930T>C
CCND1:amp	CNA		Responsive	CCND1 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CCND1		CM	ASCO 2014 (abstr 2528)									
CCND1:amp	CNA		Responsive	CCND1 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND1		CANCER	PMID:22471707									
CCND1:amp	CNA		Resistant	CCND1 amplification	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	CCND1		MB	PMID:24951114									
CCND2:amp	CNA		Responsive	CCND2 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND2		CANCER	PMID:22471707									
CCND2:amp	CNA		Responsive	CCND2 amplification	CRubio-Perez;DTamborero	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Approved	Early trials	CCND2		L	NCT02154490	Indirect								
CCND3:amp	CNA		Responsive	CCND3 amplification	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CCND3		CANCER	PMID:22471707									
CCNE1:amp	CNA		Responsive	CCNE1 amplification	RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CCNE1		CANCER	PMID:22471707									
CD274:over	EXPR		Responsive	CD274 overexpression	ARodriguez-Vida	Atezolizumab	PDL1 inhibitor	Atezolizumab (PDL1 inhibitor)	Clinical Trials	Early trials	CD274	BLCA	CM;R;CANCER	NCT01375842;doi: 10.1093/annonc/mdu337.2	Direct								
CD274:over	EXPR		Responsive	CD274 overexpression	ARodriguez-Vida	Nivolumab	PD1 Ab inhibitor	Nivolumab (PD1 Ab inhibitor)	Clinical Trials	Early trials	CD274	R	R	PMID:25452452	Indirect								
CD274:over	EXPR		Responsive	CD274 overexpression	ARodriguez-Vida	Pembrolizumab	PD1 Ab	Pembrolizumab (PD1 Ab)	Clinical Trials	Early trials	CD274	BLCA	BLCA	NCT01848834	Indirect								
CD274:amp	CNA		Responsive	CD274 amplification	RDientsmann	[]	[PDL1 inhibitor]	PDL1 inhibitors		Pre-clinical	CD274		CANCER	PMID:25079317									
CD69:under	EXPR	Cell line	Responsive	CD69 undexpression	CRubio-Perez	Bendamustine	Alkylating agent	Bendamustine (Alkylating agent)	Approved	Pre-clinical	CD69		CLL	PMID:26701728									
CDH1:.	MUT		Responsive	CDH1 oncogenic mutation	RDientsmann	Bicalutamide	AR inhibitor	Bicalutamide (AR inhibitor)		Pre-clinical	CDH1		BRCA	PMID:27397505									
CDK12:amp	CNA		Responsive	CDK12 amplification	RDientsmann	[]	[PARP inhibitors]	PARP inhibitorss		Pre-clinical	CDK12		OV	PMID:24240700;PMID:24554720									
CDK12:.	MUT		Responsive	CDK12 oncogenic mutation	RDientsmann	[]	[PARP inhibitors]	PARP inhibitorss		Pre-clinical	CDK12		OV	PMID:24240700;PMID:24554720									
CDK4:.	MUT		Responsive	CDK4 oncogenic mutation	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK4		LIP;LY;CANCER	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	Direct								
CDK4:amp	CNA		Responsive	CDK4 amplification	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK4		LIP;LY;CANCER	NCT02187783;NCT01237236; http://meetinglibrary.asco.org/content/83791-102	Direct								
CDK4:amp;RB1:norm	CNA;EXPR		Responsive	CDK4 amplification + RB1 expression	RDientsmann	[]	[CDK4 inhibitor]	CDK4 inhibitors		Early trials	CDK4;RB1		LIP	PMID:23569312									
CDK6:amp	CNA		Responsive	CDK6 amplification	RDientsmann	[]	[CDK6 inhibitor]	CDK6 inhibitors		Pre-clinical	CDK6		CANCER	PMID:22471707									
CDK6:.	MUT		Responsive	CDK6 oncogenic mutation	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK6		LIP;LY;CANCER	NCT02187783;NCT01237236	Direct								
CDK6:amp	CNA		Responsive	CDK6 amplification	CRubio-Perez;DTamborero	LEE011	CDK4/6 inhibitor	LEE011 (CDK4/6 inhibitor)	Clinical Trials	Early trials	CDK6		LIP;LY;CANCER	NCT02187783;NCT01237236;http://meetinglibrary.asco.org/content/83791-102	Direct								
CDKN1A:del	CNA		Responsive	CDKN1A deletion	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1A		CANCER	PMID:22471707;PMID:22997239									
CDKN1A:.	MUT		Responsive	CDKN1A oncogenic mutation	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1A		CANCER	PMID:22471707;PMID:22997239									
CDKN1B:del	CNA		Responsive	CDKN1B deletion	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1B		CANCER	PMID:22471707									
CDKN1B:.	MUT		Responsive	CDKN1B oncogenic mutation	RDientsmann	[]	[CDK2/4 inhibitor]	CDK2/4 inhibitors		Pre-clinical	CDKN1B		CANCER	PMID:22471707									
CDKN2A:del	CNA		Responsive	CDKN2A deletion	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CDKN2A		CM	ASCO 2013 (abstr 2500)									
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Case report	CDKN2A		CM	ASCO 2013 (abstr 2500)									
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2A		G;CANCER	PMID:22471707;PMID:22586120;PMID:22711607									
CDKN2A:del	CNA		Responsive	CDKN2A deletion	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2A		G;CANCER	PMID:22471707;PMID:22586120;PMID:22711607									
CDKN2A:.	MUT		Responsive	CDKN2A oncogenic mutation	CRubio-Perez;DTamborero	Ilorasertib	AURKA-VEGF inhibitor	Ilorasertib (AURKA-VEGF inhibitor)	Clinical Trials	Early trials	CDKN2A		CANCER	NCT02478320	Indirect								
CDKN2A:del	CNA		Responsive	CDKN2A deletion	CRubio-Perez;DTamborero	Ilorasertib	AURKA-VEGF inhibitor	Ilorasertib (AURKA-VEGF inhibitor)	Clinical Trials	Early trials	CDKN2A		CANCER	NCT02478320	Indirect								
CDKN2B:.	MUT		Responsive	CDKN2B oncogenic mutation	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2B		G;CANCER	PMID:22471707;PMID:22711607									
CDKN2B:del	CNA		Responsive	CDKN2B deletion	RDientsmann	[]	[CDK4/6 inhibitor]	CDK4/6 inhibitors		Pre-clinical	CDKN2B		G;CANCER	PMID:22471707;PMID:22711607									
CDKN2C:.	MUT		Responsive	CDKN2C oncogenic mutation	RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CDKN2C		G;CANCER	PMID:22471707;PMID:22997239;PMID:22711607									
CDKN2C:del	CNA		Responsive	CDKN2C deletion	RDientsmann	[]	[CDK2 inhibitor]	CDK2 inhibitors		Pre-clinical	CDKN2C		G;CANCER	PMID:22471707;PMID:22997239;PMID:22711607									
CHEK2:.	MUT		Responsive	CHEK2 oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	CHEK2		PRAD	PMID:26510020;AACR 2015 (abstr CT322)									
CHEK2:del	CNA		Responsive	CHEK2 deletion	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Early trials	CHEK2		PRAD	AACR 2015 (abstr CT322)									
CRBN:under	EXPR		Resistant	CRBN undexpression	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:21860026									
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		CRBN:p.Q100*	ENST00000231948	CRBN	-	inside_[cds_in_exon_3]	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.3215820_3215822delCTGinsTTA,chr3:g.3215820_3215822delCTGinsTCA;aliases=ENSP00000231948;source=Ensembl	c.298C>T	chr3:g.3215822G>A
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		CRBN:p.R283K	ENST00000231948	CRBN	-	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr3:g.3195746_3195747delTCinsCT;aliases=ENSP00000231948;source=Ensembl	c.848G>A	chr3:g.3195747C>T
CRBN:.	MUT		Resistant	CRBN oncogenic mutation	DTamborero	Lenalidomide	Immunomodulator	Lenalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:25108355									
CRBN:under	EXPR		Resistant	CRBN undexpression	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:21860026									
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		CRBN:p.Q100*	ENST00000231948	CRBN	-	inside_[cds_in_exon_3]	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.3215820_3215822delCTGinsTTA,chr3:g.3215820_3215822delCTGinsTCA;aliases=ENSP00000231948;source=Ensembl	c.298C>T	chr3:g.3215822G>A
CRBN:Q100*,R283K	MUT		Resistant	CRBN (Q100*,R283K)	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:23480694		CRBN:p.R283K	ENST00000231948	CRBN	-	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr3:g.3195746_3195747delTCinsCT;aliases=ENSP00000231948;source=Ensembl	c.848G>A	chr3:g.3195747C>T
CRBN:.	MUT		Resistant	CRBN oncogenic mutation	DTamborero	Pomalidomide	Immunomodulator	Pomalidomide (Immunomodulator)		Case report	CRBN		MYMA	PMID:25108355									
CRLF2__.	FUS		Responsive	CRLF2 fusion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	CRLF2		ALL	PMID:22904298									
CRLF2__.	FUS		Responsive	CRLF2 fusion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	CRLF2		ALL	PMID:22955920									
CSF1R:Y571D	MUT		Responsive	CSF1R (Y571D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	CSF1R		MDPS	PMID:18971950		CSF1R:p.Y571D	ENST00000286301	CSF1R	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=TAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr5:g.149441326_149441328delGTAinsATC;aliases=ENSP00000286301;source=Ensembl	c.1711T>G	chr5:g.149441328A>C
CSF3R:Q741.,Y752.,W791.,T615A,T618I	MUT		Responsive	CSF3R (Q741,Y752,W791,T615A,T618I)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CSF3R		ACML	PMID:23656643									
CSF3R:Q741.,Y752.,W791.,T615A,T618I	MUT		Responsive	CSF3R (Q741,Y752,W791,T615A,T618I)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CSF3R		ACML	PMID:23656643									
CSF3R:Q741.,Y752.,W791.,T615A,T618I	MUT		Responsive	CSF3R (Q741,Y752,W791,T615A,T618I)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CSF3R		ACML	PMID:23656643									
CSF3R:Q741.,Y752.,W791.,T615A,T618I	MUT		Responsive	CSF3R (Q741,Y752,W791,T615A,T618I)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CSF3R		ACML	PMID:23656643		CSF3R:p.T615A	ENST00000373106	CSF3R	-	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=ACC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr1:g.36933442_36933444delGGTinsTGC,chr1:g.36933442_36933444delGGTinsCGC,chr1:g.36933442_36933444delGGTinsAGC;aliases=ENSP00000362198;source=Ensembl	c.1843A>G	chr1:g.36933444T>C
CSF3R:Q741.,Y752.,W791.,T615A,T618I	MUT		Responsive	CSF3R (Q741,Y752,W791,T615A,T618I)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	CSF3R		ACML	PMID:23656643		CSF3R:p.T618I	ENST00000373106	CSF3R	-	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=ACC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr1:g.36933433_36933434delGGinsTA,chr1:g.36933433_36933434delGGinsAA;aliases=ENSP00000362198;source=Ensembl	c.1853C>T	chr1:g.36933434G>A
CTNNB1:.	MUT		Resistant	CTNNB1 oncogenic mutation	RDientsmann	[]	[Tankyrase inhibitor]	Tankyrase inhibitors		Pre-clinical	CTNNB1		COREAD	PMID:23539443									
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		CTNNB1:p.H36Y	ENST00000349496	CTNNB1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.41266109_41266111delCATinsTAC;aliases=ENSP00000344456;source=Ensembl	c.106C>T	chr3:g.41266109C>T
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		CTNNB1:p.S37C	ENST00000349496	CTNNB1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TCT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr3:g.41266113_41266114delCTinsGC;aliases=ENSP00000344456;source=Ensembl	c.110C>G	chr3:g.41266113C>G
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		CTNNB1:p.S37Y	ENST00000349496	CTNNB1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TCT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.41266113_41266114delCTinsAC;aliases=ENSP00000344456;source=Ensembl	c.110C>A	chr3:g.41266113C>A
CTNNB1:H36Y,S37C,S37Y,D32V	MUT		Responsive	CTNNB1 (H36Y,S37C,S37Y,D32V)	RDientsmann	Everolimus;Letrozole	MTOR inhibitor;Hormonal therapy	Everolimus + Letrozole (MTOR inhibitor + Hormonal therapy)		Early trials	CTNNB1		ED	PMID:25624430		CTNNB1:p.D32V	ENST00000349496	CTNNB1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr3:g.41266098_41266099delACinsTA,chr3:g.41266098_41266099delACinsTG,chr3:g.41266098_41266099delACinsTT;aliases=ENSP00000344456;source=Ensembl	c.95A>T	chr3:g.41266098A>T
CYP17A1:norm	EXPR		Responsive	CYP17A1 expression	ARodriguez-Vida	Abiraterone	AR inhibitor	Abiraterone (AR inhibitor)	Approved	Early trials	CYP17A1	PRAD	PRAD	PMID:22184395	Direct								
CYP17A1:norm	EXPR		Responsive	CYP17A1 expression	ARodriguez-Vida	Enzalutamide	AR inhibitor	Enzalutamide (AR inhibitor)	Approved	Early trials	CYP17A1	PRAD	PRAD	PMID:24882673	Indirect								
DDR2:S768R	MUT		Responsive	DDR2 (S768R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	DDR2		LUSC	PMID:22328973		DDR2:p.S768R	ENST00000367922	DDR2	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=AGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.162748390T>A,chr1:g.162748388A>C;candidate_mnv_variants=chr1:g.162748388_162748390delAGTinsCGA,chr1:g.162748388_162748390delAGTinsCGC,chr1:g.162748388_162748390delAGTinsCGG;aliases=ENSP00000356899;source=Ensembl	c.2304T>G	chr1:g.162748390T>G
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		DDR2:p.I638F	ENST00000367922	DDR2	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=ATC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.162745497_162745499delATCinsTTT;aliases=ENSP00000356899;source=Ensembl	c.1912A>T	chr1:g.162745497A>T
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		DDR2:p.L239R	ENST00000367922	DDR2	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr1:g.162729629_162729630delCTinsAG,chr1:g.162729630_162729631delTGinsGA,chr1:g.162729630_162729631delTGinsGC,chr1:g.162729630_162729631delTGinsGT,chr1:g.162729629_162729631delCTGinsAGA;aliases=ENSP00000356899;source=Ensembl	c.716T>G	chr1:g.162729630T>G
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		DDR2:p.G253C	ENST00000367922	DDR2	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.162729671_162729673delGGCinsTGT;aliases=ENSP00000356899;source=Ensembl	c.757G>T	chr1:g.162729671G>T
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		DDR2:p.G774V	ENST00000367922	DDR2	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.162748407_162748408delGGinsTA,chr1:g.162748407_162748408delGGinsTC,chr1:g.162748407_162748408delGGinsTT;aliases=ENSP00000356899;source=Ensembl	c.2321G>T	chr1:g.162748407G>T
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		DDR2:p.L63V	ENST00000367922	DDR2	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=CTG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.162724415_162724417delCTGinsGTA,chr1:g.162724415_162724417delCTGinsGTC,chr1:g.162724415_162724417delCTGinsGTT;aliases=ENSP00000356899;source=Ensembl	c.187C>G	chr1:g.162724415C>G
DDR2:I638F,L239R,G253C,G774V,L63V,G505S	MUT		Responsive	DDR2 (I638F,L239R,G253C,G774V,L63V,G505S)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	DDR2		LUSC	PMID:22328973		DDR2:p.G505S	ENST00000367922	DDR2	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=GGT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.162741822_162741824delGGTinsAGC,chr1:g.162741822_162741823delGGinsTC,chr1:g.162741822_162741824delGGTinsTCG,chr1:g.162741822_162741824delGGTinsTCC,chr1:g.162741822_162741824delGGTinsTCA;aliases=ENSP00000356899;source=Ensembl	c.1513G>A	chr1:g.162741822G>A
DDR2:S768R	MUT		Responsive	DDR2 (S768R)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	DDR2		LUSC	PMID:22328973		DDR2:p.S768R	ENST00000367922	DDR2	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=AGT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.162748390T>A,chr1:g.162748388A>C;candidate_mnv_variants=chr1:g.162748388_162748390delAGTinsCGA,chr1:g.162748388_162748390delAGTinsCGC,chr1:g.162748388_162748390delAGTinsCGG;aliases=ENSP00000356899;source=Ensembl	c.2304T>G	chr1:g.162748390T>G
DNMT3A:.	MUT		Responsive	DNMT3A oncogenic mutation	RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	DNMT3A		AML	PMID:22417203									
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA									
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		DPYD:p.I560S	ENST00000370192	DPYD	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	c.1679T>G	chr1:g.97981343A>C
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Capecitabine	Fluoropyrimidine	Capecitabine (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		DPYD:p.D949V	ENST00000370192	DPYD	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	c.2846A>T	chr1:g.97547947T>A
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA									
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		DPYD:p.I560S	ENST00000370192	DPYD	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	c.1679T>G	chr1:g.97981343A>C
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Flourouracil	Fluoropyrimidine	Flourouracil (Fluoropyrimidine)	Approved	FDA guidelines	DPYD		CANCER	FDA		DPYD:p.D949V	ENST00000370192	DPYD	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	c.2846A>T	chr1:g.97547947T>A
DPYD:.	BIA		Increased Toxicity	DPYD biallelic inactivation	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	PMID:23988873									
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	PMID:23988873		DPYD:p.I560S	ENST00000370192	DPYD	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=ATT;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr1:g.97981342_97981343delAAinsGC,chr1:g.97981343_97981344delATinsGA,chr1:g.97981342_97981344delAATinsCGA,chr1:g.97981342_97981344delAATinsGGA,chr1:g.97981342_97981344delAATinsTGA;aliases=ENSP00000359211;source=Ensembl	c.1679T>G	chr1:g.97981343A>C
DPYD:I560S,D949V	MUT		Increased Toxicity	DPYD (I560S,D949V)	DTamborero;CRubio-Perez	Tegafur	Fluoropyrimidine	Tegafur (Fluoropyrimidine)	Approved	CPIC guidelines	DPYD		CANCER	PMID:23988873		DPYD:p.D949V	ENST00000370192	DPYD	-	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=GAT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr1:g.97547946_97547947delATinsTA,chr1:g.97547946_97547947delATinsGA,chr1:g.97547946_97547947delATinsCA;aliases=ENSP00000359211;source=Ensembl	c.2846A>T	chr1:g.97547947T>A
EGFR:T790M	MUT		Resistant	EGFR (T790M)	DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Late trials	EGFR		NSCLC	PMID:19680293		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:D761Y	MUT		Resistant	EGFR (D761Y)	DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Case report	EGFR		NSCLC	PMID:19680293		EGFR:p.D761Y	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr7:g.55242511_55242513delGATinsTAC;aliases=ENSP00000275493;source=Ensembl	c.2281G>T	chr7:g.55242511G>T
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	EGFR		G	PMID:16282176;PMID:16278407									
EGFR:T790M	MUT		Resistant	EGFR (T790M)	DTamborero	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Late trials	EGFR		NSCLC	PMID:22452896		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		Early trials	EGFR		G	PMID:16282176;PMID:16278407									
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		L	ASCO 2014 (abstr 8009);ENA 2014 (abstr 10LBA);ENA 2014 (abstr 9LBA);ASCO 2015 (abstr 8001)		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		G	PMID:16282176;PMID:16278407									
EGFR:C797S	MUT		Resistant	EGFR (C797S)	RDientsmann	[]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens		Early trials	EGFR		L	PMID:25939061		EGFR:p.C797S	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr7:g.55249092G>C;candidate_mnv_variants=chr7:g.55249091_55249093delTGCinsAGT,chr7:g.55249092_55249093delGCinsCT,chr7:g.55249092_55249093delGCinsCG,chr7:g.55249092_55249093delGCinsCA;aliases=ENSP00000275493;source=Ensembl	c.2389T>A	chr7:g.55249091T>A
EGFR:T790M	MUT		Responsive	EGFR (T790M)	CRubio-Perez;RDientsmann	[Rociletinib,HM61713]	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Rociletinib,HM61713,etc)		Late trials	EGFR		NSCLC	NCT02322281		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:amp	CNA		Responsive	EGFR amplification	RDientsmann	[]	[EGFR inhibitor]	EGFR inhibitors		Case report	EGFR		HNSC	PMID:26763254									
EGFR:amp	CNA		Responsive	EGFR amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	EGFR		COREAD	PMID:18794099;PMID:17664472									
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Late trials	EGFR		L	PMID:22753918		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	EGFR		L	ESMO 2012 (abstr 4380)		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R,T790M)	RDientsmann	[]	[MEK inhibitor (alone or in combination)]	MEK inhibitor (alone or in combination)s		Pre-clinical	EGFR		L	PMID:23102728		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:S492R	MUT		Responsive	EGFR (S492R)	RDientsmann	[]	[novel EGFR mAb inhibitor]	novel EGFR mAb inhibitors		Early trials	EGFR		COREAD	PMID:25962717		EGFR:p.S492R	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	c.1476C>G	chr7:g.55228009C>G
EGFR:L798I	MUT		Resistant	EGFR (L798I)	RDientsmann	Rociletinib	EGFR inhibitor	Rociletinib (EGFR inhibitor)		Case report	EGFR		LUAD	PMID:27283993		EGFR:p.L798I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=CTC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249094_55249096delCTCinsATA,chr7:g.55249094_55249096delCTCinsATT;aliases=ENSP00000275493;source=Ensembl	c.2392C>A	chr7:g.55249094C>A
EGFR:T790M	MUT		Resistant	EGFR (T790M)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		NCCN/CAP guidelines	EGFR		L	NCCN		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:S720.	MUT		No Responsive	EGFR (S720)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:26773740									
EGFR:K757R,E746G	MUT		Responsive	EGFR (K757R,E746G)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:26773740		EGFR:p.K757R	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=AAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55242500_55242501delAGinsGA,chr7:g.55242499_55242500delAAinsCG,chr7:g.55242499_55242501delAAGinsCGA,chr7:g.55242499_55242501delAAGinsCGC,chr7:g.55242499_55242501delAAGinsCGT;aliases=ENSP00000275493;source=Ensembl	c.2270A>G	chr7:g.55242500A>G
EGFR:K757R,E746G	MUT		Responsive	EGFR (K757R,E746G)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:26773740		EGFR:p.E746G	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.55242467_55242468delAAinsGT,chr7:g.55242467_55242468delAAinsGG,chr7:g.55242467_55242468delAAinsGC;aliases=ENSP00000275493;source=Ensembl	c.2237A>G	chr7:g.55242467A>G
EGFR__RAD51	FUS		Responsive	EGFR-RAD51 fusion	EArriola	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		NSCLC	PMID:27102076									
EGFR__RAD51	FUS		Responsive	EGFR-RAD51 fusion	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Case report	EGFR		L	PMID:27102076									
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		L	ASCO2015(abstre19028)									
EGFR:L858R	MUT		Responsive	EGFR (L858R)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861.,G719.,S768I	MUT		Responsive	EGFR (L858R,L861,G719,S768I)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	NCCN		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861.,G719.,S768I	MUT		Responsive	EGFR (L858R,L861,G719,S768I)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	NCCN		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861.,G719.,S768I	MUT		Responsive	EGFR (L858R,L861,G719,S768I)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	NCCN		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861.,G719.,S768I	MUT		Responsive	EGFR (L858R,L861,G719,S768I)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	NCCN		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		EGFR:p.A289V	ENST00000275493	EGFR	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.55221822_55221823delCCinsTA,chr7:g.55221822_55221823delCCinsTG,chr7:g.55221822_55221823delCCinsTT;aliases=ENSP00000275493;source=Ensembl	c.866C>T	chr7:g.55221822C>T
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		EGFR:p.R108K	ENST00000275493	EGFR	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.55211080_55211081delGAinsAG;aliases=ENSP00000275493;source=Ensembl	c.323G>A	chr7:g.55211080G>A
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		EGFR:p.G598V	ENST00000275493	EGFR	+	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GGA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr7:g.55233043_55233044delGAinsTC,chr7:g.55233043_55233044delGAinsTG,chr7:g.55233043_55233044delGAinsTT;aliases=ENSP00000275493;source=Ensembl	c.1793G>T	chr7:g.55233043G>T
EGFR:A289V,R108K,G598V,T263P	MUT		Responsive	EGFR (A289V,R108K,G598V,T263P)	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)	Approved	Pre-clinical	EGFR		G	PMID:17177598		EGFR:p.T263P	ENST00000275493	EGFR	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=ACC;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55221743_55221745delACCinsCCT,chr7:g.55221743_55221745delACCinsCCG,chr7:g.55221743_55221745delACCinsCCA;aliases=ENSP00000275493;source=Ensembl	c.787A>C	chr7:g.55221743A>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:V843I	MUT		No Responsive	EGFR (V843I)	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Case report	EGFR		HNC	PMID:21274259		EGFR:p.V843I	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55259469_55259471delGTAinsATC,chr7:g.55259469_55259471delGTAinsATT;aliases=ENSP00000275493;source=Ensembl	c.2527G>A	chr7:g.55259469G>A
EGFR:amp	CNA		No Responsive	EGFR amplification	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Early trials	EGFR		HNC	PMID:21274259;PMID:22261807									
EGFR:amp	CNA		Responsive	EGFR amplification	RDientsmann	Gefitinib	EGFR inhibitor 1st gen	Gefitinib (EGFR inhibitor 1st gen)	Approved	Late trials	EGFR		ED	PMID:24950987									
EGFR:L858R	MUT		Responsive	EGFR (L858R)	CRubio-Perez	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	Early trials	EGFR		L	NCT02465060		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	Osimertinib	EGFR inhibitor 3rd gen	Osimertinib (EGFR inhibitor 3rd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:P546S	MUT		Responsive	EGFR (P546S)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		HNC	PMID:23578570		EGFR:p.P546S	ENST00000275493	EGFR	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=CCA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55231430_55231432delCCAinsTCT,chr7:g.55231430_55231432delCCAinsTCG,chr7:g.55231430_55231432delCCAinsTCC,chr7:g.55231430_55231432delCCAinsAGC,chr7:g.55231430_55231432delCCAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.1636C>T	chr7:g.55231430C>T
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		EGFR:p.S492R	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	c.1476C>G	chr7:g.55228009C>G
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		EGFR:p.G465R	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	c.1393G>A	chr7:g.55227926G>A
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		EGFR:p.R451C	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55227884_55227886delCGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.1351C>T	chr7:g.55227884C>T
EGFR:S492R,G465R,R451C,K467T	MUT		Resistant	EGFR (S492R,G465R,R451C,K467T)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724;PMID:26059438;PMID:25623215;PMID:22270724;PMID:26888827		EGFR:p.K467T	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=AAA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.55227933_55227934delAAinsCG,chr7:g.55227933_55227934delAAinsCT,chr7:g.55227933_55227934delAAinsCC;aliases=ENSP00000275493;source=Ensembl	c.1400A>C	chr7:g.55227933A>C
EGFR:over	EXPR		Responsive	EGFR overexpression	CRubio-Perez	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	FDA guidelines	EGFR		COREAD	FDA									
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	PMID:25623215		EGFR:p.S464L	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=TCA;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.55227923_55227924delTCinsCT,chr7:g.55227924_55227925delCAinsTG,chr7:g.55227923_55227925delTCAinsCTT,chr7:g.55227923_55227925delTCAinsCTG,chr7:g.55227923_55227925delTCAinsCTC;aliases=ENSP00000275493;source=Ensembl	c.1391C>T	chr7:g.55227924C>T
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	PMID:25623215		EGFR:p.G465R	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	c.1393G>A	chr7:g.55227926G>A
EGFR:S464L,G465R,I491M	MUT		Resistant	EGFR (S464L,G465R,I491M)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Pre-clinical	EGFR		COREAD	PMID:25623215		EGFR:p.I491M	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATA;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.1473A>G	chr7:g.55228006A>G
EGFR:S492R	MUT		Responsive	EGFR (S492R)	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:22270724		EGFR:p.S492R	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=AGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55228009C>A,chr7:g.55228007A>C;candidate_mnv_variants=chr7:g.55228007_55228009delAGCinsCGA,chr7:g.55228007_55228009delAGCinsCGG,chr7:g.55228007_55228009delAGCinsCGT;aliases=ENSP00000275493;source=Ensembl	c.1476C>G	chr7:g.55228009C>G
EGFR:G465R	MUT		Resistant	EGFR (G465R)	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	EGFR		COREAD	PMID:26059438		EGFR:p.G465R	ENST00000275493	EGFR	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr7:g.55227926G>C;candidate_mnv_variants=chr7:g.55227926_55227928delGGAinsAGG,chr7:g.55227926_55227928delGGAinsCGC,chr7:g.55227926_55227928delGGAinsCGG,chr7:g.55227926_55227928delGGAinsCGT;aliases=ENSP00000275493;source=Ensembl	c.1393G>A	chr7:g.55227926G>A
EGFR:over	EXPR		Resistant	EGFR overexpression	CRubio-Perez;RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	FDA guidelines	EGFR		COREAD	FDA guidelines									
EGFR:P753S	MUT		Responsive	EGFR (P753S)	RDientsmann	Cetuximab;Sirolimus	EGFR mAb inhibitor;MTOR inhibitor	Cetuximab + Sirolimus (EGFR mAb inhibitor + MTOR inhibitor)		Case report	EGFR		HNC	PMID:24934779		EGFR:p.P753S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242487_55242489delCCGinsTCT,chr7:g.55242487_55242489delCCGinsTCC,chr7:g.55242487_55242489delCCGinsTCA,chr7:g.55242487_55242489delCCGinsAGC,chr7:g.55242487_55242489delCCGinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2257C>T	chr7:g.55242487C>T
EGFR:E690K	MUT		Responsive	EGFR (E690K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)	Approved	Case report	EGFR		ED	PMID:22885469		EGFR:p.E690K	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr7:g.55241620_55241622delGAGinsAAA;aliases=ENSP00000275493;source=Ensembl	c.2068G>A	chr7:g.55241620G>A
EGFR:T790M	MUT		Resistant	EGFR (T790M)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)		NCCN/CAP guidelines	EGFR		L	NCCN		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	FDA guidelines	EGFR		NSCLC	FDA		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R	MUT		Responsive	EGFR (L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861Q,L861R)	RDientsmann	Afatinib	ERBB2 inhibitor&EGFR inhibitor 2nd gen	Afatinib (ERBB2 inhibitor&EGFR inhibitor 2nd gen)	Approved	NCCN guidelines	EGFR		NSCLC	FDA		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.L858R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259514_55259515delCTinsAG,chr7:g.55259515_55259516delTGinsGA,chr7:g.55259515_55259516delTGinsGC,chr7:g.55259515_55259516delTGinsGT,chr7:g.55259514_55259516delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2573T>G	chr7:g.55259515T>G
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.L861Q	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsAA;aliases=ENSP00000275493;source=Ensembl	c.2582T>A	chr7:g.55259524T>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.G719A	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsCA,chr7:g.55241708_55241709delGCinsCG,chr7:g.55241708_55241709delGCinsCT;aliases=ENSP00000275493;source=Ensembl	c.2156G>C	chr7:g.55241708G>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.G719S	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsAGT,chr7:g.55241707_55241708delGGinsTC,chr7:g.55241707_55241709delGGCinsTCT,chr7:g.55241707_55241709delGGCinsTCG,chr7:g.55241707_55241709delGGCinsTCA;aliases=ENSP00000275493;source=Ensembl	c.2155G>A	chr7:g.55241707G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.G719C	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.55241707_55241709delGGCinsTGT;aliases=ENSP00000275493;source=Ensembl	c.2155G>T	chr7:g.55241707G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.G719D	ENST00000275493	EGFR	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr7:g.55241708_55241709delGCinsAT;aliases=ENSP00000275493;source=Ensembl	c.2156G>A	chr7:g.55241708G>A
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.L747S	ENST00000275493	EGFR	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTA;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr7:g.55242470_55242471delTAinsCT,chr7:g.55242470_55242471delTAinsCG,chr7:g.55242470_55242471delTAinsCC,chr7:g.55242469_55242471delTTAinsAGC,chr7:g.55242469_55242471delTTAinsAGT;aliases=ENSP00000275493;source=Ensembl	c.2240T>C	chr7:g.55242470T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.S768I	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=AGC;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.55249005_55249006delGCinsTA,chr7:g.55249005_55249006delGCinsTT;aliases=ENSP00000275493;source=Ensembl	c.2303G>T	chr7:g.55249005G>T
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.L861P	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr7:g.55259524_55259525delTGinsCT,chr7:g.55259524_55259525delTGinsCA,chr7:g.55259524_55259525delTGinsCC;aliases=ENSP00000275493;source=Ensembl	c.2582T>C	chr7:g.55259524T>C
EGFR:L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R	MUT		Responsive	EGFR (L858R,L861Q,G719A,G719S,G719C,G719D,L747S,S768I,L861P,L861R)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	ESMO 2012 (abstr 1289)		EGFR:p.L861R	ENST00000275493	EGFR	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=CTG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.55259523_55259524delCTinsAG,chr7:g.55259524_55259525delTGinsGA,chr7:g.55259524_55259525delTGinsGC,chr7:g.55259524_55259525delTGinsGT,chr7:g.55259523_55259525delCTGinsAGA;aliases=ENSP00000275493;source=Ensembl	c.2582T>G	chr7:g.55259524T>G
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	Afatinib;Cetuximab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Cetuximab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	PMID:25074459		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EGFR:T790M	MUT		Responsive	EGFR (T790M)	RDientsmann	Afatinib;Nimotuzumab	ERBB2 inhibitor&EGFR inhibitor 2nd gen;EGFR mAb inhibitor	Afatinib + Nimotuzumab (ERBB2 inhibitor&EGFR inhibitor 2nd gen + EGFR mAb inhibitor)		Early trials	EGFR		L	PMID:26667485		EGFR:p.T790M	ENST00000275493	EGFR	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=ACG;candidate_codons=ATG;aliases=ENSP00000275493;source=Ensembl	c.2369C>T	chr7:g.55249071C>T
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	EPHA2		LUSC	PMID:20360610		EPHA2:p.G391R	ENST00000358432	EPHA2	-	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	c.1171G>A	chr1:g.16464489C>T
EPHA2:amp	CNA		Responsive	EPHA2 amplification	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		CANCER	PMID:18047674;PMID:19010823;PMID:19861960									
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		LUSC	PMID:20360610		EPHA2:p.G391R	ENST00000358432	EPHA2	-	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	c.1171G>A	chr1:g.16464489C>T
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	EPHA2		LUSC	PMID:20360610		EPHA2:p.G391R	ENST00000358432	EPHA2	-	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	c.1171G>A	chr1:g.16464489C>T
EPHA2:amp	CNA		Responsive	EPHA2 amplification	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		CANCER	PMID:18047674;PMID:19010823;PMID:19861960									
EPHA2:G391R	MUT		Responsive	EPHA2 (G391R)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	EPHA2		LUSC	PMID:20360610		EPHA2:p.G391R	ENST00000358432	EPHA2	-	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.16464489C>G;candidate_mnv_variants=chr1:g.16464487_16464489delTCCinsCCT,chr1:g.16464487_16464489delTCCinsGCG,chr1:g.16464487_16464489delTCCinsCCG,chr1:g.16464487_16464489delTCCinsACG;aliases=ENSP00000351209;source=Ensembl	c.1171G>A	chr1:g.16464489C>T
EPHA3:amp	CNA		Responsive	EPHA3 amplification	RDientsmann	[]	[EPHA3 inhibitor]	EPHA3 inhibitors		Pre-clinical	EPHA3		CANCER	PMID:25125683									
EPHA3:amp	CNA		Responsive	EPHA3 amplification	RDientsmann	[]	[EPHA3 inhibitor]	EPHA3 inhibitors		Pre-clinical	EPHA3		CANCER	PMID:25125683									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB2		ST	AACR 2014 (abstr CT228)									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Lapatinib;Chemotherapy	ERBB2 inhibitor;Chemotherapy	Lapatinib + Chemotherapy (ERBB2 inhibitor + Chemotherapy)		Early trials	ERBB2		ST	PMID:25694417;NCT02015169									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		ST	PMID:24960402									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Late trials	ERBB2		COREAD	ASCO 2015 (abstr 3508);NCT01104571;EBCC10									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Pre-clinical	ERBB2		ED	PMID:25294905									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	[]	[ERBB2 inhibitor;CDK4/6 inhibitor]	ERBB2 inhibitor + CDK4/6 inhibitors		Pre-clinical	ERBB2		BRCA	PMID:26977878									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Ado-Trastuzumab Emtansine	EGFR mAb inhibitor	Ado-Trastuzumab Emtansine (EGFR mAb inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Late trials	ERBB2		BRCA	PMID:20142587;PMID:22418700;PMID:23632474									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann;CRubio-Perez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Late trials	ERBB2		BRCA	PMID:20142587;PMID:22418700;PMID:23632474									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann;CRubio-Perez	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		ST;GEJA	FDA									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann;CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;Everolimus;Chemotherapy	ERBB2 mAb inhibitor;MTOR inhibitor;Chemotherapy	Trastuzumab + Everolimus + Chemotherapy (ERBB2 mAb inhibitor + MTOR inhibitor + Chemotherapy)		Early trials	ERBB2		BRCA	PMID:21107682;PMID:20975068									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab;HSP90 inhibitor	ERBB2 mAb inhibitor;HSP90 inhibitor	Trastuzumab + HSP90 inhibitor (ERBB2 mAb inhibitor + HSP90 inhibitor)		Early trials	ERBB2		BRCA	PMID:21558407									
ERBB2:K753E	MUT		Responsive	ERBB2 (K753E)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:27697991		ERBB2:p.K753E	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37880213_37880215delAAAinsGAG;aliases=ENSP00000269571;source=Ensembl	c.2257A>G	chr17:g.37880213A>G
ERBB2:K753E	MUT		Resistant	ERBB2 (K753E)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:27697991		ERBB2:p.K753E	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37880213_37880215delAAAinsGAG;aliases=ENSP00000269571;source=Ensembl	c.2257A>G	chr17:g.37880213A>G
ERBB2:amp	CNA		Resistant	ERBB2 amplification	EArriola	[]	[EGFR inhibitor]	EGFR inhibitors		Pre-clinical	ERBB2		LUAD	PMID:22956644									
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation	EArriola	Dacomitinib	Pan ERBB inhibitor	Dacomitinib (Pan ERBB inhibitor)		Early trials	ERBB2		NSCLC	PMID:25899785									
ERBB2:amp	CNA		Resistant	ERBB2 amplification	EArriola	Osimertinib	3rd generation EGFR inhibitor	Osimertinib (3rd generation EGFR inhibitor)	Approved	Case report	ERBB2		LUAD	PMID:27252416									
ERBB2:amp	CNA		Resistant	ERBB2 amplification	EArriola	Rociletinib	3rd generation EGFR inhibitor	Rociletinib (3rd generation EGFR inhibitor)		Case report	ERBB2		LUAD	PMID:27252416									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB2		BLCA	PMID:27044931									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	ERBB2		BT	ASCO 2015 (abstr e15137)									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		BT	ASCO 2015 (abstr e15137)									
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		BT	ASCO 2015 (abstr e15137)									
ERBB2:amp	CNA		Resistant	ERBB2 amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	ERBB2		COREAD	PMID:22586653;PMID:23348520									
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Ado-Trastuzumab Emtansine	ERBB2 mAb inhibitor	Ado-Trastuzumab Emtansine (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.D769Y	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	c.2305G>T	chr17:g.37880261G>T
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.D769H	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	c.2305G>C	chr17:g.37880261G>C
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.R896C	ENST00000269571	ERBB2	+	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	c.2686C>T	chr17:g.37881616C>T
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.V777L	ENST00000269571	ERBB2	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr17:g.37881000G>T;candidate_mnv_variants=chr17:g.37881000_37881002delGTGinsCTT,chr17:g.37881000_37881002delGTGinsCTA,chr17:g.37881000_37881002delGTGinsCTC,chr17:g.37881000_37881002delGTGinsTTA;aliases=ENSP00000269571;source=Ensembl	c.2329G>C	chr17:g.37881000G>C
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.V842I	ENST00000269571	ERBB2	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881332_37881334delGTAinsATC,chr17:g.37881332_37881334delGTAinsATT;aliases=ENSP00000269571;source=Ensembl	c.2524G>A	chr17:g.37881332G>A
ERBB2:D769Y,D769H,R896C,V777L,V842I,G309A	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,V777L,V842I,G309A)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.G309A	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsCC,chr17:g.37868205_37868206delGAinsCG,chr17:g.37868205_37868206delGAinsCT;aliases=ENSP00000269571;source=Ensembl	c.926G>C	chr17:g.37868205G>C
ERBB2:V659E	MUT		Responsive	ERBB2 (V659E)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Case report	ERBB2		BRCA;LUAD	PMID:23950206		ERBB2:p.V659E	ENST00000269571	ERBB2	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GTT;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37879601_37879602delTTinsAA;aliases=ENSP00000269571;source=Ensembl	c.1976_1977delTTinsAG	chr17:g.37879601_37879602delTTinsAG
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	DCasadevall	MK2206;Trastuzumab	Allosteric AKT inhibitor;ERBB2 mAb inhibitor	MK2206 + Trastuzumab (Allosteric AKT inhibitor + ERBB2 mAb inhibitor)		Early trials	ERBB2		SOLID	ASCO 2013 (abstr 2605);PMID:26104654									
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.L755S	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=TTG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr17:g.37880220_37880221delTGinsCT,chr17:g.37880220_37880221delTGinsCC,chr17:g.37880220_37880221delTGinsCA,chr17:g.37880219_37880221delTTGinsAGC,chr17:g.37880219_37880221delTTGinsAGT;aliases=ENSP00000269571;source=Ensembl	c.2264T>C	chr17:g.37880220T>C
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.G309A	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GGA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsCC,chr17:g.37868205_37868206delGAinsCG,chr17:g.37868205_37868206delGAinsCT;aliases=ENSP00000269571;source=Ensembl	c.926G>C	chr17:g.37868205G>C
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.D769Y	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	c.2305G>T	chr17:g.37880261G>T
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.D769H	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	c.2305G>C	chr17:g.37880261G>C
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.R896C	ENST00000269571	ERBB2	+	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	c.2686C>T	chr17:g.37881616C>T
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.V777L	ENST00000269571	ERBB2	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=GTG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr17:g.37881000G>T;candidate_mnv_variants=chr17:g.37881000_37881002delGTGinsCTT,chr17:g.37881000_37881002delGTGinsCTA,chr17:g.37881000_37881002delGTGinsCTC,chr17:g.37881000_37881002delGTGinsTTA;aliases=ENSP00000269571;source=Ensembl	c.2329G>C	chr17:g.37881000G>C
ERBB2:L755S,G309A,D769Y,D769H,R896C,V777L,V842I	MUT		Responsive	ERBB2 (L755S,G309A,D769Y,D769H,R896C,V777L,V842I)	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Pre-clinical	ERBB2		BRCA	PMID:23220880		ERBB2:p.V842I	ENST00000269571	ERBB2	+	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr17:g.37881332_37881334delGTAinsATC,chr17:g.37881332_37881334delGTAinsATT;aliases=ENSP00000269571;source=Ensembl	c.2524G>A	chr17:g.37881332G>A
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation	RDientsmann	Neratinib	ERBB2 inhibitor	Neratinib (ERBB2 inhibitor)		Early trials	ERBB2		LUAD	ESMO 2014 (abstr LBA39_PR)									
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:.	MUT		Responsive	ERBB2 oncogenic mutation	RDientsmann	Tensirolimus	MTOR inhibitor	Tensirolimus (MTOR inhibitor)		Early trials	ERBB2		LUAD	ESMO 2014 (abstr LBA39_PR)									
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		BRCA	FDA									
ERBB2:over	EXPR		Responsive	ERBB2 overexpression	CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)	Approved	FDA guidelines	ERBB2		ST;GEJA	FDA									
ERBB2:amp	CNA		No Responsive	ERBB2 amplification	DTamborero;RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		ED	PMID:26099744;PMID:19840887									
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		ERBB2:p.D769Y	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsTAT;aliases=ENSP00000269571;source=Ensembl	c.2305G>T	chr17:g.37880261G>T
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		ERBB2:p.D769H	ENST00000269571	ERBB2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.37880261_37880263delGACinsCAT;aliases=ENSP00000269571;source=Ensembl	c.2305G>C	chr17:g.37880261G>C
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		ERBB2:p.R896C	ENST00000269571	ERBB2	+	inside_[cds_in_exon_22]	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr17:g.37881616_37881618delCGCinsTGT;aliases=ENSP00000269571;source=Ensembl	c.2686C>T	chr17:g.37881616C>T
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		ERBB2:p.G309E	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsAG;aliases=ENSP00000269571;source=Ensembl	c.926G>A	chr17:g.37868205G>A
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		ERBB2:p.S310F	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	c.929C>T	chr17:g.37868208C>T
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		ERBB2:p.S310Y	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsAT;aliases=ENSP00000269571;source=Ensembl	c.929C>A	chr17:g.37868208C>A
ERBB2:D769Y,D769H,R896C,G309E,S310F,S310Y,C311R	MUT		Responsive	ERBB2 (D769Y,D769H,R896C,G309E,S310F,S310Y,C311R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		BRCA;CANCER	PMID:23220880;PMID:22908275		ERBB2:p.C311R	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37868210_37868212delTGCinsAGG,chr17:g.37868210_37868212delTGCinsAGA,chr17:g.37868210_37868212delTGCinsCGA,chr17:g.37868210_37868212delTGCinsCGG,chr17:g.37868210_37868212delTGCinsCGT;aliases=ENSP00000269571;source=Ensembl	c.931T>C	chr17:g.37868210T>C
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		ERBB2:p.G309E	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GGA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr17:g.37868205_37868206delGAinsAG;aliases=ENSP00000269571;source=Ensembl	c.926G>A	chr17:g.37868205G>A
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		ERBB2:p.S310F	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsTT;aliases=ENSP00000269571;source=Ensembl	c.929C>T	chr17:g.37868208C>T
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		ERBB2:p.S310Y	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TCC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr17:g.37868208_37868209delCCinsAT;aliases=ENSP00000269571;source=Ensembl	c.929C>A	chr17:g.37868208C>A
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		ERBB2:p.C311R	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr17:g.37868210_37868212delTGCinsAGG,chr17:g.37868210_37868212delTGCinsAGA,chr17:g.37868210_37868212delTGCinsCGA,chr17:g.37868210_37868212delTGCinsCGG,chr17:g.37868210_37868212delTGCinsCGT;aliases=ENSP00000269571;source=Ensembl	c.931T>C	chr17:g.37868210T>C
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		ERBB2:p.E321G	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr17:g.37868241_37868242delAGinsGT,chr17:g.37868241_37868242delAGinsGA,chr17:g.37868241_37868242delAGinsGC;aliases=ENSP00000269571;source=Ensembl	c.962A>G	chr17:g.37868241A>G
ERBB2:G309E,S310F,S310Y,C311R,E321G,C334S	MUT		Responsive	ERBB2 (G309E,S310F,S310Y,C311R,E321G,C334S)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB2		CANCER	PMID:22908275		ERBB2:p.C334S	ENST00000269571	ERBB2	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr17:g.37868280G>C;candidate_mnv_variants=chr17:g.37868279_37868281delTGCinsAGT,chr17:g.37868280_37868281delGCinsCT,chr17:g.37868280_37868281delGCinsCG,chr17:g.37868280_37868281delGCinsCA;aliases=ENSP00000269571;source=Ensembl	c.1000T>A	chr17:g.37868279T>A
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Case report	ERBB2		HNC	PMID:21380780									
ERBB2:G776L	MUT		Responsive	ERBB2 (G776L)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Case report	ERBB2		LUAD	PMID:16775247		ERBB2:p.G776L	ENST00000269571	ERBB2	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=GGT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr17:g.37880997_37880999delGGTinsCTG,chr17:g.37880997_37880999delGGTinsCTA,chr17:g.37880997_37880999delGGTinsCTC,chr17:g.37880997_37880999delGGTinsTTA,chr17:g.37880997_37880999delGGTinsTTG;aliases=ENSP00000269571;source=Ensembl	c.2326_2327delGGinsCT	chr17:g.37880997_37880998delGGinsCT
ERBB2:amp	CNA		Responsive	ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	ERBB2		OV	PMID:20003286;PMID:12525520									
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	DTamborero;CRubio-Perez	Abemaciclib	CDK4/6 inhibitor	Abemaciclib (CDK4/6 inhibitor)		Early trials	ERBB2;ESR1		BRCA	PMID:26658964									
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	JAlbanell;ARovira	[Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist]	[Hormonal therapy]	Hormonal therapys (Tamoxifen,Letrozole,Anastrozole,Exemestane,Fulvestrant,LHRH analogues or antagonist,etc)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	FDA									
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	JAlbanell;ARovira	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	FDA									
ERBB2:norm;ESR1:over	EXPR;EXPR		Responsive	ERBB2 expression + ESR1 overexpression	CRubio-Perez	Palbociclib	CDK4/6 inhibitor	Palbociclib (CDK4/6 inhibitor)	Approved	FDA guidelines	ERBB2;ESR1		BRCA	FDA									
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	PMID:27044931		ERBB3:p.G284R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	c.850G>A	chr12:g.56481922G>A
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	PMID:27044931		ERBB3:p.V104M	ENST00000267101	ERBB3	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000267101;source=Ensembl	c.310G>A	chr12:g.56478854G>A
ERBB3:G284R,V104M,R103G	MUT		Responsive	ERBB3 (G284R,V104M,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	PMID:27044931		ERBB3:p.R103G	ENST00000267101	ERBB3	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CGC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr12:g.56478851_56478853delCGCinsGGT,chr12:g.56478851_56478853delCGCinsGGG,chr12:g.56478851_56478853delCGCinsGGA;aliases=ENSP00000267101;source=Ensembl	c.307C>G	chr12:g.56478851C>G
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	[]	[ERBB3 mAb inhibitor]	ERBB3 mAb inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.P262H	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	c.785C>A	chr12:g.56481857C>A
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	[]	[ERBB3 mAb inhibitor]	ERBB3 mAb inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.G284R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	c.850G>A	chr12:g.56481922G>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.P262H	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	c.785C>A	chr12:g.56481857C>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.G284R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	c.850G>A	chr12:g.56481922G>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.Q809R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	c.2426A>G	chr12:g.56490980A>G
ERBB3:amp	CNA		Resistant	ERBB3 amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	ERBB3		COREAD	PMID:25520391									
ERBB3:G284R,R103G	MUT		Responsive	ERBB3 (G284R,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	ASCO 2015 (abstr e15516)		ERBB3:p.G284R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	c.850G>A	chr12:g.56481922G>A
ERBB3:G284R,R103G	MUT		Responsive	ERBB3 (G284R,R103G)	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	ERBB3		BLCA	ASCO 2015 (abstr e15516)		ERBB3:p.R103G	ENST00000267101	ERBB3	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CGC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr12:g.56478851_56478853delCGCinsGGT,chr12:g.56478851_56478853delCGCinsGGG,chr12:g.56478851_56478853delCGCinsGGA;aliases=ENSP00000267101;source=Ensembl	c.307C>G	chr12:g.56478851C>G
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.P262H	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	c.785C>A	chr12:g.56481857C>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.G284R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	c.850G>A	chr12:g.56481922G>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.Q809R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	c.2426A>G	chr12:g.56490980A>G
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.P262H	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	c.785C>A	chr12:g.56481857C>A
ERBB3:P262H,G284R	MUT		Responsive	ERBB3 (P262H,G284R)	RDientsmann	Pertuzumab	ERBB2 mAb inhibitor	Pertuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.G284R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	c.850G>A	chr12:g.56481922G>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.P262H	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CCT;candidate_codons=CAT,CAC;candidate_mnv_variants=chr12:g.56481857_56481858delCTinsAC;aliases=ENSP00000267101;source=Ensembl	c.785C>A	chr12:g.56481857C>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.G284R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr12:g.56481922G>C;candidate_mnv_variants=chr12:g.56481922_56481924delGGAinsAGG,chr12:g.56481922_56481924delGGAinsCGC,chr12:g.56481922_56481924delGGAinsCGG,chr12:g.56481922_56481924delGGAinsCGT;aliases=ENSP00000267101;source=Ensembl	c.850G>A	chr12:g.56481922G>A
ERBB3:P262H,G284R,Q809R	MUT		Responsive	ERBB3 (P262H,G284R,Q809R)	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Pre-clinical	ERBB3		CANCER	PMID:23680147		ERBB3:p.Q809R	ENST00000267101	ERBB3	+	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=CAG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr12:g.56490979_56490980delCAinsAG,chr12:g.56490980_56490981delAGinsGA,chr12:g.56490980_56490981delAGinsGC,chr12:g.56490980_56490981delAGinsGT,chr12:g.56490979_56490981delCAGinsAGA;aliases=ENSP00000267101;source=Ensembl	c.2426A>G	chr12:g.56490980A>G
ERBB4:H809G	MUT		Resistant	ERBB4 (H809G)	RDientsmann	[Lapatinib]	[ERBB2 inhibitor]	ERBB2 inhibitors (Lapatinib,etc)		Case report	ERBB4		BRCA	PMID:26530965		ERBB4:p.H809G	ENST00000342788	ERBB4	-	inside_[cds_in_exon_20]	CSQN=Missense;reference_codon=CAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr2:g.212426688_212426690delGTGinsACC,chr2:g.212426688_212426690delGTGinsCCC,chr2:g.212426688_212426690delGTGinsTCC;aliases=ENSP00000342235;source=Ensembl	c.2425_2426delCAinsGG	chr2:g.212426689_212426690delTGinsCC
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		ERBB4:p.E317K	ENST00000342788	ERBB4	-	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212578306_212578308delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	c.949G>A	chr2:g.212578308C>T
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		ERBB4:p.E452K	ENST00000342788	ERBB4	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212566825_212566827delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	c.1354G>A	chr2:g.212566827C>T
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		ERBB4:p.R544W	ENST00000342788	ERBB4	-	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000342235;source=Ensembl	c.1630C>T	chr2:g.212537975G>A
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		ERBB4:p.R393W	ENST00000342788	ERBB4	-	inside_[cds_in_exon_10]	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000342235;source=Ensembl	c.1177C>T	chr2:g.212570064G>A
ERBB4:E317K,E452K,R544W,R393W,E872K	MUT		Responsive	ERBB4 (E317K,E452K,R544W,R393W,E872K)	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	ERBB4		CM	PMID:19718025		ERBB4:p.E872K	ENST00000342788	ERBB4	-	inside_[cds_in_exon_21]	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr2:g.212295697_212295699delTTCinsCTT;aliases=ENSP00000342235;source=Ensembl	c.2614G>A	chr2:g.212295699C>T
ERBB4__.	FUS		Responsive	ERBB4 fusion	RDientsmann	Lapatinib;Afatinib	ERBB2 inhibitor;ERBB2 inhibitor&EGFR inhibitor 2nd gen	Lapatinib + Afatinib (ERBB2 inhibitor + ERBB2 inhibitor&EGFR inhibitor 2nd gen)		Pre-clinical	ERBB4		LUAD	PMID:24727320									
ERCC1:.	MUT		Responsive	ERCC1 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC1		L	PMID:23275151;PMID:23934192									
ERCC1:del	CNA		Responsive	ERCC1 deletion	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC1		L	PMID:23275151;PMID:23934192									
ERCC1:over	EXPR		Resistant	ERCC1 overexpression	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Pre-clinical	ERCC1	BLCA	BLCA	PMID:20846399;PMID:21177407									
ERCC1:.	MUT		Responsive	ERCC1 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ERCC1		L	PMID:23934192									
ERCC1:del	CNA		Responsive	ERCC1 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	ERCC1		L	PMID:23934192									
ERCC2:.	MUT		Responsive	ERCC2 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	ERCC2		BLCA	PMID:25096233									
ERCC4:.	MUT		Responsive	ERCC4 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC4		OV	PMID:25634215									
ERCC6:.	MUT		Responsive	ERCC6 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Pre-clinical	ERCC6		OV	PMID:25634215									
EREG:amp	CNA		Responsive	EREG amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	EREG		COREAD	PMID:19738126;PMID:26341080									
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Responsive	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	[GDC-0810]	[novel ER degrader]	novel ER degraders (GDC-0810,etc)		Case report	ESR1		BRCA	AACR 2015 (abstr CT231)		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Responsive	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	[GDC-0810]	[novel ER degrader]	novel ER degraders (GDC-0810,etc)		Case report	ESR1		BRCA	AACR 2015 (abstr CT231)		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Responsive	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	[GDC-0810]	[novel ER degrader]	novel ER degraders (GDC-0810,etc)		Case report	ESR1		BRCA	AACR 2015 (abstr CT231)		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Responsive	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	[GDC-0810]	[novel ER degrader]	novel ER degraders (GDC-0810,etc)		Case report	ESR1		BRCA	AACR 2015 (abstr CT231)		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Responsive	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	[GDC-0810]	[novel ER degrader]	novel ER degraders (GDC-0810,etc)		Case report	ESR1		BRCA	AACR 2015 (abstr CT231)		ESR1:p.P535H	ENST00000440973	ESR1	+	inside_[cds_in_exon_10]	CSQN=Missense;reference_codon=CCC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr6:g.152419917_152419918delCCinsAT;aliases=ENSP00000405330;source=Ensembl	c.1604C>A	chr6:g.152419917C>A
ESR1:.	MUT		Resistant	ESR1 oncogenic mutation	RDientsmann	Exemestane	Hormonal therapy	Exemestane (Hormonal therapy)		Late trials	ESR1		BRCA	PMID:27269946									
ESR1:.	MUT		Responsive	ESR1 oncogenic mutation	RDientsmann	Fluvestrant	Hormonal therapy	Fluvestrant (Hormonal therapy)		Late trials	ESR1		BRCA	PMID:27269946									
ESR1__YAP1	FUS		Resistant	ESR1-YAP1 fusion	RDientsmann	[]	[ESR1 inhibitor]	ESR1 inhibitors		Pre-clinical	ESR1		BRCA	PMID:24055055									
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Resistant	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Early trials	ESR1		BRCA	PMID:24185512;PMID:24185510;PMID:24398047		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Resistant	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Early trials	ESR1		BRCA	PMID:24185512;PMID:24185510;PMID:24398047		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Resistant	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Early trials	ESR1		BRCA	PMID:24185512;PMID:24185510;PMID:24398047		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Resistant	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Early trials	ESR1		BRCA	PMID:24185512;PMID:24185510;PMID:24398047		ESR1:p.E380Q	ENST00000440973	ESR1	+	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GAA;candidate_codons=CAA,CAG;candidate_mnv_variants=chr6:g.152332832_152332834delGAAinsCAG;aliases=ENSP00000405330;source=Ensembl	c.1138G>C	chr6:g.152332832G>C
ESR1:E380Q,.537.,.538.,L536.,P535H	MUT		Resistant	ESR1 (E380Q,537,538,L536,P535H)	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Early trials	ESR1		BRCA	PMID:24185512;PMID:24185510;PMID:24398047		ESR1:p.P535H	ENST00000440973	ESR1	+	inside_[cds_in_exon_10]	CSQN=Missense;reference_codon=CCC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr6:g.152419917_152419918delCCinsAT;aliases=ENSP00000405330;source=Ensembl	c.1604C>A	chr6:g.152419917C>A
EZH2:Y641.,A677.	MUT	Cell line	Responsive	EZH2 (Y641,A677)	RDientsmann;ECampo	[EPZ-005687,EPZ-6438]	[EZH2 inhibitor]	EZH2 inhibitors (EPZ-005687,EPZ-6438,etc)	Pre-clinical	Pre-clinical	EZH2		LY	PMID:23023262;PMID:24563539	Direct								
EZH2:Y641.,A677.	MUT	Cell line	Responsive	EZH2 (Y641,A677)	RDientsmann;ECampo	[EPZ-005687,EPZ-6438]	[EZH2 inhibitor]	EZH2 inhibitors (EPZ-005687,EPZ-6438,etc)	Pre-clinical	Pre-clinical	EZH2		LY	PMID:23023262;PMID:24563539	Direct								
FANCA:.	MUT		Responsive	FANCA oncogenic mutation	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	FANCA		PRAD	PMID:26510020									
FANCA:del	CNA		Responsive	FANCA deletion	RDientsmann	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	FANCA		PRAD	PMID:26510020									
FANCC:.	MUT		Responsive	FANCC oncogenic mutation	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	FANCC	BLCA	BLCA	PMID:26238431	Indirect								
FANCC:del	CNA		Responsive	FANCC deletion	ARodriguez-Vida	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	FANCC	BLCA	BLCA	PMID:26238431	Indirect								
FAT1:.	MUT		Responsive	FAT1 oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	FAT1		HNSC	PMID:27397505									
FBXW7:.	MUT		Responsive	FBXW7 oncogenic mutation	RDientsmann	[]	[Steroid]	Steroids		Late trials	FBXW7		ALL	PMID:20861909									
FBXW7:del	CNA		Resistant	FBXW7 deletion	RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	FBXW7		CANCER	PMID:21368834									
FBXW7:.	MUT		Resistant	FBXW7 oncogenic mutation	RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	FBXW7		CANCER	PMID:21368834									
FBXW7:del	CNA	Cell line	Responsive	FBXW7 deletion	CRubio-Perez	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)	Approved	Pre-clinical	FBXW7		COREAD	PMID:23558291	Indirect								
FGF3:amp	CNA		Responsive	FGF3 amplification	JAlbanell;ARovira	Lucitanib	FGFR inhibitor	Lucitanib (FGFR inhibitor)	Clinical Trials	Early trials	FGF3		BRCA	PMID:25193991	Indirect								
FGF3:amp	CNA		Responsive	FGF3 amplification	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Early trials	FGF3		BRCA	PMID:23658459									
FGF4:amp	CNA		Responsive	FGF4 amplification	JAlbanell;ARovira	Lucitanib	FGFR inhibitor	Lucitanib (FGFR inhibitor)	Clinical Trials	Early trials	FGF4		BRCA	PMID:25193991	Indirect								
FGF4:amp	CNA		Responsive	FGF4 amplification	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Early trials	FGF4		BRCA	PMID:23658459									
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR1		LUSC	AACR 2012 (abstr LB-122);AACR 2013 (abstr LB-145)									
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR1		HNC	PMID:23418312									
FGFR1:amp	CNA		Responsive	FGFR1 amplification	RDientsmann;JAlbanell	[Lucitanib]	[FGFR inhibitor]	FGFR inhibitors (Lucitanib,etc)		Early trials	FGFR1		BRCA	PMID:25193991									
FGFR2:amp	CNA		Responsive	FGFR2 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		ST	ASCO 2015 (abstr 2508)									
FGFR2:V565I	MUT		Responsive	FGFR2 (V565I)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	ENA 2014 (abstr 381)		FGFR2:p.V565I	ENST00000457416	FGFR2	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr10:g.123256217_123256219delAACinsGAT,chr10:g.123256217_123256219delAACinsTAT;aliases=ENSP00000410294;source=Ensembl	c.1693G>A	chr10:g.123256219C>T
FGFR2:amp	CNA		Responsive	FGFR2 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR2		BRCA	PMID:25193991									
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.M536I	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATG;candidate_codons=ATC,ATA,ATT;candidate_snv_variants=chr10:g.123258076C>T,chr10:g.123258076C>A;aliases=ENSP00000410294;source=Ensembl	c.1608G>C	chr10:g.123258076C>G
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.M538I	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATG;candidate_codons=ATC,ATA,ATT;candidate_snv_variants=chr10:g.123258070C>T,chr10:g.123258070C>A;aliases=ENSP00000410294;source=Ensembl	c.1614G>C	chr10:g.123258070C>G
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.I548V	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr10:g.123258040_123258042delGATinsTAC,chr10:g.123258040_123258042delGATinsCAC,chr10:g.123258040_123258042delGATinsAAC;aliases=ENSP00000410294;source=Ensembl	c.1642A>G	chr10:g.123258042T>C
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.I548V	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr10:g.123258040_123258042delGATinsTAC,chr10:g.123258040_123258042delGATinsCAC,chr10:g.123258040_123258042delGATinsAAC;aliases=ENSP00000410294;source=Ensembl	c.1642A>G	chr10:g.123258042T>C
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.E566G	ENST00000457416	FGFR2	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr10:g.123256214_123256215delCTinsAC,chr10:g.123256214_123256215delCTinsTC,chr10:g.123256214_123256215delCTinsGC;aliases=ENSP00000410294;source=Ensembl	c.1697A>G	chr10:g.123256215T>C
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.L618M	ENST00000457416	FGFR2	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000410294;source=Ensembl	c.1852T>A	chr10:g.123256060A>T
FGFR2:M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Responsive	FGFR2 (M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.K660E	ENST00000457416	FGFR2	-	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=AAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr10:g.123247514_123247516delCTTinsTTC;aliases=ENSP00000410294;source=Ensembl	c.1978A>G	chr10:g.123247516T>C
FGFR2__.	FUS		Responsive	FGFR2 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR2		BT	ASCO 2016 (abstr 109)									
FGFR2:S252W,N550K	MUT		Responsive	FGFR2 (S252W,N550K)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	PMID:18552176;PMID:22238366;PMID:23002168		FGFR2:p.S252W	ENST00000457416	FGFR2	-	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TCG;candidate_codons=TGG;aliases=ENSP00000410294;source=Ensembl	c.755C>G	chr10:g.123279677G>C
FGFR2:S252W,N550K	MUT		Responsive	FGFR2 (S252W,N550K)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		ED	PMID:18552176;PMID:22238366;PMID:23002168		FGFR2:p.N550K	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=AAT;candidate_codons=AAG,AAA;candidate_snv_variants=chr10:g.123258034A>T;aliases=ENSP00000410294;source=Ensembl	c.1650T>G	chr10:g.123258034A>C
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	PMID:23786770;PMID:25035393		FGFR2:p.W290C	ENST00000457416	FGFR2	-	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=TGG;candidate_codons=TGT,TGC;candidate_snv_variants=chr10:g.123279562C>G;aliases=ENSP00000410294;source=Ensembl	c.870G>T	chr10:g.123279562C>A
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	PMID:23786770;PMID:25035393		FGFR2:p.S320C	ENST00000457416	FGFR2	-	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=TCC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr10:g.123278323_123278324delGGinsAC;aliases=ENSP00000410294;source=Ensembl	c.959C>G	chr10:g.123278324G>C
FGFR2:W290C,S320C,K660N	MUT		Responsive	FGFR2 (W290C,S320C,K660N)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR2		LUSC	PMID:23786770;PMID:25035393		FGFR2:p.K660N	ENST00000457416	FGFR2	-	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr10:g.123247514C>A;aliases=ENSP00000410294;source=Ensembl	c.1980G>C	chr10:g.123247514C>G
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.V565I	ENST00000457416	FGFR2	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr10:g.123256217_123256219delAACinsGAT,chr10:g.123256217_123256219delAACinsTAT;aliases=ENSP00000410294;source=Ensembl	c.1693G>A	chr10:g.123256219C>T
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.M536I	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATG;candidate_codons=ATC,ATA,ATT;candidate_snv_variants=chr10:g.123258076C>T,chr10:g.123258076C>A;aliases=ENSP00000410294;source=Ensembl	c.1608G>C	chr10:g.123258076C>G
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.M538I	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATG;candidate_codons=ATC,ATA,ATT;candidate_snv_variants=chr10:g.123258070C>T,chr10:g.123258070C>A;aliases=ENSP00000410294;source=Ensembl	c.1614G>C	chr10:g.123258070C>G
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.I548V	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr10:g.123258040_123258042delGATinsTAC,chr10:g.123258040_123258042delGATinsCAC,chr10:g.123258040_123258042delGATinsAAC;aliases=ENSP00000410294;source=Ensembl	c.1642A>G	chr10:g.123258042T>C
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.I548V	ENST00000457416	FGFR2	-	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=ATC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr10:g.123258040_123258042delGATinsTAC,chr10:g.123258040_123258042delGATinsCAC,chr10:g.123258040_123258042delGATinsAAC;aliases=ENSP00000410294;source=Ensembl	c.1642A>G	chr10:g.123258042T>C
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.E566G	ENST00000457416	FGFR2	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GAG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr10:g.123256214_123256215delCTinsAC,chr10:g.123256214_123256215delCTinsTC,chr10:g.123256214_123256215delCTinsGC;aliases=ENSP00000410294;source=Ensembl	c.1697A>G	chr10:g.123256215T>C
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.L618M	ENST00000457416	FGFR2	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=TTG;candidate_codons=ATG;aliases=ENSP00000410294;source=Ensembl	c.1852T>A	chr10:g.123256060A>T
FGFR2:V565I,M536I,M538I,I548V,N550.,E566G,L618M,K660E	MUT		Resistant	FGFR2 (V565I,M536I,M538I,I548V,N550,E566G,L618M,K660E)	RDientsmann	Dovitinib	FGFR inhibitor	Dovitinib (FGFR inhibitor)		Pre-clinical	FGFR2		ED	PMID:23908597		FGFR2:p.K660E	ENST00000457416	FGFR2	-	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=AAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr10:g.123247514_123247516delCTTinsTTC;aliases=ENSP00000410294;source=Ensembl	c.1978A>G	chr10:g.123247516T>C
FGFR3:.	MUT		Responsive	FGFR3 oncogenic mutation	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR3		BLCA	AACR 2014 (abstr CT326)									
FGFR3:K650.,Y373C	MUT		Responsive	FGFR3 (K650,Y373C)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		MYMA	PMID:16091734;PMID:20439987;PMID:22869148									
FGFR3:K650.,Y373C	MUT		Responsive	FGFR3 (K650,Y373C)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		MYMA	PMID:16091734;PMID:20439987;PMID:22869148		FGFR3:p.Y373C	ENST00000440486	FGFR3	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr4:g.1806099_1806100delATinsGC;aliases=ENSP00000414914;source=Ensembl	c.1118A>G	chr4:g.1806099A>G
FGFR3__.	FUS		Responsive	FGFR3 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Case report	FGFR3		BLCA	PMID:26324363									
FGFR3__.	FUS		Responsive	FGFR3 fusion	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Early trials	FGFR3		G	PMID:26324363									
FGFR3__TACC3	FUS		Responsive	FGFR3-TACC3 fusion	EArriola		[FGFR inhibitor]	FGFR inhibitors (,etc)		Pre-clinical	FGFR3		NSCLC	PMID:25294908									
FGFR3:V555M	MUT		Resistant	FGFR3 (V555M)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR3		MYMA	PMID:22869148		FGFR3:p.V555M	ENST00000440486	FGFR3	+	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000414914;source=Ensembl	c.1663G>A	chr4:g.1807494G>A
FGFR3:Y373C	MUT		Resistant	FGFR3 (Y373C)	RDientsmann	Bortezomib	Proteasome inhibitor	Bortezomib (Proteasome inhibitor)		Pre-clinical	FGFR3		MYMA	PMID:19331127;PMID:21273588		FGFR3:p.Y373C	ENST00000440486	FGFR3	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr4:g.1806099_1806100delATinsGC;aliases=ENSP00000414914;source=Ensembl	c.1118A>G	chr4:g.1806099A>G
FGFR3:K650.	MUT		Responsive	FGFR3 (K650)	RDientsmann	Bortezomib	Proteasome inhibitor	Bortezomib (Proteasome inhibitor)		Pre-clinical	FGFR3		MYMA	PMID:19331127;PMID:21273588									
FGFR4:N535.,V550.	MUT		Responsive	FGFR4 (N535,V550)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR4		RHBDS	PMID:19809159;PMID:24124571									
FGFR4:N535.,V550.	MUT		Responsive	FGFR4 (N535,V550)	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FGFR4		RHBDS	PMID:19809159;PMID:24124571									
FLCN:.	MUT		Responsive	FLCN oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	FLCN		R	PMID:23995526									
FLCN:del	CNA		Responsive	FLCN deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	FLCN		TH	PMID:25295501									
VEGFR1:over	EXPR	Cell line	Responsive	FLT1 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	FLT1		R	PMID:24086736;PMID:21478036	Direct								
VEGFR2:over	EXPR	Cell line	Responsive	FLT1 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	FLT1		R	PMID:24086736;PMID:21478036	Direct								
FLT3:F691.	MUT		Responsive	FLT3 (F691)	RDientsmann	[]	[novel FLT3 inhibitor]	novel FLT3 inhibitors		Pre-clinical	FLT3		AML	PMID:25847190									
FLT3:N676.	MUT		Responsive	FLT3 (N676)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	FLT3		AML	PMID:24619500									
FLT3:D835.	MUT		Responsive	FLT3 (D835)	RDientsmann	Lestaurtinib	Pan-TK inhibitor	Lestaurtinib (Pan-TK inhibitor)		Case report	FLT3		AML	PMID:16857985									
FLT3:D835.	MUT		Responsive	FLT3 (D835)	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Case report	FLT3		AML	PMID:20733134									
FLT3:N676.	MUT		Responsive	FLT3 (N676)	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:24619500									
FLT3:D835.,Y842.	MUT		Resistant	FLT3 (D835,Y842)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:23430109									
FLT3:D835.,Y842.	MUT		Resistant	FLT3 (D835,Y842)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:23430109									
FLT3:F691.,D835.,N676.,Y842.	MUT		Resistant	FLT3 (F691,D835,N676,Y842)	RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:22504184;PMID:23878140									
FLT3:F691.,D835.,N676.,Y842.	MUT		Resistant	FLT3 (F691,D835,N676,Y842)	RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:22504184;PMID:23878140									
FLT3:F691.,D835.,N676.,Y842.	MUT		Resistant	FLT3 (F691,D835,N676,Y842)	RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:22504184;PMID:23878140									
FLT3:F691.,D835.,N676.,Y842.	MUT		Resistant	FLT3 (F691,D835,N676,Y842)	RDientsmann	Quizartinib	Pan-TK inhibitor	Quizartinib (Pan-TK inhibitor)		Pre-clinical	FLT3		AML	PMID:22504184;PMID:23878140									
FOXA1:amp	CNA		Responsive	FOXA1 amplification	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	FOXA1		COREAD	PMID:27397505									
FRS2:amp	CNA		Responsive	FRS2 amplification	RDientsmann	[]	[FGFR inhibitor]	FGFR inhibitors		Pre-clinical	FRS2		LIP	PMID:23393200									
G6PD:.	BIA		Increased Toxicity (Haemolytic Anemia)	G6PD biallelic inactivation	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD		CANCER	FDA									
G6PD:S218F	MUT		Increased Toxicity (Haemolytic Anemia)	G6PD (S218F)	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD		CANCER	FDA		G6PD:p.S218F	ENST00000393562	G6PD	-	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=TCC;candidate_codons=TTT,TTC;candidate_mnv_variants=chrX:g.153762633_153762634delGGinsAA;aliases=ENSP00000377192;source=Ensembl	c.653C>T	chrX:g.153762634G>A
G6PD:V98M;G6PD:N156D	MUT;MUT		Increased Toxicity (Haemolytic Anemia)	G6PD (V98M) + G6PD (N156D)	DTamborero;CRubio-Perez	Dabrafenib	BRAF inhibitor	Dabrafenib (BRAF inhibitor)	Approved	FDA guidelines	G6PD;G6PD		CANCER	FDA									
GATA3:.	MUT		Responsive	GATA3 oncogenic mutation	RDientsmann	[]	[Aromatase ihibitor]	Aromatase ihibitors		Pre-clinical	GATA3		BRCA	PMID:24758297									
GLI2:amp	CNA		Resistant	GLI2 amplification	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	GLI2		MB	PMID:24951114									
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNA11		CM	PMID:22733540;PMID:22808163		GNA11:p.Q209L	ENST00000078429	GNA11	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	c.626A>T	chr19:g.3118942A>T
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNA11		CM	PMID:22733540;PMID:22808163		GNA11:p.Q209P	ENST00000078429	GNA11	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	c.626A>C	chr19:g.3118942A>C
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNA11		CM	ASCO 2013 (abstr CRA9003)		GNA11:p.Q209L	ENST00000078429	GNA11	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	c.626A>T	chr19:g.3118942A>T
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNA11		CM	ASCO 2013 (abstr CRA9003)		GNA11:p.Q209P	ENST00000078429	GNA11	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	c.626A>C	chr19:g.3118942A>C
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Vorinostat	HDAC inhibitor	Vorinostat (HDAC inhibitor)		Pre-clinical	GNA11		CM	NCT01587352		GNA11:p.Q209L	ENST00000078429	GNA11	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CAG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsTT,chr19:g.3118942_3118943delAGinsTA,chr19:g.3118942_3118943delAGinsTC,chr19:g.3118941_3118942delCAinsTT,chr19:g.3118941_3118943delCAGinsTTA;aliases=ENSP00000078429;source=Ensembl	c.626A>T	chr19:g.3118942A>T
GNA11:Q209L,Q209P	MUT		Responsive	GNA11 (Q209L,Q209P)	RDientsmann	Vorinostat	HDAC inhibitor	Vorinostat (HDAC inhibitor)		Pre-clinical	GNA11		CM	NCT01587352		GNA11:p.Q209P	ENST00000078429	GNA11	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.3118942_3118943delAGinsCT,chr19:g.3118942_3118943delAGinsCA,chr19:g.3118942_3118943delAGinsCC;aliases=ENSP00000078429;source=Ensembl	c.626A>C	chr19:g.3118942A>C
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	GNAQ		CM	NCT01587352									
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	[]	[PKC inhibitor]	PKC inhibitors		Pre-clinical	GNAQ		CM	PMID:22653968;PMID:22253748									
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	GNAQ		CM	PMID:22733540;PMID:22808163									
GNAQ:Q209.	MUT		Responsive	GNAQ (Q209)	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	GNAQ		CM	ASCO 2013 (abstr CRA9003)									
GNAS:R201.	MUT		Responsive	GNAS (R201)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	GNAS		CANCER	PMID:21835143									
HDAC2:.	BIA		Responsive	HDAC2 biallelic inactivation	RDientsmann;CRubio-Perez	Olaparib	PARP inhibitor	Olaparib (PARP inhibitor)		Case report	HDAC2		PRAD	PMID:26510020									
HGF:over	EXPR	Xenograft	Responsive	HGF overexpression	CRubio-Perez;ARodriguez-Vida	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)	Approved	Pre-clinical	HGF		UTC	PMID:25534569	Indirect								
HGF:amp;ERBB2:amp	CNA;CNA		Resistant	HGF amplification + ERBB2 amplification	RDientsmann;CRubio-Perez	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	HGF;ERBB2		BRCA	PMID:22850551									
HIF1A:over	EXPR	Cell line	Responsive	HIF1A overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	HIF1A		R	PMID:24086736	Indirect								
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	HRAS		CESC	PMID:22345164									
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	HRAS		CANCER	NCT02383927									
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)	Clinical Trials	Early trials	HRAS		CANCER	NCT02383927									
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	HRAS		CER	PMID:15950068									
HRAS:.	MUT		Responsive	HRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor +/- MTOR inhibitor]	MEK inhibitor +/- MTOR inhibitors		Pre-clinical	HRAS		AML	PMID:22399013;PMID:22507781									
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	RDientsmann	[]	[IDH1 inhibitor]	IDH1 inhibitors		Early trials	IDH1		AML	ENA 2014 (abstr 1LBA)									
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	IDH1		AML	PMID:25599133									
IDH1:R132.	MUT		Responsive	IDH1 (R132)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	IDH1		BT	PMID:27231123									
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	MMartínez;RDientsmann;CRubio-Perez	AG-120	IDH1 inhibitor	AG-120 (IDH1 inhibitor)	Clinical Trials	Early trials	IDH1		G	NCT02073994;PMID:23558169	Direct								
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	IDH1		AML	PMID:27520294									
IDH1:.	MUT		Responsive	IDH1 oncogenic mutation	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Clinical Trials	Early trials	IDH1		CH	NCT02428855	Indirect								
IDH2:R172.	MUT		Responsive	IDH2 (R172)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	IDH2		BT	PMID:27231123									
IDH2:.	MUT		Responsive	IDH2 oncogenic mutation	DTamborero;CRubio-Perez	Venetoclax	BCL2 inhibitor	Venetoclax (BCL2 inhibitor)		Early trials	IDH2		AML	PMID:27520294									
IDH2:R140K,R172K	MUT		Responsive	IDH2 (R140K,R172K)	RDientsmann	AG-221	IDH2 inhibitor	AG-221 (IDH2 inhibitor)	Clinical Trials	Early trials	IDH2		HEMATO	AACR 2014 (abstr CT103)	Direct	IDH2:p.R140K	ENST00000330062	IDH2	-	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=CGG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.90631933_90631935delCCGinsTTT;aliases=ENSP00000331897;source=Ensembl	c.418_419delCGinsAA	chr15:g.90631934_90631935delCGinsTT
IDH2:R140K,R172K	MUT		Responsive	IDH2 (R140K,R172K)	RDientsmann	AG-221	IDH2 inhibitor	AG-221 (IDH2 inhibitor)	Clinical Trials	Early trials	IDH2		HEMATO	AACR 2014 (abstr CT103)	Direct	IDH2:p.R172K	ENST00000330062	IDH2	-	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=AGG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.90631837_90631838delCCinsTT;aliases=ENSP00000331897;source=Ensembl	c.515G>A	chr15:g.90631838C>T
IDH2:.	MUT		Responsive	IDH2 oncogenic mutation	CRubio-Perez	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)	Clinical Trials	Early trials	IDH2		CH	NCT02428855	Indirect								
IGF1R:amp	CNA		Resistant	IGF1R amplification	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	IGF1R		LUAD	PMID:24458568									
IGF2:amp	CNA		Resistant	IGF2 amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	IGF2		COREAD	PMID:25632036									
IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del	MUT;CNA		Responsive	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	IL7R;SH2B3		ALL	PMID:22955920									
IL7R:S185C;SH2B3:del	MUT;CNA		Responsive	IL7R (S185C) + SH2B3 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	IL7R;SH2B3		ALL	PMID:22955920									
IL7R::consequence::inframe_insertion:237-255,::inframe_deletion:237-255;SH2B3:del	MUT;CNA		Responsive	IL7R inframe insertion (237-255),inframe deletion (237-255) + SH2B3 deletion	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	IL7R;SH2B3		ALL	PMID:22897847;PMID:22955920									
IL7R:S185C;SH2B3:del	MUT;CNA		Responsive	IL7R (S185C) + SH2B3 deletion	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	IL7R;SH2B3		ALL	PMID:22897847;PMID:22955920									
INPP4B:del	CNA		Responsive	INPP4B deletion	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	INPP4B		BRCA	PMID:23551093									
INPP4B:.	MUT		Responsive	INPP4B oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	INPP4B		BRCA	PMID:23551093									
JAK1:S646F;R683.	MUT		Responsive	JAK1 (S646F;R683)	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	JAK1		ALL	PMID:22955920;PMID:18805579									
JAK1:.	MUT		Resistant	JAK1 oncogenic mutation	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK1		CM	PMID:27433843									
JAK2:V617F	MUT		Responsive	JAK2 (V617F)	RDientsmann	[]	[JAK inhibitor (alone or in combination)]	JAK inhibitor (alone or in combination)s		Pre-clinical	JAK2		AML	PMID:22829971		JAK2:p.V617F	ENST00000381652	JAK2	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	c.1849G>T	chr9:g.5073770G>T
JAK2:V617F	MUT		Responsive	JAK2 (V617F)	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Early trials	JAK2		AML	PMID:22422826		JAK2:p.V617F	ENST00000381652	JAK2	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	c.1849G>T	chr9:g.5073770G>T
JAK2__BRAF	FUS		Responsive	JAK2-BRAF fusion	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)		Pre-clinical	JAK2		ALL	PMID:22875628;PMID:22899477									
JAK2:amp	CNA		Responsive	JAK2 amplification	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK2		BRCA	PMID:27075627									
JAK2:.	MUT		Resistant	JAK2 oncogenic mutation	RDientsmann	[]	[PD1 inhibitor]	PD1 inhibitors		Case report	JAK2		CM	PMID:27433843									
JAK2:V617F	MUT		Responsive	JAK2 (V617F)	RDientsmann	Ruxolitinib	JAK inhibitor	Ruxolitinib (JAK inhibitor)	Approved	FDA guidelines	JAK2		MY	FDA		JAK2:p.V617F	ENST00000381652	JAK2	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=GTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr9:g.5073770_5073772delGTCinsTTT;aliases=ENSP00000371067;source=Ensembl	c.1849G>T	chr9:g.5073770G>T
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	PMID:18397343		JAK3:p.R657Q	ENST00000458235	JAK3	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr19:g.17945968_17945969delCCinsTT;aliases=ENSP00000391676;source=Ensembl	c.1970G>A	chr19:g.17945969C>T
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	PMID:18397343		JAK3:p.I87T	ENST00000458235	JAK3	-	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=ATC;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr19:g.17954633_17954634delGAinsTG,chr19:g.17954633_17954634delGAinsCG,chr19:g.17954633_17954634delGAinsAG;aliases=ENSP00000391676;source=Ensembl	c.260T>C	chr19:g.17954634A>G
JAK3:R657Q,I87T,Q501H	MUT		Responsive	JAK3 (R657Q,I87T,Q501H)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		MKB	PMID:18397343		JAK3:p.Q501H	ENST00000458235	JAK3	-	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=CAG;candidate_codons=CAT,CAC;candidate_snv_variants=chr19:g.17949138C>G;aliases=ENSP00000391676;source=Ensembl	c.1503G>T	chr19:g.17949138C>A
JAK3:A572V,A573V	MUT		Responsive	JAK3 (A572V,A573V)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		LY	PMID:22705984		JAK3:p.A572V	ENST00000458235	JAK3	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GCA;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.17948008_17948009delTGinsGA,chr19:g.17948008_17948009delTGinsCA,chr19:g.17948008_17948009delTGinsAA;aliases=ENSP00000391676;source=Ensembl	c.1715C>T	chr19:g.17948009G>A
JAK3:A572V,A573V	MUT		Responsive	JAK3 (A572V,A573V)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	JAK3		LY	PMID:22705984		JAK3:p.A573V	ENST00000458235	JAK3	-	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GCG;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.17948005_17948006delCGinsTA,chr19:g.17948005_17948006delCGinsGA,chr19:g.17948005_17948006delCGinsAA;aliases=ENSP00000391676;source=Ensembl	c.1718C>T	chr19:g.17948006G>A
KCNJ5:L168R	MUT	Cell line	Responsive	KCNJ5 (L168R)	ECampo	Amiloride	Na-Ca chanel blocker	Amiloride (Na-Ca chanel blocker)	Approved	Pre-clinical	KCNJ5		AA	PMID:24506072	Indirect	KCNJ5:p.L168R	ENST00000529694	KCNJ5	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CTC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.128781671_128781672delTCinsGA,chr11:g.128781671_128781672delTCinsGG,chr11:g.128781671_128781672delTCinsGT,chr11:g.128781670_128781672delCTCinsAGG,chr11:g.128781670_128781672delCTCinsAGA;aliases=ENSP00000433295;source=Ensembl	c.503T>G	chr11:g.128781671T>G
KCNJ5:L168R	MUT	Cell line	Responsive	KCNJ5 (L168R)	ECampo	Verapamil	Na-Ca chanel blocker	Verapamil (Na-Ca chanel blocker)	Approved	Pre-clinical	KCNJ5		AA	PMID:24506072	Indirect	KCNJ5:p.L168R	ENST00000529694	KCNJ5	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CTC;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr11:g.128781671_128781672delTCinsGA,chr11:g.128781671_128781672delTCinsGG,chr11:g.128781671_128781672delTCinsGT,chr11:g.128781670_128781672delCTCinsAGG,chr11:g.128781670_128781672delCTCinsAGA;aliases=ENSP00000433295;source=Ensembl	c.503T>G	chr11:g.128781671T>G
KDR:A1065T	MUT		Responsive	KDR (A1065T)	RDientsmann	[]	[VEGFR inhibitor]	VEGFR inhibitors		Pre-clinical	KDR		CANCER	PMID:24569783		KDR:p.A1065T	ENST00000263923	KDR	-	inside_[cds_in_exon_24]	CSQN=Missense;reference_codon=GCT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr4:g.55955967_55955969delAGCinsTGT,chr4:g.55955967_55955969delAGCinsCGT,chr4:g.55955967_55955969delAGCinsGGT;aliases=ENSP00000263923;source=Ensembl	c.3193G>A	chr4:g.55955969C>T
KIT:788-828,449-514	MUT		Responsive	KIT mutation in exon 9 or 17	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	KIT		GIST	PMID:21737509									
KIT:788-828,449-514	MUT		Responsive	KIT mutation in exon 9 or 17	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	KIT		GIST	PMID:21737509									
KIT:550-592	MUT		Responsive	KIT mutation in exon 11	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Early trials	KIT		GIST	PMID:22898035									
KIT:D816V	MUT		Responsive	KIT (D816V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		SM	PMID:18559612		KIT:p.D816V	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	c.2447A>T	chr4:g.55599321A>T
KIT:D816V	MUT		Responsive	KIT (D816V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		AML	PMID:18986703		KIT:p.D816V	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	c.2447A>T	chr4:g.55599321A>T
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		CM	PMID:19671763									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		CM	PMID:19671763									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		CM	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		CM	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812									
KIT:627-664,664-714,449-514	MUT		Resistant	KIT (627-664,664-714,449-514)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		GIST	PMID:18955458;PMID:18955451;PMID:16624552									
KIT:627-664,664-714,449-514	MUT		Resistant	KIT (627-664,664-714,449-514)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		GIST	PMID:18955458;PMID:18955451;PMID:16624552									
KIT:627-664,664-714,449-514	MUT		Resistant	KIT (627-664,664-714,449-514)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials	KIT		GIST	PMID:18955458;PMID:18955451;PMID:16624552									
KIT:Y553N	MUT		Responsive	KIT (Y553N)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		THYM	PMID:21969494		KIT:p.Y553N	ENST00000288135	KIT	+	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=TAT;candidate_codons=AAC,AAT;candidate_mnv_variants=chr4:g.55593591_55593593delTATinsAAC;aliases=ENSP00000288135;source=Ensembl	c.1657T>A	chr4:g.55593591T>A
KIT:D820Y	MUT		Responsive	KIT (D820Y)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		CM	PMID:23775962		KIT:p.D820Y	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599332_55599334delGATinsTAC;aliases=ENSP00000288135;source=Ensembl	c.2458G>T	chr4:g.55599332G>T
KIT:788-828	MUT		Resistant	KIT mutation in exon 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23840364									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		CM	PMID:22068222;PMID:25695690									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		CM	PMID:22068222;PMID:25695690									
KIT:788-828	MUT		Responsive	KIT mutation in exon 17	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Early trials	KIT		GIST	PMID:22119758;PMID:21456006									
KIT:D820Y	MUT		Responsive	KIT (D820Y)	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Case report	KIT		CM	PMID:25695690		KIT:p.D820Y	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599332_55599334delGATinsTAC;aliases=ENSP00000288135;source=Ensembl	c.2458G>T	chr4:g.55599332G>T
KIT:788-828,829-860,550-592	MUT		Responsive	KIT (788-828,829-860,550-592)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Early trials	KIT		GIST	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)									
KIT:788-828,829-860,550-592	MUT		Responsive	KIT (788-828,829-860,550-592)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Early trials	KIT		GIST	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)									
KIT:788-828,829-860,550-592	MUT		Responsive	KIT (788-828,829-860,550-592)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Early trials	KIT		GIST	ASCO 2015 (abstr 10517);PMID:25239608;ASCO 2015 (abstr 10535)									
KIT:550-592,627-664,788-828,829-860	MUT		Responsive	KIT (550-592,627-664,788-828,829-860)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		CM	PMID:18936790;PMID:20372153									
KIT:550-592,627-664,788-828,829-860	MUT		Responsive	KIT (550-592,627-664,788-828,829-860)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		CM	PMID:18936790;PMID:20372153									
KIT:550-592,627-664,788-828,829-860	MUT		Responsive	KIT (550-592,627-664,788-828,829-860)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		CM	PMID:18936790;PMID:20372153									
KIT:550-592,627-664,788-828,829-860	MUT		Responsive	KIT (550-592,627-664,788-828,829-860)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		CM	PMID:18936790;PMID:20372153									
KIT:D820E	MUT		Responsive	KIT (D820E)	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Case report	KIT		THYM	PMID:19461405		KIT:p.D820E	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAT;candidate_codons=GAG,GAA;candidate_snv_variants=chr4:g.55599334T>A;aliases=ENSP00000288135;source=Ensembl	c.2460T>G	chr4:g.55599334T>G
KIT:550-592,449-514	MUT		Responsive	KIT mutation in exon 9 or 11	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	KIT		GIST	PMID:22270258									
KIT:550-592,449-514	MUT		Responsive	KIT mutation in exon 9 or 11	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	KIT		GIST	PMID:22270258									
KIT:788-828	MUT		Responsive	KIT mutation in exon 17	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:23840364									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		CM	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		CM	PMID:18421059;PMID:21642685;PMID:21690468;PMID:22261812									
KIT:550-592	MUT		Resistant	KIT mutation in exon 11	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials	KIT		GIST	PMID:18955458									
KIT:H697Y	MUT		Responsive	KIT (H697Y)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		THYM	PMID:19861435		KIT:p.H697Y	ENST00000288135	KIT	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	c.2089C>T	chr4:g.55595599C>T
KIT:amp	CNA		No Responsive	KIT amplification	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Early trials	KIT		CM	PMID:22261812									
KIT:Y553N	MUT		Responsive	KIT (Y553N)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Case report	KIT		THYM	PMID:23375402		KIT:p.Y553N	ENST00000288135	KIT	+	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=TAT;candidate_codons=AAC,AAT;candidate_mnv_variants=chr4:g.55593591_55593593delTATinsAAC;aliases=ENSP00000288135;source=Ensembl	c.1657T>A	chr4:g.55593591T>A
KIT:788-828	MUT		Resistant	KIT mutation in exon 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:23840364									
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)	CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	PMID:16397263		KIT:p.D816Y	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55599320_55599322delGACinsTAT;aliases=ENSP00000288135;source=Ensembl	c.2446G>T	chr4:g.55599320G>T
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)	CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	PMID:16397263		KIT:p.D816F	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr4:g.55599320_55599322delGACinsTTT;aliases=ENSP00000288135;source=Ensembl	c.2446_2447delGAinsTT	chr4:g.55599320_55599321delGAinsTT
KIT:D816Y,D816F,D816V	MUT		Responsive	KIT (D816Y,D816F,D816V)	CRubio-Perez;RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		CANCER	PMID:16397263		KIT:p.D816V	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55599321_55599322delACinsTA,chr4:g.55599321_55599322delACinsTG,chr4:g.55599321_55599322delACinsTT;aliases=ENSP00000288135;source=Ensembl	c.2447A>T	chr4:g.55599321A>T
KIT:N822K	MUT		Responsive	KIT (N822K)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	KIT		AML	PMID:23149070		KIT:p.N822K	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=AAT;candidate_codons=AAG,AAA;candidate_snv_variants=chr4:g.55599340T>A;aliases=ENSP00000288135;source=Ensembl	c.2466T>G	chr4:g.55599340T>G
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:D816.	MUT		Resistant	KIT (D816)	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	KIT		GIST;MDS;MDPS;HES;ECL;CML;ALL;SM	FDA									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	KIT		CM	NCCN									
KIT:550-592,627-664	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	KIT		CM	NCCN									
KIT:788-828,829-860	MUT		Resistant	KIT mutation in exon 17 or 18	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	KIT		CM	PMID:21690468;PMID:21642685									
KIT:788-828,829-860	MUT		Resistant	KIT mutation in exon 17 or 18	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	KIT		CM	PMID:21690468;PMID:21642685									
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.V559I	ENST00000288135	KIT	+	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=GTT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55593609_55593611delGTTinsATC,chr4:g.55593609_55593611delGTTinsATA;aliases=ENSP00000288135;source=Ensembl	c.1675G>A	chr4:g.55593609G>A
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.H697Y	ENST00000288135	KIT	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	c.2089C>T	chr4:g.55595599C>T
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.H697Y	ENST00000288135	KIT	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	c.2089C>T	chr4:g.55595599C>T
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.V654A	ENST00000288135	KIT	+	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GTG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr4:g.55594258_55594259delTGinsCA,chr4:g.55594258_55594259delTGinsCC,chr4:g.55594258_55594259delTGinsCT;aliases=ENSP00000288135;source=Ensembl	c.1961T>C	chr4:g.55594258T>C
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.A829P	ENST00000288135	KIT	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr4:g.55602664_55602666delGCTinsCCG,chr4:g.55602664_55602666delGCTinsCCA,chr4:g.55602664_55602666delGCTinsCCC;aliases=ENSP00000288135;source=Ensembl	c.2485G>C	chr4:g.55602664G>C
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.A829P	ENST00000288135	KIT	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr4:g.55602664_55602666delGCTinsCCG,chr4:g.55602664_55602666delGCTinsCCA,chr4:g.55602664_55602666delGCTinsCCC;aliases=ENSP00000288135;source=Ensembl	c.2485G>C	chr4:g.55602664G>C
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.A829P	ENST00000288135	KIT	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr4:g.55602664_55602666delGCTinsCCG,chr4:g.55602664_55602666delGCTinsCCA,chr4:g.55602664_55602666delGCTinsCCC;aliases=ENSP00000288135;source=Ensembl	c.2485G>C	chr4:g.55602664G>C
KIT:V559I,H697Y,T670.,V654A,A829P,D816.,N822.,Y823D	MUT		Resistant	KIT (V559I,H697Y,T670,V654A,A829P,D816,N822,Y823D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	KIT		GIST	PMID:23582185;PMID:21689725;PMID:17259998		KIT:p.Y823D	ENST00000288135	KIT	+	inside_[cds_in_exon_17]	CSQN=Missense;reference_codon=TAT;candidate_codons=GAC,GAT;candidate_mnv_variants=chr4:g.55599341_55599343delTATinsGAC;aliases=ENSP00000288135;source=Ensembl	c.2467T>G	chr4:g.55599341T>G
KIT:amp	CNA		No Responsive	KIT amplification	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	KIT		CM	PMID:23775962									
KIT:T670I	MUT		Resistant	KIT (T670I)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KIT		GIST	PMID:24687822		KIT:p.T670I	ENST00000288135	KIT	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55595519_55595520delCAinsTC,chr4:g.55595519_55595520delCAinsTT;aliases=ENSP00000288135;source=Ensembl	c.2009C>T	chr4:g.55595519C>T
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:25239608		KIT:p.A829P	ENST00000288135	KIT	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GCT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr4:g.55602664_55602666delGCTinsCCG,chr4:g.55602664_55602666delGCTinsCCA,chr4:g.55602664_55602666delGCTinsCCC;aliases=ENSP00000288135;source=Ensembl	c.2485G>C	chr4:g.55602664G>C
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:25239608		KIT:p.V654A	ENST00000288135	KIT	+	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=GTG;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr4:g.55594258_55594259delTGinsCA,chr4:g.55594258_55594259delTGinsCC,chr4:g.55594258_55594259delTGinsCT;aliases=ENSP00000288135;source=Ensembl	c.1961T>C	chr4:g.55594258T>C
KIT:A829P,V654A,T670I	MUT		Responsive	KIT (A829P,V654A,T670I)	RDientsmann	Ponatinib	BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Ponatinib (BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KIT		GIST	PMID:25239608		KIT:p.T670I	ENST00000288135	KIT	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55595519_55595520delCAinsTC,chr4:g.55595519_55595520delCAinsTT;aliases=ENSP00000288135;source=Ensembl	c.2009C>T	chr4:g.55595519C>T
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:449-514,550-592,627-664,664-714,788-828	MUT		Responsive	KIT mutation in exon 9,11,13,14 or 17	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	FDA guidelines	KIT		GIST	FDA									
KIT:H697Y	MUT		Responsive	KIT (H697Y)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	KIT		THYM	PMID:19861435		KIT:p.H697Y	ENST00000288135	KIT	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55595599_55595601delCATinsTAC;aliases=ENSP00000288135;source=Ensembl	c.2089C>T	chr4:g.55595599C>T
KMT2D:.	MUT		Responsive	KMT2D oncogenic mutation	RDientsmann	Bicalutamide	AR inhibitor	Bicalutamide (AR inhibitor)		Pre-clinical	KMT2D		LUSC	PMID:27397505									
KRAS:.	MUT		No Responsive	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Early trials	KRAS		PA	ASCO 2015 (abstr 4119)									
KRAS:G12.	MUT		Responsive	KRAS (G12)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	KRAS		ALL	PMID:18701506									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	KRAS		ED;MYMA	PMID:21984976;PMID:22662154;PMID:22985491									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor;PI3K pathway inhibitor]	MEK inhibitor + PI3K pathway inhibitors		Pre-clinical	KRAS		COREAD	PMID:22392911									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor;BCL-XL inhibitor]	MEK inhibitor + BCL-XL inhibitors		Pre-clinical	KRAS		COREAD	PMID:23245996									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	KRAS		COREAD	PMID:23614898									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor;IGF1R inhibitor]	MEK inhibitor + IGF1R inhibitors		Pre-clinical	KRAS		COREAD	PMID:24045180									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MTOR inhibitor;BH3 mimetics]	MTOR inhibitor + BH3 mimeticss		Pre-clinical	KRAS		COREAD	PMID:24163374									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor;MEK inhibitor]	EGFR mAb inhibitor + MEK inhibitors		Pre-clinical	KRAS		COREAD	PMID:24553387									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	KRAS		CANCER	PMID:26552009									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Decitabine;BCL2 inhibitor	Chemotherapy;BCL2 inhibitor	Decitabine + BCL2 inhibitor (Chemotherapy + BCL2 inhibitor)		Pre-clinical	KRAS		OV	PMID:25968887									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Gemcitabine;MEK inhibitor	Chemotherapy;MEK inhibitor	Gemcitabine + MEK inhibitor (Chemotherapy + MEK inhibitor)		Early trials	KRAS		PA	PMID:23583440									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Sorafenib;MEK inhibitor	Pan-TK inhibitor;MEK inhibitor	Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)		Early Trials,Case Report	KRAS		HC	PMID:25294897									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	Trastuzumab;Lapatinib	ERBB2 mAb inhibitor;ERBB2 inhibitor	Trastuzumab + Lapatinib (ERBB2 mAb inhibitor + ERBB2 inhibitor)		Late trials	KRAS		COREAD	ASCO 2015 (abstr 3508);NCT01104571;EBCC10									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[FAS inhibitor]	FAS inhibitors		Case report	KRAS		L	AACR 2016;abstr									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[CDK4 inhibitor]	CDK4 inhibitors		Pre-clinical	KRAS		L	PMID:20609353									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[HSP90 inhibitor (in combination)]	HSP90 inhibitor (in combination)s		Pre-clinical	KRAS		L	PMID:23012248;PMID:21907929									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	KRAS		L	PMID:23129625;PMID:24045185									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Early trials	KRAS		L;BT	PMID:23200175;PMID:24947927;PMID:25667274;PMID:25722381;PMID:23391555									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	KRAS		L	PMID:23358651									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[JAK/TBK1/IKKε inhibitor]	JAK/TBK1/IKKε inhibitors		Pre-clinical	KRAS		L	PMID:24444711									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Early trials	KRAS		L	PMID:25516890									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	DTamborero;CRubio-Perez	[Palbociclib,Abemaciclib]	[CDK4/6 inhibitor]	CDK4/6 inhibitors (Palbociclib,Abemaciclib,etc)		Early trials	KRAS		NSCLC	PMID:26658964;NCT01291017									
KRAS:.	MUT		No Responsive	KRAS oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	KRAS		L	PMID:26802155									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[pan-RAF inhibitor]	pan-RAF inhibitors		Case report	KRAS		ED;L	AACR 2016 (abstr CT005)									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[FAS inhibitor]	FAS inhibitors		Case report	KRAS		L	AACR 2016, abstr LB214									
KRAS:G13D	MUT		No Responsive	KRAS (G13D)	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	KRAS		COREAD	PMID:27114605		KRAS:p.G13D	ENST00000256078	KRAS	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr12:g.25398280_25398281delGCinsAT;aliases=ENSP00000256078;source=Ensembl	c.38G>A	chr12:g.25398281C>T
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Abemaciclib	CDK4/6 inhibitor	Abemaciclib (CDK4/6 inhibitor)		Early trials	KRAS		LUAD	PMID:27231123									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	Trametinib;Ponatinib	MEK inhibitor;BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor	Trametinib + Ponatinib (MEK inhibitor + BCR-ABL inhibitor 3rd gen&Pan-TK inhibitor)		Pre-clinical	KRAS		LUAD	PMID:27338794									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	EArriola	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)	Clinical Trials	Early trials	KRAS		NSCLC	NCT00890825									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	DTamborero	[]	[EGFR inhibitor]	EGFR inhibitors		Pre-clinical	KRAS		NSCLC	PMID:19238210									
KRAS:amp	CNA		Resistant	KRAS amplification	RDientsmann	[]	[BRAF inhibitor;EGFR mAb inhibitor]	BRAF inhibitor + EGFR mAb inhibitors		Case report	KRAS		COREAD	ENA 2014 (abstr 428)									
KRAS:amp	CNA		Resistant	KRAS amplification	RDientsmann	[]	[BRAF inhibitor;MEK inhibitor]	BRAF inhibitor + MEK inhibitors		Case report	KRAS		COREAD	ENA 2014 (abstr 428)									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		NCCN guidelines	KRAS		L	PMID:20921461									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EGFR inhibitor 2nd gen]	EGFR inhibitor 2nd gens		NCCN guidelines	KRAS		L	PMID:20921461									
KRAS:.	MUT		Responsive	KRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	KRAS		AML;CER;OV	PMID:22507781;PMID:22169769;PMID:19018267									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Pre-clinical	KRAS		ST	PMID:22614881;PMID:22290393									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	KRAS		ED	PMID:22662154									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	CRubio-Perez;RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	FDA guidelines	KRAS		COREAD	FDA guidelines									
KRAS:G12.	MUT		Resistant	KRAS (G12)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	KRAS		GIST	PMID:24687822									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	CRubio-Perez;RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	FDA guidelines	KRAS		COREAD	FDA guidelines									
KRAS:.	MUT		Resistant	KRAS oncogenic mutation	CRubio-Perez;RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)		FDA guidelines	KRAS	COREAD	COREAD	FDA guidelines									
LRP1B:.	MUT		Resistant	LRP1B oncogenic mutation	RDientsmann	Liposomal Doxorubicin	Chemotherapy	Liposomal Doxorubicin (Chemotherapy)		Early trials	LRP1B		OV	PMID:22896685									
LRP1B:del	CNA		Resistant	LRP1B deletion	RDientsmann	Liposomal Doxorubicin	Chemotherapy	Liposomal Doxorubicin (Chemotherapy)		Early trials	LRP1B		OV	PMID:22896685									
MAP2K1:F129L,L215P,I103N,P124.	MUT		Responsive	MAP2K1 (F129L,L215P,I103N,P124)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:23614898		MAP2K1:p.F129L	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr15:g.66729179C>A,chr15:g.66729179C>G;candidate_mnv_variants=chr15:g.66729177_66729179delTTCinsCTT,chr15:g.66729177_66729179delTTCinsCTG,chr15:g.66729177_66729179delTTCinsCTA;aliases=ENSP00000302486;source=Ensembl	c.385T>C	chr15:g.66729177T>C
MAP2K1:F129L,L215P,I103N,P124.	MUT		Responsive	MAP2K1 (F129L,L215P,I103N,P124)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:23614898		MAP2K1:p.L215P	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=CTC;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66774168_66774169delTCinsCT,chr15:g.66774168_66774169delTCinsCG,chr15:g.66774168_66774169delTCinsCA;aliases=ENSP00000302486;source=Ensembl	c.644T>C	chr15:g.66774168T>C
MAP2K1:F129L,L215P,I103N,P124.	MUT		Responsive	MAP2K1 (F129L,L215P,I103N,P124)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:23614898		MAP2K1:p.I103N	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr15:g.66729100_66729101delTCinsAT;aliases=ENSP00000302486;source=Ensembl	c.308T>A	chr15:g.66729100T>A
MAP2K1:F129L,L215P,I103N,P124.	MUT		Responsive	MAP2K1 (F129L,L215P,I103N,P124)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:23614898		MAP2K1:p.I103N	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr15:g.66729100_66729101delTCinsAT;aliases=ENSP00000302486;source=Ensembl	c.308T>A	chr15:g.66729100T>A
MAP2K1:C121S	MUT		Responsive	MAP2K1 (C121S)	RDientsmann	[]	[novel MEK inhibitor]	novel MEK inhibitors		Pre-clinical	MAP2K1		CM	PMID:24448821		MAP2K1:p.C121S	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr15:g.66729154G>C;candidate_mnv_variants=chr15:g.66729153_66729155delTGCinsAGT,chr15:g.66729154_66729155delGCinsCT,chr15:g.66729154_66729155delGCinsCG,chr15:g.66729154_66729155delGCinsCA;aliases=ENSP00000302486;source=Ensembl	c.361T>A	chr15:g.66729153T>A
MAP2K1:P124.	MUT		Responsive	MAP2K1 (P124)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	MAP2K1		CM	PMID:25370473									
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144		MAP2K1:p.Q56P	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	c.167A>C	chr15:g.66727451A>C
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144		MAP2K1:p.P124S	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr15:g.66729162_66729164delCCGinsTCT,chr15:g.66729162_66729164delCCGinsTCC,chr15:g.66729162_66729164delCCGinsTCA,chr15:g.66729162_66729164delCCGinsAGC,chr15:g.66729162_66729164delCCGinsAGT;aliases=ENSP00000302486;source=Ensembl	c.370C>T	chr15:g.66729162C>T
MAP2K1:Q56P,P124S,P124L	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L)	DTamborero	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144		MAP2K1:p.P124L	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CCG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr15:g.66729163_66729164delCGinsTT,chr15:g.66729163_66729164delCGinsTA,chr15:g.66729163_66729164delCGinsTC,chr15:g.66729162_66729163delCCinsTT,chr15:g.66729162_66729164delCCGinsTTA;aliases=ENSP00000302486;source=Ensembl	c.371C>T	chr15:g.66729163C>T
MAP2K1:Q56P,P124S,P124L;C121S	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L;C121S)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:21383288		MAP2K1:p.Q56P	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	c.167A>C	chr15:g.66727451A>C
MAP2K1:Q56P,P124S,P124L;C121S	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L;C121S)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:21383288		MAP2K1:p.P124S	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr15:g.66729162_66729164delCCGinsTCT,chr15:g.66729162_66729164delCCGinsTCC,chr15:g.66729162_66729164delCCGinsTCA,chr15:g.66729162_66729164delCCGinsAGC,chr15:g.66729162_66729164delCCGinsAGT;aliases=ENSP00000302486;source=Ensembl	c.370C>T	chr15:g.66729162C>T
MAP2K1:Q56P,P124S,P124L;C121S	MUT		Resistant	MAP2K1 (Q56P,P124S,P124L;C121S)	RDientsmann;DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:21383288		MAP2K1:p.P124S	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr15:g.66729162_66729164delCCGinsTCT,chr15:g.66729162_66729164delCCGinsTCC,chr15:g.66729162_66729164delCCGinsTCA,chr15:g.66729162_66729164delCCGinsAGC,chr15:g.66729162_66729164delCCGinsAGT;aliases=ENSP00000302486;source=Ensembl	c.370C>T	chr15:g.66729162C>T
MAP2K1:K57T	MUT		Responsive	MAP2K1 (K57T)	RDientsmann	Panitumumab;Trametinib	EGFR mAb inhibitor;MEK inhibitor	Panitumumab + Trametinib (EGFR mAb inhibitor + MEK inhibitor)		Case report	MAP2K1		COREAD	PMID:26644315		MAP2K1:p.K57T	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=AAG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr15:g.66727454_66727455delAGinsCA,chr15:g.66727454_66727455delAGinsCT,chr15:g.66727454_66727455delAGinsCC;aliases=ENSP00000302486;source=Ensembl	c.170A>C	chr15:g.66727454A>C
MAP2K1:Q56P	MUT		Responsive	MAP2K1 (Q56P)	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	MAP2K1		CANCER	PMID:26582713		MAP2K1:p.Q56P	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	c.167A>C	chr15:g.66727451A>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.I99T	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=ATT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr15:g.66729088_66729089delTTinsCA,chr15:g.66729088_66729089delTTinsCG,chr15:g.66729088_66729089delTTinsCC;aliases=ENSP00000302486;source=Ensembl	c.296T>C	chr15:g.66729088T>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.I99T	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=ATT;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr15:g.66729088_66729089delTTinsCA,chr15:g.66729088_66729089delTTinsCG,chr15:g.66729088_66729089delTTinsCC;aliases=ENSP00000302486;source=Ensembl	c.296T>C	chr15:g.66729088T>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.G128D	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr15:g.66729175_66729176delGCinsAT;aliases=ENSP00000302486;source=Ensembl	c.383G>A	chr15:g.66729175G>A
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.F129L	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr15:g.66729179C>A,chr15:g.66729179C>G;candidate_mnv_variants=chr15:g.66729177_66729179delTTCinsCTT,chr15:g.66729177_66729179delTTCinsCTG,chr15:g.66729177_66729179delTTCinsCTA;aliases=ENSP00000302486;source=Ensembl	c.385T>C	chr15:g.66729177T>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.V211D	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GTC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr15:g.66774156_66774157delTCinsAT;aliases=ENSP00000302486;source=Ensembl	c.632T>A	chr15:g.66774156T>A
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.L215P	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=CTC;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66774168_66774169delTCinsCT,chr15:g.66774168_66774169delTCinsCG,chr15:g.66774168_66774169delTCinsCA;aliases=ENSP00000302486;source=Ensembl	c.644T>C	chr15:g.66774168T>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.I103N	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr15:g.66729100_66729101delTCinsAT;aliases=ENSP00000302486;source=Ensembl	c.308T>A	chr15:g.66729100T>A
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.K104N	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=AAA;candidate_codons=AAC,AAT;candidate_snv_variants=chr15:g.66729104A>T;aliases=ENSP00000302486;source=Ensembl	c.312A>C	chr15:g.66729104A>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.I111N	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=ATC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr15:g.66729124_66729125delTCinsAT;aliases=ENSP00000302486;source=Ensembl	c.332T>A	chr15:g.66729124T>A
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.H119P	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CAT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66729148_66729149delATinsCG,chr15:g.66729148_66729149delATinsCA,chr15:g.66729148_66729149delATinsCC;aliases=ENSP00000302486;source=Ensembl	c.356A>C	chr15:g.66729148A>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.E120D	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=GAG;candidate_codons=GAC,GAT;candidate_snv_variants=chr15:g.66729152G>T;aliases=ENSP00000302486;source=Ensembl	c.360G>C	chr15:g.66729152G>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.F133L	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr15:g.66729191C>A,chr15:g.66729191C>G;candidate_mnv_variants=chr15:g.66729189_66729191delTTCinsCTT,chr15:g.66729189_66729191delTTCinsCTG,chr15:g.66729189_66729191delTTCinsCTA;aliases=ENSP00000302486;source=Ensembl	c.397T>C	chr15:g.66729189T>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.F133L	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr15:g.66729191C>A,chr15:g.66729191C>G;candidate_mnv_variants=chr15:g.66729189_66729191delTTCinsCTT,chr15:g.66729189_66729191delTTCinsCTG,chr15:g.66729189_66729191delTTCinsCTA;aliases=ENSP00000302486;source=Ensembl	c.397T>C	chr15:g.66729189T>C
MAP2K1:I99T,L115.,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124.,D67N	MUT		Resistant	MAP2K1 (I99T,L115,G128D,F129L,V211D,L215P,I103N,K104N,I111N,H119P,E120D,F133L,P124,D67N)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K1		CANCER	PMID:19915144		MAP2K1:p.D67N	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GAC;candidate_codons=AAC,AAT;candidate_mnv_variants=chr15:g.66727483_66727485delGACinsAAT;aliases=ENSP00000302486;source=Ensembl	c.199G>A	chr15:g.66727483G>A
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:23444215;PMID:21383288		MAP2K1:p.P124L	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=CCG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr15:g.66729163_66729164delCGinsTT,chr15:g.66729163_66729164delCGinsTA,chr15:g.66729163_66729164delCGinsTC,chr15:g.66729162_66729163delCCinsTT,chr15:g.66729162_66729164delCCGinsTTA;aliases=ENSP00000302486;source=Ensembl	c.371C>T	chr15:g.66729163C>T
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:23444215;PMID:21383288		MAP2K1:p.K57N	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr15:g.66727455G>T;aliases=ENSP00000302486;source=Ensembl	c.171G>C	chr15:g.66727455G>C
MAP2K1:P124L,K57N,C121S	MUT		Resistant	MAP2K1 (P124L,K57N,C121S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K1		CM	PMID:19915144;PMID:23444215;PMID:21383288		MAP2K1:p.C121S	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr15:g.66729154G>C;candidate_mnv_variants=chr15:g.66729153_66729155delTGCinsAGT,chr15:g.66729154_66729155delGCinsCT,chr15:g.66729154_66729155delGCinsCG,chr15:g.66729154_66729155delGCinsCA;aliases=ENSP00000302486;source=Ensembl	c.361T>A	chr15:g.66729153T>A
MAP2K1:P124.	MUT		Resistant	MAP2K1 (P124)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	MAP2K1		CM	PMID:25370473									
MAP2K1:.	MUT		Resistant	MAP2K1 oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Case report	MAP2K1		COREAD	PMID:26030179									
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	PMID:23569304		MAP2K1:p.E203K	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr15:g.66774131_66774133delGAGinsAAA;aliases=ENSP00000302486;source=Ensembl	c.607G>A	chr15:g.66774131G>A
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	PMID:23569304		MAP2K1:p.Q56P	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr15:g.66727451_66727452delAGinsCT,chr15:g.66727451_66727452delAGinsCA,chr15:g.66727451_66727452delAGinsCC;aliases=ENSP00000302486;source=Ensembl	c.167A>C	chr15:g.66727451A>C
MAP2K1:E203K,Q56P,K57E	MUT		Resistant	MAP2K1 (E203K,Q56P,K57E)	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	MAP2K1		CM	PMID:23569304		MAP2K1:p.K57E	ENST00000307102	MAP2K1	+	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=AAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr15:g.66727453_66727455delAAGinsGAA;aliases=ENSP00000302486;source=Ensembl	c.169A>G	chr15:g.66727453A>G
MAP2K1:P124S,I111S;BRAF:.	MUT;MUT		Responsive	MAP2K1 (P124S,I111S) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K1;BRAF		CM	PMID:22588879									
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.V35M	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000262948;source=Ensembl	c.103G>A	chr19:g.4117617C>T
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.L46F	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CTT;candidate_codons=TTT,TTC;candidate_mnv_variants=chr19:g.4117582_4117584delAAGinsGAA;aliases=ENSP00000262948;source=Ensembl	c.136C>T	chr19:g.4117584G>A
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.N126D	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.4110579_4110581delGTTinsATC;aliases=ENSP00000262948;source=Ensembl	c.376A>G	chr19:g.4110581T>C
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.C125S	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr19:g.4110583C>G;candidate_mnv_variants=chr19:g.4110582_4110584delGCAinsACT,chr19:g.4110582_4110583delGCinsAG,chr19:g.4110582_4110583delGCinsCG,chr19:g.4110582_4110583delGCinsTG;aliases=ENSP00000262948;source=Ensembl	c.373T>A	chr19:g.4110584A>T
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.V35M	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GTG;candidate_codons=ATG;aliases=ENSP00000262948;source=Ensembl	c.103G>A	chr19:g.4117617C>T
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.L46F	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CTT;candidate_codons=TTT,TTC;candidate_mnv_variants=chr19:g.4117582_4117584delAAGinsGAA;aliases=ENSP00000262948;source=Ensembl	c.136C>T	chr19:g.4117584G>A
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.N126D	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.4110579_4110581delGTTinsATC;aliases=ENSP00000262948;source=Ensembl	c.376A>G	chr19:g.4110581T>C
MAP2K2:V35M,L46F,N126D,C125S	MUT		Resistant	MAP2K2 (V35M,L46F,N126D,C125S)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	MAP2K2		CM	PMID:24265153		MAP2K2:p.C125S	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_3]	CSQN=Missense;reference_codon=TGC;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_snv_variants=chr19:g.4110583C>G;candidate_mnv_variants=chr19:g.4110582_4110584delGCAinsACT,chr19:g.4110582_4110583delGCinsAG,chr19:g.4110582_4110583delGCinsCG,chr19:g.4110582_4110583delGCinsTG;aliases=ENSP00000262948;source=Ensembl	c.373T>A	chr19:g.4110584A>T
MAP2K2:Q60P	MUT		Resistant	MAP2K2 (Q60P)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MAP2K2		CM	PMID:24265154		MAP2K2:p.Q60P	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.4117540_4117541delCTinsAG,chr19:g.4117540_4117541delCTinsTG,chr19:g.4117540_4117541delCTinsGG;aliases=ENSP00000262948;source=Ensembl	c.179A>C	chr19:g.4117541T>G
MAP2K2:Q60P	MUT		Resistant	MAP2K2 (Q60P)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Case report	MAP2K2		CM	PMID:24265154		MAP2K2:p.Q60P	ENST00000262948	MAP2K2	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=CAG;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr19:g.4117540_4117541delCTinsAG,chr19:g.4117540_4117541delCTinsTG,chr19:g.4117540_4117541delCTinsGG;aliases=ENSP00000262948;source=Ensembl	c.179A>C	chr19:g.4117541T>G
MCL1:amp	CNA		Resistant	MCL1 amplification	RDientsmann	[]	[Tubulin inhibitor]	Tubulin inhibitors		Pre-clinical	MCL1		CANCER	PMID:21368834									
MDM2:amp	CNA		Responsive	MDM2 amplification	RDientsmann	[]	[MDM2 inhibitor]	MDM2 inhibitors		Early trials	MDM2		LIP	PMID:23084521;ASCO 2015 (abstr 10564)									
MDM2:amp	CNA		Resistant	MDM2 amplification	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	MDM2		MGCT	PMID:27646943									
MDM4:amp	CNA		Responsive	MDM4 amplification	RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	MDM4		S	PMID:24336067									
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		HC	ENA 2015 (abstract A55)									
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Pre-clinical	MET		ST	PMID:22729845;PMID:23327903									
MET:H1112R	MUT		Responsive	MET (H1112R)	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Early trials	MET		R	PMID:23213094		MET:p.H1112R	ENST00000318493	MET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.116417464_116417465delATinsGA,chr7:g.116417464_116417465delATinsGC,chr7:g.116417464_116417465delATinsGG,chr7:g.116417463_116417465delCATinsAGG,chr7:g.116417463_116417465delCATinsAGA;aliases=ENSP00000317272;source=Ensembl	c.3335A>G	chr7:g.116417464A>G
MET:M1268T	MUT		Responsive	MET (M1268T)	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Case report	MET		R	PMID:23610116		MET:p.M1268T	ENST00000318493	MET	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.116423474_116423475delTGinsCA,chr7:g.116423474_116423475delTGinsCT,chr7:g.116423474_116423475delTGinsCC;aliases=ENSP00000317272;source=Ensembl	c.3803T>C	chr7:g.116423474T>C
MET:amp	CNA		Responsive	MET amplification	EArriola;CRubio-Perez	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Clinical Trials	Early trials	MET		NSCLC	NCT02499614;ASCO 2015 (abstr 2595)									
MET:amp	CNA		Responsive	MET amplification	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	MET		LUAD;ST	ASCO 2014 (abstr 8001);ASCO 2015 (abstr 2595);ASCO GI 2015 (abstr 1)									
MET:amp	CNA		Responsive	MET amplification	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	MET		G	PMID:22162573									
MET__.	FUS		Responsive	MET fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	MET		G	PMID:27748748									
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[MET inhibitor]	MET inhibitors		Early trials	MET		R	PMID:23213094;AACR 2016 (abstr CT2006)									
MET:1132-1330	MUT		Responsive	MET mutation in exon 16-19	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	MET		R	AACR 2016 (abstr CT2006)									
MET:amp	CNA		Resistant	MET amplification	EArriola	Osimertinib	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Osimertinib,etc)	Approved	Case report	MET		LUAD	PMID:27252416									
MET:amp	CNA		Resistant	MET amplification	EArriola	Rociletinib	[EGFR inhibitor 3rd gen]	EGFR inhibitor 3rd gens (Rociletinib,etc)		Case report	MET		LUAD	PMID:27252416									
MET:amp	CNA		Responsive	MET amplification	RDientsmann	[]	[BCL2 inhibitor]	BCL2 inhibitors		Pre-clinical	MET		COREAD	PMID:27397505									
MET:amp	CNA		Responsive	MET amplification	RDientsmann	Cabozantinib;Panitumumab	Pan-kinase inhibitor;EGFR mAb inhibitor	Cabozantinib + Panitumumab (Pan-kinase inhibitor + EGFR mAb inhibitor)	Clinical Trials	Case report	MET		COREAD	ENA 2015 (abstr A52)									
MET:amp	CNA		Resistant	MET amplification	DTamborero	[]	[EGFR inhibitor 1st gen]	EGFR inhibitor 1st gens		Early trials	MET		NSCLC;COREAD	PMID:22189054;PMID:23729478									
MET:amp	CNA		Resistant	MET amplification	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Early trials	MET		COREAD	PMID:23729478									
MET:H1112L	MUT		Responsive	MET (H1112L)	RDientsmann	[Crizotinib]	[MET inhibitor]	MET inhibitors (Crizotinib,etc)		Pre-clinical	MET		CANCER	AACR 2012 (abstr 1786)		MET:p.H1112L	ENST00000318493	MET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=CAT;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.116417464_116417465delATinsTG,chr7:g.116417464_116417465delATinsTA,chr7:g.116417464_116417465delATinsTC,chr7:g.116417463_116417465delCATinsTTA,chr7:g.116417463_116417465delCATinsTTG;aliases=ENSP00000317272;source=Ensembl	c.3335A>T	chr7:g.116417464A>T
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		MET:p.V1110I	ENST00000318493	MET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=GTA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.116417457_116417459delGTAinsATC,chr7:g.116417457_116417459delGTAinsATT;aliases=ENSP00000317272;source=Ensembl	c.3328G>A	chr7:g.116417457G>A
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		MET:p.H1112R	ENST00000318493	MET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=CAT;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr7:g.116417464_116417465delATinsGA,chr7:g.116417464_116417465delATinsGC,chr7:g.116417464_116417465delATinsGG,chr7:g.116417463_116417465delCATinsAGG,chr7:g.116417463_116417465delCATinsAGA;aliases=ENSP00000317272;source=Ensembl	c.3335A>G	chr7:g.116417464A>G
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		MET:p.M1268T	ENST00000318493	MET	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr7:g.116423474_116423475delTGinsCA,chr7:g.116423474_116423475delTGinsCT,chr7:g.116423474_116423475delTGinsCC;aliases=ENSP00000317272;source=Ensembl	c.3803T>C	chr7:g.116423474T>C
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		MET:p.R988C	ENST00000318493	MET	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=CGC;candidate_codons=TGT,TGC;candidate_mnv_variants=chr7:g.116411923_116411925delCGCinsTGT;aliases=ENSP00000317272;source=Ensembl	c.2962C>T	chr7:g.116411923C>T
MET:V1110I,H1112R,M1268T,R988C,T1010I	MUT		Responsive	MET (V1110I,H1112R,M1268T,R988C,T1010I)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355		MET:p.T1010I	ENST00000318493	MET	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=ACT;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr7:g.116411990_116411991delCTinsTC,chr7:g.116411990_116411991delCTinsTA;aliases=ENSP00000317272;source=Ensembl	c.3029C>T	chr7:g.116411990C>T
MET:Y1230C;Y1235D	MUT		Resistant	MET (Y1230C;Y1235D)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Pre-clinical	MET		CANCER	PMID:17483355									
MET:amp;BRAF:V600E	CNA;MUT		Resistant	MET amplification + BRAF (V600E)	RDientsmann	Vemurafenib;Panitumumab	BRAF inhibitor;EGFR mAb inhibitor	Vemurafenib + Panitumumab (BRAF inhibitor + EGFR mAb inhibitor)		Case report	MET;BRAF		COREAD	PMID:27325282									
MET:amp;BRAF:V600E	CNA;MUT		Responsive	MET amplification + BRAF (V600E)	RDientsmann	Crizotinib;Vemurafenib	ALK inhibitor;BRAF inhibitor	Crizotinib + Vemurafenib (ALK inhibitor + BRAF inhibitor)		Case report	MET;BRAF		COREAD	PMID:27325282									
MET:amp;EGFR:.	CNA;MUT		Resistant	MET amplification + EGFR oncogenic mutation	RDientsmann	[]	[EGFR TK inhibitor]	EGFR TK inhibitors		Early trials	MET;EGFR		LUAD	ASCO 2015 (abstr 8089)									
MET:amp;ERBB2:amp	CNA;CNA		Responsive	MET amplification + ERBB2 amplification	RDientsmann	Crizotinib;Trastuzumab	ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)		Case report	MET;ERBB2		ST	PMID:26432108									
MET:amp;ERBB2:amp	CNA;CNA		Responsive	MET amplification + ERBB2 amplification	RDientsmann	Crizotinib;Trastuzumab	ALK inhibitor;ERBB2 mAb inhibitor	Crizotinib + Trastuzumab (ALK inhibitor + ERBB2 mAb inhibitor)		Case report	MET;ERBB2		ST	PMID:26432108									
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	MET;ERBB2		ST	PMID:22238368									
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	MET;ERBB2		BRCA	PMID:22850551									
MET:amp;ERBB2:amp	CNA;CNA		Resistant	MET amplification + ERBB2 amplification	RDientsmann	Trastuzumab	ERBB2 mAb inhibitor	Trastuzumab (ERBB2 mAb inhibitor)		Early trials	MET;ERBB2		BRCA;ST	PMID:22850551; PMID:26432108									
MITF:amp	CNA		Resistant	MITF amplification	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MITF		CM	PMID:24265153									
MITF:amp	CNA		Resistant	MITF amplification	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	MITF		CM	PMID:24265153									
MKI67:over	EXPR	Cell line	Responsive	MKI67 overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	MKI67		R	PMID:24086736	Indirect								
MLL__.	FUS		Responsive	MLL fusion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	MLL		AML	PMID:21964340									
MLL__.	FUS		Responsive	MLL fusion	ECampo;RDientsmann	Belinostat	HDAC inhibitor	Belinostat (HDAC inhibitor)	Approved	Early trials	MLL		AML	NCT00351975;NCT00357032;PMID:22015773	Indirect								
MLL__.	FUS		Responsive	MLL fusion	RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	MLL		AML	PMID:22417203									
MLL__.	FUS		Responsive	MLL fusion	ECampo;RDientsmann	EPZ-5676	DOTL1 inhibitor	EPZ-5676 (DOTL1 inhibitor)	Clinical Trials	Early trials	MLL		AML;ALL;MDS	NCT02141828;NCT01684150;PMID:21741596	Indirect								
MPL:W515F	MUT		Responsive	MPL (W515F)	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	MPL		MDPS	PMID:16834459		MPL:p.W515F	ENST00000372470	MPL	+	inside_[cds_in_exon_10]	CSQN=Missense;reference_codon=TGG;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.43815009_43815010delGGinsTC;aliases=ENSP00000361548;source=Ensembl	c.1544_1545delGGinsTT	chr1:g.43815009_43815010delGGinsTT
MSH3:.	MUT		Responsive	MSH3 oncogenic mutation	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	MSH3		CANCER	PMID:24556366									
MTOR:F2108L	MUT		Responsive	MTOR (F2108L)	RDientsmann	[]	[MTOR kinase inhibitor]	MTOR kinase inhibitors		Pre-clinical	MTOR		CANCER	PMID:25295501		MTOR:p.F2108L	ENST00000361445	MTOR	-	inside_[cds_in_exon_45]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr1:g.11187094G>T,chr1:g.11187094G>C;candidate_mnv_variants=chr1:g.11187094_11187096delGAAinsAAG,chr1:g.11187094_11187096delGAAinsCAG,chr1:g.11187094_11187096delGAAinsTAG;aliases=ENSP00000354558;source=Ensembl	c.6322T>C	chr1:g.11187096A>G
MTOR:K1771R	MUT		Responsive	MTOR (K1771R)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		ST;AG	ASCO 2015 (abstr 11010);PMID:26859683		MTOR:p.K1771R	ENST00000361445	MTOR	-	inside_[cds_in_exon_38]	CSQN=Missense;reference_codon=AAA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_mnv_variants=chr1:g.11193188_11193189delTTinsCC,chr1:g.11193189_11193190delTTinsCG,chr1:g.11193188_11193190delTTTinsGCG,chr1:g.11193188_11193190delTTTinsCCG,chr1:g.11193188_11193190delTTTinsACG;aliases=ENSP00000354558;source=Ensembl	c.5312A>G	chr1:g.11193189T>C
MTOR:Q2223K	MUT		Responsive	MTOR (Q2223K)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		R	PMID:24622468		MTOR:p.Q2223K	ENST00000361445	MTOR	-	inside_[cds_in_exon_48]	CSQN=Missense;reference_codon=CAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11182177_11182179delCTGinsTTT;aliases=ENSP00000354558;source=Ensembl	c.6667C>A	chr1:g.11182179G>T
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	PMID:24625776		MTOR:p.E2014K	ENST00000361445	MTOR	-	inside_[cds_in_exon_44]	CSQN=Missense;reference_codon=GAG;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11187855_11187857delCTCinsTTT;aliases=ENSP00000354558;source=Ensembl	c.6040G>A	chr1:g.11187857C>T
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	PMID:24625776		MTOR:p.E2419K	ENST00000361445	MTOR	-	inside_[cds_in_exon_53]	CSQN=Missense;reference_codon=GAA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr1:g.11174418_11174420delTTCinsCTT;aliases=ENSP00000354558;source=Ensembl	c.7255G>A	chr1:g.11174420C>T
MTOR:E2014K,E2419K,N1421D	MUT		Responsive	MTOR (E2014K,E2419K,N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		BLCA	PMID:24625776		MTOR:p.N1421D	ENST00000361445	MTOR	-	inside_[cds_in_exon_29]	CSQN=Missense;reference_codon=AAT;candidate_codons=GAC,GAT;candidate_mnv_variants=chr1:g.11227565_11227567delATTinsGTC;aliases=ENSP00000354558;source=Ensembl	c.4261A>G	chr1:g.11227567T>C
MTOR:I1973F	MUT		Responsive	MTOR (I1973F)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		AS;R	ASCO 2015 (abstr 11010);PMID:26859683		MTOR:p.I1973F	ENST00000361445	MTOR	-	inside_[cds_in_exon_43]	CSQN=Missense;reference_codon=ATC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr1:g.11188175_11188177delGATinsAAA;aliases=ENSP00000354558;source=Ensembl	c.5917A>T	chr1:g.11188177T>A
MTOR:N1421D	MUT		Responsive	MTOR (N1421D)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		ST	PMID:26859683		MTOR:p.N1421D	ENST00000361445	MTOR	-	inside_[cds_in_exon_29]	CSQN=Missense;reference_codon=AAT;candidate_codons=GAC,GAT;candidate_mnv_variants=chr1:g.11227565_11227567delATTinsGTC;aliases=ENSP00000354558;source=Ensembl	c.4261A>G	chr1:g.11227567T>C
MTOR:F2108L	MUT		Resistant	MTOR (F2108L)	DTamborero;RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	MTOR		THCA	PMID:25295501		MTOR:p.F2108L	ENST00000361445	MTOR	-	inside_[cds_in_exon_45]	CSQN=Missense;reference_codon=TTC;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_snv_variants=chr1:g.11187094G>T,chr1:g.11187094G>C;candidate_mnv_variants=chr1:g.11187094_11187096delGAAinsAAG,chr1:g.11187094_11187096delGAAinsCAG,chr1:g.11187094_11187096delGAAinsTAG;aliases=ENSP00000354558;source=Ensembl	c.6322T>C	chr1:g.11187096A>G
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	PMID:24631838		MTOR:p.L1460P	ENST00000361445	MTOR	-	inside_[cds_in_exon_30]	CSQN=Missense;reference_codon=CTT;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr1:g.11217298_11217299delAAinsCG,chr1:g.11217298_11217299delAAinsTG,chr1:g.11217298_11217299delAAinsGG;aliases=ENSP00000354558;source=Ensembl	c.4379T>C	chr1:g.11217299A>G
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	PMID:24631838		MTOR:p.S2215Y	ENST00000361445	MTOR	-	inside_[cds_in_exon_47]	CSQN=Missense;reference_codon=TCT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr1:g.11184572_11184573delAGinsGT;aliases=ENSP00000354558;source=Ensembl	c.6644C>A	chr1:g.11184573G>T
MTOR:L1460P,S2215Y,R2505P	MUT		Responsive	MTOR (L1460P,S2215Y,R2505P)	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Pre-clinical	MTOR		CANCER	PMID:24631838		MTOR:p.R2505P	ENST00000361445	MTOR	-	inside_[cds_in_exon_56]	CSQN=Missense;reference_codon=CGA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr1:g.11169360_11169361delTCinsAG,chr1:g.11169360_11169361delTCinsCG,chr1:g.11169360_11169361delTCinsGG;aliases=ENSP00000354558;source=Ensembl	c.7514G>C	chr1:g.11169361C>G
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	Temozolomide	Chemotherapy	Temozolomide (Chemotherapy)		Pre-clinical	MYC		COREAD	PMID:27397505									
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[FACT inhibitor]	FACT inhibitors		Pre-clinical	MYC		NB	PMID:26537256									
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	MYC		MYMA;NB	PMID:21889194;PMID:23430699									
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[CDK7 inhibitor]	CDK7 inhibitors		Pre-clinical	MYC		NB	PMID:25416950									
MYC:amp	CNA		Responsive	MYC amplification	RDientsmann	[]	[PIM inhibitor]	PIM inhibitors		Pre-clinical	MYC		PRAD	PMID:25505253									
MYCN:amp	CNA		Resistant	MYCN amplification	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	MYCN		MB	PMID:24951114									
NF1:D1644A	MUT		Responsive	NF1 (D1644A)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC	ASCO 2015 (abstr 11010);PMID:26859683		NF1:p.D1644A	ENST00000358273	NF1	+	inside_[cds_in_exon_37]	CSQN=Missense;reference_codon=GAC;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr17:g.29652933_29652934delACinsCA,chr17:g.29652933_29652934delACinsCG,chr17:g.29652933_29652934delACinsCT;aliases=ENSP00000351015;source=Ensembl	c.4931A>C	chr17:g.29652933A>C
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		MPN	PMID:23221341									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		MPN	PMID:23221341									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[AURK inhibitor]	AURK inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[BRD4 inhibitor]	BRD4 inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[BRD4 inhibitor]	BRD4 inhibitors		Pre-clinical	NF1		MPN	PMID:24373973									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MTOR inhibitor;HSP90 inhibitor]	MTOR inhibitor + HSP90 inhibitors		Pre-clinical	NF1		MPN	PMID:21907929									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor;HSP90 inhibitor]	MTOR inhibitor + HSP90 inhibitors		Pre-clinical	NF1		MPN	PMID:21907929									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	NF1		CM	ASCO 2016 (abstr 105)									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	NF1		CM	ASCO 2016 (abstr 105)									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF1		G;MPN;LK	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF1		G;MPN;LK	PMID:19573811;PMID:18483311;PMID:20505189;PMID:24509877									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[KIT inhibitor;MTOR inhibitor]	KIT inhibitor + MTOR inhibitors		Pre-clinical	NF1		MPN	PMID:24718867									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[KIT inhibitor;MTOR inhibitor]	KIT inhibitor + MTOR inhibitors		Pre-clinical	NF1		MPN	PMID:24718867									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		G;LK	PMID:22573716;PMID:19727076									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF1		G;LK	PMID:22573716;PMID:19727076									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	[]	[Pan-RAF inhibitor;MEK inhibitor]	Pan-RAF inhibitor + MEK inhibitors		Pre-clinical	NF1		CM	PMID:26351322									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	[]	[Pan-RAF inhibitor;MEK inhibitor]	Pan-RAF inhibitor + MEK inhibitors		Pre-clinical	NF1		CM	PMID:26351322									
NF1:del	CNA		Resistant	NF1 deletion	RDientsmann	[]	[Retinoic Acid]	Retinoic Acids		Pre-clinical	NF1		NB	PMID:20655465									
NF1:.	MUT		Resistant	NF1 oncogenic mutation	RDientsmann	[]	[Retinoic Acid]	Retinoic Acids		Pre-clinical	NF1		NB	PMID:20655465									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Case report	NF1		G	PMID:24232489;PMID:2485933									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Case report	NF1		G	PMID:24232489;PMID:2485933									
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Cediranib	ALK inhibitor	Cediranib (ALK inhibitor)		Early trials	NF1		PLEN	NCT00326872									
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Cediranib	ALK inhibitor	Cediranib (ALK inhibitor)		Early trials	NF1		PLEN	NCT00326872									
NF1:del	CNA		Resistant	NF1 deletion	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		L	PMID:24296828									
NF1:.	MUT		Resistant	NF1 oncogenic mutation	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		L	PMID:24296828									
NF1:del	CNA		Resistant	NF1 deletion	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	NF1		L	PMID:24535670									
NF1:.	MUT		Resistant	NF1 oncogenic mutation	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Pre-clinical	NF1		L	PMID:24535670									
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF1		MPN	NCT01365468									
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF1		MPN	NCT01365468									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC;SG	PMID:26859683;ASCO 2016 (abstr e17557)									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	NF1		HNC;SG	PMID:26859683;ASCO 2016 (abstr e17557)									
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Everolimus;Bevacizumab	MTOR inhibitor;VEGFR mAb inhibitor	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)		Early trials	NF1		MPN	ASCO 2016 (abstr 11053)									
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus;Bevacizumab	MTOR inhibitor;VEGFR mAb inhibitor	Everolimus + Bevacizumab (MTOR inhibitor + VEGFR mAb inhibitor)		Early trials	NF1		MPN	ASCO 2016 (abstr 11053)									
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Everolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:24634382									
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Everolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:24634382									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Everolimus;Pazopanib	MTOR inhibitor;VEGFR inhibitor	Everolimus + Pazopanib (MTOR inhibitor + VEGFR inhibitor)		Case report	NF1		HC	PMID:24931142									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	NF1		PLEN	PMID:23099009									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Early trials	NF1		PLEN	PMID:23099009									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		PLEN;MPN	PMID:24173684									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	NF1		PLEN;MPN	PMID:24173684									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	PLX3397	Pan-TK inhibitor	PLX3397 (Pan-TK inhibitor)		Pre-clinical	NF1		PLEN	PMID:23099891									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	PLX3397	Pan-TK inhibitor	PLX3397 (Pan-TK inhibitor)		Pre-clinical	NF1		PLEN	PMID:23099891									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	NF1		PLEN	ASCO 2014 (abstr 10018)									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Early trials	NF1		PLEN	ASCO 2014 (abstr 10018)									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	NF1		PLEN	PMID:25314964									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	NF1		PLEN	PMID:25314964									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Sirolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:22434731									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Sirolimus;Erlotinib	MTOR inhibitor;EGFR inhibitor 1st gen	Sirolimus + Erlotinib (MTOR inhibitor + EGFR inhibitor 1st gen)		Case report	NF1		G	PMID:22434731									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Sorafenib;Sirolimus	Pan-TK inhibitor;MTOR inhibitor	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)		Pre-clinical	NF1		MPN	PMID:25810463									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Sorafenib;Sirolimus	Pan-TK inhibitor;MTOR inhibitor	Sorafenib + Sirolimus (Pan-TK inhibitor + MTOR inhibitor)		Pre-clinical	NF1		MPN	PMID:25810463									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Pre-clinical	NF1		MPN	PMID:21075781									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Tamoxifen	Hormonal therapy	Tamoxifen (Hormonal therapy)		Pre-clinical	NF1		MPN	PMID:21075781									
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	NF1		PLEN	PMID:24500418									
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Tipifarnib	Farnesyltransferase inhibitor	Tipifarnib (Farnesyltransferase inhibitor)		Early trials	NF1		PLEN	PMID:24500418									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		G	PMID:26936308									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		G	PMID:26936308									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	NF1		CM	PMID:24576830;PMID:2524381									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Pre-clinical	NF1		CM	PMID:24576830;PMID:2524381									
NF1:del	CNA		No Responsive	NF1 deletion	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		OS	PMID:26325560									
NF1:.	MUT		No Responsive	NF1 oncogenic mutation	RDientsmann	Trametinib	MEK inhibitor	Trametinib (MEK inhibitor)		Case report	NF1		OS	PMID:26325560									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Vinblastine	Chemotherapy	Vinblastine (Chemotherapy)		Early trials	NF1		G	ASCO 2016 (abstr 2019)									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Vinblastine	Chemotherapy	Vinblastine (Chemotherapy)		Early trials	NF1		G	ASCO 2016 (abstr 2019)									
NF1:del	CNA		Responsive	NF1 deletion	RDientsmann	Vinblastine;Nilotinib	Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)		Case report	NF1		G	ASCO 2016 (abstr 10555)									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	RDientsmann	Vinblastine;Nilotinib	Chemotherapy;BCR-ABL inhibitor 2nd gen	Vinblastine + Nilotinib (Chemotherapy + BCR-ABL inhibitor 2nd gen)		Case report	NF1		G	ASCO 2016 (abstr 10555)									
NF1:.	MUT		Responsive	NF1 oncogenic mutation	MMartínez	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Late trials	NF1		NF	NCT01365468	Indirect								
NF1:.	BIA		Resistant	NF1 biallelic inactivation	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Pre-clinical	NF1		CM	PMID:23171796									
NF1:del;BRAF:.	CNA;MUT		Resistant	NF1 deletion + BRAF oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	NF1;BRAF		CM	PMID:23444215									
NF1:.;BRAF:.	MUT;MUT		Resistant	NF1 oncogenic mutation + BRAF oncogenic mutation	RDientsmann	Selumetinib	MEK inhibitor	Selumetinib (MEK inhibitor)		Case report	NF1;BRAF		CM	PMID:23444215									
NF1:del;BRAF:.	CNA;MUT		Resistant	NF1 deletion + BRAF oncogenic mutation	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	NF1;BRAF		CM	PMID:23288408;PMID:231718									
NF1:.;BRAF:.	MUT;MUT		Resistant	NF1 oncogenic mutation + BRAF oncogenic mutation	RDientsmann	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Case report	NF1;BRAF		CM	PMID:23288408;PMID:231718									
SLC44A4:over	EXPR		Responsive	SLC44A4 overexpression	CRubio-Perez	[]	[SLC44A4 inhibitor]	SLC44A4 inhibitors		Pre-clinical	SLC44A4		PRAD;PAAD	PMID:27550944 									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Early trials	NF2		MESO	ENA 2012 (abstr 610)									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Early trials	NF2		MESO	ENA 2012 (abstr 610)									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	NF2		MESO;OV	PMID:24848258;PMID:24786638									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[FAK inhibitor]	FAK inhibitors		Pre-clinical	NF2		MESO;OV	PMID:24848258;PMID:24786638									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NF2		MEN	PMID:23714726									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NF2		MEN	PMID:23714726									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	NF2		SCHW;MEN	PMID:23960073;PMID:25596744									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	NF2		SCHW;MEN	PMID:23960073;PMID:25596744									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[PDK1 inhibitor]	PDK1 inhibitors		Pre-clinical	NF2		SCHW	PMID:19359162									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[PDK1 inhibitor]	PDK1 inhibitors		Pre-clinical	NF2		SCHW	PMID:19359162									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF2		TH	PMID:26359368									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NF2		TH	PMID:26359368									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Pre-clinical	NF2		SCHW	PMID:21778190									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Pre-clinical	NF2		SCHW	PMID:21778190									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Early trials	NF2		MEN	ASCO 2016 (abstr 2558)									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	AR42	HDAC inhibitor	AR42 (HDAC inhibitor)		Early trials	NF2		MEN	ASCO 2016 (abstr 2558)									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Early trials	NF2		SCHW	PMID:19587327;PMID:22805104;PMID:26022982									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Bevacizumab	VEGFR mAb inhibitor	Bevacizumab (VEGFR mAb inhibitor)		Early trials	NF2		SCHW	PMID:19587327;PMID:22805104;PMID:26022982									
NF2:del	CNA		No Responsive	NF2 deletion	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Early trials	NF2		SCHW	PMID:20736812									
NF2:.	MUT		No Responsive	NF2 oncogenic mutation	RDientsmann	Erlotinib	EGFR inhibitor 1st gen	Erlotinib (EGFR inhibitor 1st gen)		Early trials	NF2		SCHW	PMID:20736812									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF2		SCHW	PMID:24311643;2556735									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	NF2		SCHW	PMID:24311643;2556735									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Everolimus;Octreotide	MTOR inhibitor;Somatostatin analog	Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)		Pre-clinical	NF2		MEN	PMID:26015296									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Everolimus;Octreotide	MTOR inhibitor;Somatostatin analog	Everolimus + Octreotide (MTOR inhibitor + Somatostatin analog)		Pre-clinical	NF2		MEN	PMID:26015296									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	NF2		SCHW	PMID:19509233;PMID:2290085									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	NF2		SCHW	PMID:19509233;PMID:2290085									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann;MMartínez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	NF2		SCHW;NF	PMID:22844108;NCT00973739									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann;MMartínez	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Early trials	NF2		SCHW;NF	PMID:22844108;NCT00973739									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	Tensirolimus;Chemotherapy	MTOR inhibitor;Chemotherapy	Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)		Case report	NF2		BRCA	PMID:25878190									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	Tensirolimus;Chemotherapy	MTOR inhibitor;Chemotherapy	Tensirolimus + Chemotherapy (MTOR inhibitor + Chemotherapy)		Case report	NF2		BRCA	PMID:25878190									
NF2:del	CNA		Responsive	NF2 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF2		MEN	PMID:19451225;PMID:2242646									
NF2:.	MUT		Responsive	NF2 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	NF2		MEN	PMID:19451225;PMID:2242646									
NF2:del;EGFR:.	CNA;MUT		Resistant	NF2 deletion + EGFR oncogenic mutation	RDientsmann	Erlotinib;Cetuximab	EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)		Case report	NF2;EGFR		L	PMID:24813888									
NF2:.;EGFR:.	MUT;MUT		Resistant	NF2 oncogenic mutation + EGFR oncogenic mutation	RDientsmann	Erlotinib;Cetuximab	EGFR inhibitor 1st gen;EGFR mAb inhibitor	Erlotinib + Cetuximab (EGFR inhibitor 1st gen + EGFR mAb inhibitor)		Case report	NF2;EGFR		L	PMID:24813888									
NOTCH1__.	FUS		Responsive	NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		ALL	PMID:16688224;PMID:23033986									
NOTCH1__.	FUS		Responsive	NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		BRCA	PMID:22101766									
NOTCH1:.	MUT		Responsive	NOTCH1 activating mutation (missense in TAD or truncating in Cterm domain)	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH1		MCL	PMID:22210878									
NOTCH2__.	FUS		Responsive	NOTCH2 activating mutation (missense in TAD or truncating in Cterm domain)	RDientsmann	[]	[Gamma secretase inhibitor]	Gamma secretase inhibitors		Pre-clinical	NOTCH2		BRCA	PMID:22101766									
NPM1:.	MUT		Responsive	NPM1 oncogenic mutation	RDientsmann	[]	[DOT1L inhibitors;MLL1 inhibitors]	DOT1L inhibitors + MLL1 inhibitorss		Pre-clinical	NPM1		AML	PMID:27535106									
NPM1:.	MUT		Responsive	NPM1 oncogenic mutation	RDientsmann	Daunorubicin	Chemotherapy	Daunorubicin (Chemotherapy)	Approved	FDA guidelines	NPM1		AML	PMID:22417203									
NRAS:Q61.	MUT		Responsive	NRAS (Q61)	RDientsmann	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors		Case report	NRAS		CM	ESMO 2015 (abstract 300)									
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor +/- PI3K pathway inhibitor]	MEK inhibitor +/- PI3K pathway inhibitors		Pre-clinical	NRAS		COREAD	PMID:23274911;PMID:22392911									
NRAS:Q61.	MUT		Responsive	NRAS (Q61)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	NRAS		CM	PMID:23538902									
NRAS:Q61.	MUT		Resistant	NRAS (Q61)	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Early trials	NRAS		CM	PMID:23569304;PMID:24265153									
NRAS:Q61.	MUT		Responsive	NRAS (Q61)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	NRAS		CM	PMID:23614898									
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	Sorafenib;MEK inhibitor	Pan-TK inhibitor;MEK inhibitor	Sorafenib + MEK inhibitor (Pan-TK inhibitor + MEK inhibitor)		Early trials,Case report	NRAS		HC	PMID:25294897									
NRAS:Q61.	MUT		Responsive	NRAS (Q61)	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Late trials	NRAS		CM	PMID:23414587,ASCO 2016 (abstr 9500)									
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	DTamborero;CRubio-Perez;RDientsmann	[]	[CDK4/6 inhibitor;MEK inhibitor]	CDK4/6 inhibitor + MEK inhibitors	Approved	Early trials	NRAS		CM	PMID:26658964;NCT01781572;NCT02065063;NCT02022982;ASCO 2014 (abstr 9009)	Indirect								
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	NRAS		AML;LUAD;ALL	PMID:22507781;PMID:23515407;PMID:18701506									
NRAS:.	MUT		Responsive	NRAS oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	NRAS		MYMA	PMID:22985491									
NRAS:G12C	MUT		Responsive	NRAS (G12C)	RDientsmann	[]	[ERK inhibitor]	ERK inhibitors		Pre-clinical	NRAS		CANCER	PMID:23614898		NRAS:p.G12C	ENST00000369535	NRAS	-	inside_[cds_in_exon_2]	CSQN=Missense;reference_codon=GGT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.115258746_115258748delACCinsGCA;aliases=ENSP00000358548;source=Ensembl	c.34G>T	chr1:g.115258748C>A
NRAS:.	MUT		Resistant	NRAS oncogenic mutation	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	NCCN guidelines	NRAS		COREAD	PMID:24024839;PMID:20619739;PMID:23325582									
NRAS:.	MUT		Resistant	NRAS oncogenic mutation	RDientsmann	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)	Approved	NCCN guidelines	NRAS		COREAD	PMID:24024839;PMID:20619739;PMID:23325582									
NRAS:.	MUT		Resistant	NRAS oncogenic mutation	DTamborero	Vemurafenib	BRAF inhibitor	Vemurafenib (BRAF inhibitor)		Pre-clinical	NRAS		CM	PMID:20179705									
NRG1__.	FUS		Responsive	NRG1 fusion	RDientsmann	Afatinib	ERBB2&EGFR inhibitor 2nd gen	Afatinib (ERBB2&EGFR inhibitor 2nd gen)		Case report	NRG1		LUAD	AACR 2016 (abstr 2631)									
NRG1__.	FUS		Responsive	NRG1 fusion	RDientsmann	Lapatinib	ERBB2 inhibitor	Lapatinib (ERBB2 inhibitor)		Pre-clinical	NRG1		LUAD	PMID:24727320									
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	[]	[Pan-TK inhibitor]	Pan-TK inhibitors		Pre-clinical	NTRK1		LUAD	PMID:24162815									
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	NTRK1		LUAD	ASCO 2013 (abstr 8023)									
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	[]	[Pan-TKR inhibitor]	Pan-TKR inhibitors		Early trials	NTRK1		CANCER	AACR 2016 (abstr CT007), AACR 2016 (abstr CT008)									
NTRK1__.	FUS		Responsive	NTRK1 fusion	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	PMID:26546295									
NTRK1:G595R,G667C	MUT		Resistant	NTRK1 (G595R,G667C)	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	PMID:26546295		NTRK1:p.G595R	ENST00000524377	NTRK1	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=GGG;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr1:g.156846342G>C;candidate_mnv_variants=chr1:g.156846342_156846344delGGGinsAGA,chr1:g.156846342_156846344delGGGinsCGA,chr1:g.156846342_156846344delGGGinsCGC,chr1:g.156846342_156846344delGGGinsCGT;aliases=ENSP00000431418;source=Ensembl	c.1783G>A	chr1:g.156846342G>A
NTRK1:G595R,G667C	MUT		Resistant	NTRK1 (G595R,G667C)	RDientsmann	[Entrectinib]	[Pan-TK inhibitor]	Pan-TK inhibitors (Entrectinib,etc)		Case report	NTRK1		COREAD	PMID:26546295		NTRK1:p.G667C	ENST00000524377	NTRK1	+	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=GGT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr1:g.156849107_156849109delGGTinsTGC;aliases=ENSP00000431418;source=Ensembl	c.1999G>T	chr1:g.156849107G>T
NTRK3__.	FUS		Responsive	NTRK3 fusion	RDientsmann	[]	[IGF1R inhibitor]	IGF1R inhibitors		Pre-clinical	NTRK3		BRCA	PMID:21148487;PMID:23131561									
NTRK3__.	FUS		Responsive	NTRK3 fusion	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	NTRK3		BRCA	PMID:21148487;PMID:23131561									
NTRK3__.	FUS		Responsive	NTRK3 fusion	RDientsmann	Midostaurin	Pan-TK inhibitor	Midostaurin (Pan-TK inhibitor)		Pre-clinical	NTRK3		BRCA	PMID:21148487;PMID:23131561									
PAK1:amp	CNA		Responsive	PAK1 amplification	RDientsmann	[]	[PAK inhibitor]	PAK inhibitors		Pre-clinical	PAK1		CM	PMID:23535073									
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	PALB2		PRAD	AACR 2015 (abstr CT322);PMID:26510020									
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	PALB2		PRAD	AACR 2015 (abstr CT322);PMID:26510020									
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	PALB2		PA	PMID:25263539;NCT01585805									
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	PALB2		PA	PMID:25263539;NCT01585805									
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	Mytomycin C	Chemotherapy	Mytomycin C (Chemotherapy)		Case report	PALB2		PA	PMID:21135251									
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	Mytomycin C	Chemotherapy	Mytomycin C (Chemotherapy)		Case report	PALB2		PA	PMID:21135251									
PALB2:.	MUT		Responsive	PALB2 oncogenic mutation	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	PALB2		PA	PMID:25719666									
PALB2:del	CNA		Responsive	PALB2 deletion	RDientsmann	Platinum Agent	Chemotherapy	Platinum Agent (Chemotherapy)		Case report	PALB2		PA	PMID:25719666									
PBRM1:del	CNA		Responsive	PBRM1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	PBRM1		CANCER	PMID:26552009									
PBRM1:.	MUT		Responsive	PBRM1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	PBRM1		CANCER	PMID:26552009									
PBRM1:under	EXPR	Cell line	Responsive	PBRM1 undexpression	ARodriguez-Vida	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Pre-clinical	PBRM1		R	PMID:25997916									
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	PDGFRA		GIST	PMID:18794084		PDGFRA:p.D842V	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	c.2525A>T	chr4:g.55152093A>T
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)	RDientsmann	Dasatinib	BCR-ABL inhibitor 2nd gen	Dasatinib (BCR-ABL inhibitor 2nd gen)		Pre-clinical	PDGFRA		GIST	PMID:18794084		PDGFRA:p.D842V	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	c.2525A>T	chr4:g.55152093A>T
PDGFRA:D842V	MUT		Resistant	PDGFRA (D842V)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Late trials,Pre-clinical	PDGFRA		GIST	PMID:22718859;PMID:16638875		PDGFRA:p.D842V	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	c.2525A>T	chr4:g.55152093A>T
PDGFRA:D842V	MUT		Resistant	PDGFRA (D842V)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Late trials,Pre-clinical	PDGFRA		GIST	PMID:22718859;PMID:16638875		PDGFRA:p.D842V	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	c.2525A>T	chr4:g.55152093A>T
PDGFRA:D842V	MUT		Responsive	PDGFRA (D842V)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Early trials	PDGFRA		GIST	ASCO 2016 (abstr 11010)		PDGFRA:p.D842V	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GAC;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr4:g.55152093_55152094delACinsTA,chr4:g.55152093_55152094delACinsTG,chr4:g.55152093_55152094delACinsTT;aliases=ENSP00000257290;source=Ensembl	c.2525A>T	chr4:g.55152093A>T
PDGFRA:over	EXPR	Cell line	Responsive	PDGFRA overexpression	ARodriguez-Vida	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	Pre-clinical	PDGFRA		R	PMID:24086736	Direct								
PDGFRA:amp	CNA		No Responsive	PDGFRA amplification	RDientsmann	[]	[PDGFR inhibitor]	PDGFR inhibitors		Pre-clinical	PDGFRA		G	PMID:23544171									
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.V658A	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=GTA;candidate_codons=GCA,GCC,GCG,GCT;candidate_mnv_variants=chr4:g.55144144_55144145delTAinsCC,chr4:g.55144144_55144145delTAinsCG,chr4:g.55144144_55144145delTAinsCT;aliases=ENSP00000257290;source=Ensembl	c.1973T>C	chr4:g.55144144T>C
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.P577S	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr4:g.55141083_55141085delCCGinsTCT,chr4:g.55141083_55141085delCCGinsTCC,chr4:g.55141083_55141085delCCGinsTCA,chr4:g.55141083_55141085delCCGinsAGC,chr4:g.55141083_55141085delCCGinsAGT;aliases=ENSP00000257290;source=Ensembl	c.1729C>T	chr4:g.55141083C>T
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.R841K	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr4:g.55152090_55152091delGAinsAG;aliases=ENSP00000257290;source=Ensembl	c.2522G>A	chr4:g.55152090G>A
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.H845Y	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55152101_55152103delCATinsTAC;aliases=ENSP00000257290;source=Ensembl	c.2533C>T	chr4:g.55152101C>T
PDGFRA:V658A,P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (V658A,P577S,R841K,H845Y,G853D)	RDientsmann	Crenolanib	FLT3 inhibitor	Crenolanib (FLT3 inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.G853D	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr4:g.55152126_55152127delGCinsAT;aliases=ENSP00000257290;source=Ensembl	c.2558G>A	chr4:g.55152126G>A
PDGFRA__FIP1L1	FUS		Responsive	PDGFRA-FIP1L1 fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFRA		HES;ECL	EMA									
PDGFRA__.	FUS		Responsive	PDGFRA fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFRA		MDS;MDPS	EMA									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:R748G,Y894C	MUT		Responsive	PDGFRA (R748G,Y894C)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines		PDGFRA:p.R748G	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=AGG;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr4:g.55146568_55146570delAGGinsGGT,chr4:g.55146568_55146570delAGGinsGGA,chr4:g.55146568_55146570delAGGinsGGC;aliases=ENSP00000257290;source=Ensembl	c.2242A>G	chr4:g.55146568A>G
PDGFRA:T674I	MUT		Resistant	PDGFRA (T674I)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Case report	PDGFRA		HES	PMID:12660384		PDGFRA:p.T674I	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=ACA;candidate_codons=ATC,ATA,ATT;candidate_mnv_variants=chr4:g.55144547_55144548delCAinsTC,chr4:g.55144547_55144548delCAinsTT;aliases=ENSP00000257290;source=Ensembl	c.2021C>T	chr4:g.55144547C>T
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.P577S	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_12]	CSQN=Missense;reference_codon=CCG;candidate_codons=AGC,AGT,TCT,TCG,TCC,TCA;candidate_mnv_variants=chr4:g.55141083_55141085delCCGinsTCT,chr4:g.55141083_55141085delCCGinsTCC,chr4:g.55141083_55141085delCCGinsTCA,chr4:g.55141083_55141085delCCGinsAGC,chr4:g.55141083_55141085delCCGinsAGT;aliases=ENSP00000257290;source=Ensembl	c.1729C>T	chr4:g.55141083C>T
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.R841K	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=AGA;candidate_codons=AAG,AAA;candidate_mnv_variants=chr4:g.55152090_55152091delGAinsAG;aliases=ENSP00000257290;source=Ensembl	c.2522G>A	chr4:g.55152090G>A
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.H845Y	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=CAT;candidate_codons=TAT,TAC;candidate_mnv_variants=chr4:g.55152101_55152103delCATinsTAC;aliases=ENSP00000257290;source=Ensembl	c.2533C>T	chr4:g.55152101C>T
PDGFRA:P577S,R841K,H845Y,G853D	MUT		Responsive	PDGFRA (P577S,R841K,H845Y,G853D)	RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PDGFRA		CM	PMID:24132921		PDGFRA:p.G853D	ENST00000257290	PDGFRA	+	inside_[cds_in_exon_18]	CSQN=Missense;reference_codon=GGC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr4:g.55152126_55152127delGCinsAT;aliases=ENSP00000257290;source=Ensembl	c.2558G>A	chr4:g.55152126G>A
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Regorafenib	Pan-kinase inhibitor	Regorafenib (Pan-kinase inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRA:552-596,631-668,814-854	MUT		Responsive	PDGFRA (552-596,631-668,814-854)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)	Approved	NCCN guidelines	PDGFRA		GIST	NCCN guidelines									
PDGFRB__COL1A1	FUS		Responsive	PDGFRB-COL1A1 fusion	CRubio-Perez;DTamborero;RDientsmann	Imatinib	BCR-ABL inhibitor 1st gen&KIT inhibitor	Imatinib (BCR-ABL inhibitor 1st gen&KIT inhibitor)	Approved	FDA guidelines	PDGFRB		MDS;MDPS	EMA									
PDPK1:amp	CNA		Responsive	PDPK1 amplification	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PDPK1		BRCA	PMID:19602588									
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Early trials	PIK3CA		BRCA	ASCO 2015 (abstr 2500)									
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor (alone or in combination)]	PI3K pathway inhibitor (alone or in combination)s		Pre-clinical	PIK3CA		L;COREAD	PMID:23136191;PMID:23475782;PMID:22392911									
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CA		BLCA;HNC;L	ASCO 2015 (abstr 2516);ASCO 2015 (abstr 6049);ESMO 2013 (abstr P017)									
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Early trials	PIK3CA		BRCA;OV;CESC;ED	PMID:22271473;PMID:27672108;AACR 2013 (abstr LB-66);PMID:25231405;ASCO 2013 (abstr 2531);ASCO 2014 (abstr 5513)									
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PIK3CA inhibitor]	PIK3CA inhibitors		Early trials	PIK3CA		BRCA	AACR 2013 (abstr LB-64);ESMO 2013 (abstr P017)									
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PIK3CA inhibitor]	PIK3CA inhibitors		Case report	PIK3CA		ST	ASCO 2015 (abstr 2501)									
PIK3CA:.	MUT		Resistant	PIK3CA oncogenic mutation	RDientsmann	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)		Late trials	PIK3CA		COREAD	PMID:19223544;PMID:20619739									
PIK3CA:E545*	MUT		Resistant	PIK3CA (E545*)	DTamborero	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	PIK3CA		CM	PMC3936420		PIK3CA:p.E545*	ENST00000263967	PIK3CA	+	inside_[cds_in_exon_10]	CSQN=Nonsense;reference_codon=GAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr3:g.178936091_178936093delGAGinsTAA,chr3:g.178936091_178936093delGAGinsTGA;aliases=ENSP00000263967;source=Ensembl	c.1633G>T	chr3:g.178936091G>T
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CA		HNSC	PMID:26787751;PMID:26763254									
PIK3CA:.	MUT		Responsive	PIK3CA oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CA		G;THCA	PMID:19671762;PMID:21289267									
PIK3CA:amp	CNA		Resistant	PIK3CA amplification	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CA		BRCA	PMID:24366379									
PIK3CA:.;ERBB2:amp	MUT;CNA		Responsive	PIK3CA oncogenic mutation + ERBB2 amplification	RDientsmann	Everolimus;Trastuzumab;Chemotherapy	MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)		Late trials	PIK3CA;ERBB2		BRCA	PMID:27091708									
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3CB		HNSC	PMID:23619167									
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Pre-clinical	PIK3CB		HNSC	PMID:23619167									
PIK3CB:D1067Y	MUT		Responsive	PIK3CB (D1067Y)	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3CB		BRCA	PMID:26759240		PIK3CB:p.D1067Y	ENST00000477593	PIK3CB	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	c.3199G>T	chr3:g.138374245C>A
PIK3CB:D1067Y	MUT		Responsive	PIK3CB (D1067Y)	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Pre-clinical	PIK3CB		BRCA	PMID:26759240		PIK3CB:p.D1067Y	ENST00000477593	PIK3CB	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	c.3199G>T	chr3:g.138374245C>A
PIK3CB:D1067Y	MUT		Resistant	PIK3CB (D1067Y)	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3CB		BRCA	PMID:26759240		PIK3CB:p.D1067Y	ENST00000477593	PIK3CB	-	inside_[cds_in_exon_23]	CSQN=Missense;reference_codon=GAC;candidate_codons=TAT,TAC;candidate_mnv_variants=chr3:g.138374243_138374245delGTCinsATA;aliases=ENSP00000418143;source=Ensembl	c.3199G>T	chr3:g.138374245C>A
PIK3CB:.	MUT		Responsive	PIK3CB oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PIK3CB		HNSC	PMID:23619167									
PIK3R1:.	MUT		Responsive	PIK3R1 oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Case report	PIK3R1		ED	ASCO 2015 (abstr 11075)									
PIK3R1:.	MUT		Responsive	PIK3R1 oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Pre-clinical	PIK3R1		G	PMID:23166678									
PIK3R2:A171V,N561D	MUT		Responsive	PIK3R2 (A171V,N561D)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	PIK3R2		ED	PMID:21984976;PMID:19962665		PIK3R2:p.A171V	ENST00000222254	PIK3R2	+	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=GCT;candidate_codons=GTA,GTC,GTG,GTT;candidate_mnv_variants=chr19:g.18271909_18271910delCTinsTA,chr19:g.18271909_18271910delCTinsTC,chr19:g.18271909_18271910delCTinsTG;aliases=ENSP00000222254;source=Ensembl	c.512C>T	chr19:g.18271909C>T
PIK3R2:A171V,N561D	MUT		Responsive	PIK3R2 (A171V,N561D)	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	PIK3R2		ED	PMID:21984976;PMID:19962665		PIK3R2:p.N561D	ENST00000222254	PIK3R2	+	inside_[cds_in_exon_13]	CSQN=Missense;reference_codon=AAC;candidate_codons=GAC,GAT;candidate_mnv_variants=chr19:g.18278061_18278063delAACinsGAT;aliases=ENSP00000222254;source=Ensembl	c.1681A>G	chr19:g.18278061A>G
PLCG2:R665W,L845F	MUT		Resistant	PLCG2 (R665W,L845F)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)	Approved	Early trials	PLCG2		CLL	PMID:24869598		PLCG2:p.R665W	ENST00000359376	PLCG2	+	inside_[cds_in_exon_19]	CSQN=Missense;reference_codon=CGG;candidate_codons=TGG;aliases=ENSP00000352336;source=Ensembl	c.1993C>T	chr16:g.81946260C>T
PLCG2:R665W,L845F	MUT		Resistant	PLCG2 (R665W,L845F)	RDientsmann	Ibrutinib	BTK inhibitor	Ibrutinib (BTK inhibitor)	Approved	Early trials	PLCG2		CLL	PMID:24869598		PLCG2:p.L845F	ENST00000359376	PLCG2	+	inside_[cds_in_exon_24]	CSQN=Missense;reference_codon=TTA;candidate_codons=TTT,TTC;candidate_snv_variants=chr16:g.81962183A>C;aliases=ENSP00000352336;source=Ensembl	c.2535A>T	chr16:g.81962183A>T
PML__RARA	FUS		Responsive	PML-RARA fusion	DTamborero;CRubio-Perez	Tretinoin	Retinoid	Tretinoin (Retinoid)	Approved	FDA guidelines	PML		APML	FDA									
PML__RARA	FUS		Responsive	PML-RARA fusion	RDientsmann	Tretinoin;Arsenic Trioxide	Retinoid;Chemotherapy	Tretinoin + Arsenic Trioxide (Retinoid + Chemotherapy)	Approved	FDA guidelines	PML		AML	FDA									
PML__RARA	FUS		Responsive	PML-RARA fusion	ECampo	Volasertib	PLK1 inhibitor	Volasertib (PLK1 inhibitor)	Clinical Trials	Early trials	PML		AML	NCT02198482;NCT01662505	Indirect								
PRKCH:amp;ABL1__BCR	CNA;FUS		Responsive	PRKCH amplification + ABL1-BCR fusion	RDientsmann	Trametinib;Imatinib	MEK inhibitor;BCR-ABL inhibitor 1st gen&KIT inhibitor	Trametinib + Imatinib (MEK inhibitor + BCR-ABL inhibitor 1st gen&KIT inhibitor)		Pre-clinical	PRKCH;ABL1		CML	PMID:25186176									
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation	RDientsmann	Foretinib	MET inhibitor	Foretinib (MET inhibitor)		Pre-clinical	PTCH1		MB	PMID:25391241									
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors	Approved	Pre-clinical	PTCH1		MB	PMID:24651015 									
PTCH1:.	MUT		Responsive	PTCH1 oncogenic mutation	RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)	Approved	FDA guidelines	PTCH1		BCC;MB	PMID:19726763;PMID:19726761									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PIK3CB inhibitor]	PIK3CB inhibitors		Case report	PTEN		PRAD	ASCO 2014 (abstr 2514)									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PIK3CB inhibitor]	PIK3CB inhibitors		Case report	PTEN		PRAD	ASCO 2014 (abstr 2514)									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PTEN		TH;G;L;OV;BRCA;CANCER;ED	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PI3K pathway inhibitor]	PI3K pathway inhibitors		Pre-clinical	PTEN		TH;G;L;OV;BRCA;CANCER;ED	PMID:21289267;PMID:21325073;PMID:21191045;PMID:17804702;PMID:23136191;PMID:21632463;PMID:21673091;PMID:23287563;PMID:21998291;PMID:22662154;PMID:23085766;PMID:22932669									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;AR antagonist]	PI3K pathway inhibitor + AR antagonists		Pre-clinical	PTEN		PRAD	PMID:21575859									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PI3K pathway inhibitor;AR antagonist]	PI3K pathway inhibitor + AR antagonists		Pre-clinical	PTEN		PRAD	PMID:21575859									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	PTEN		OV	PMID:21632463									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PI3K pathway inhibitor;MEK inhibitor]	PI3K pathway inhibitor + MEK inhibitors		Pre-clinical	PTEN		OV	PMID:21632463									
PTEN:del	CNA		No Responsive	PTEN deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	PTEN		ED	PMID:21788564;PMID:23238879									
PTEN:.	MUT		No Responsive	PTEN oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	PTEN		ED	PMID:21788564;PMID:23238879									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Case report	PTEN		PA	PMID:22025163									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[AKT inhibitor]	AKT inhibitors		Case report	PTEN		PA	PMID:22025163									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	PTEN		PRAD	PMID:23582881									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Early trials	PTEN		PRAD	PMID:23582881									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	PTEN		CANCER	ASCO 2013 (abstr 2532)									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	Sirolimus	MTOR inhibitor	Sirolimus (MTOR inhibitor)		Early trials	PTEN		CANCER	ASCO 2013 (abstr 2532)									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	PTEN		CM	PMID:26645196									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PD1 Ab inhibitor]	PD1 Ab inhibitors		Early trials	PTEN		CM	PMID:26645196									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[ATM inhibitor]	ATM inhibitors		Pre-clinical	PTEN		BRCA	PMID:27397505									
PTEN:del	CNA		Resistant	PTEN deletion	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	PTEN		COREAD	PMID:21163703;PMID:19398573									
PTEN:.	MUT		Resistant	PTEN oncogenic mutation	RDientsmann	[]	[EGFR mAb inhibitor]	EGFR mAb inhibitors		Late trials	PTEN		COREAD	PMID:21163703;PMID:19398573									
PTEN:del	CNA		Responsive	PTEN deletion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	PTEN		ED	PMID:21468130;PMID:20944090									
PTEN:.	MUT		Responsive	PTEN oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Case report	PTEN		ED	PMID:21468130;PMID:20944090									
PTEN:.	BIA		Resistant	PTEN biallelic inactivation	DTamborero	BYL719	PIK3CA inhibitor	BYL719 (PIK3CA inhibitor)	Clinical Trials	Case report	PTEN		BRCA	PMID:25409150									
PTEN:.	BIA		Resistant	PTEN biallelic inactivation	DTamborero	Cetuximab	EGFR mAb inhibitor	Cetuximab (EGFR mAb inhibitor)	Approved	Case report	PTEN		COREAD	Caris molecular intelligence									
PTEN:.	BIA		Resistant	PTEN biallelic inactivation	DTamborero	Panitumumab	EGFR mAb inhibitor	Panitumumab (EGFR mAb inhibitor)		Case report	PTEN		COREAD	Caris molecular intelligence									
PTEN:del;BRAF:.	CNA;MUT		Resistant	PTEN deletion + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:21317224;PMID:21725359									
PTEN:.;BRAF:.	MUT;MUT		Resistant	PTEN oncogenic mutation + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:21317224;PMID:21725359									
PTEN:del;BRAF:.	CNA;MUT		Resistant	PTEN deletion + BRAF oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:23039341									
PTEN:.;BRAF:.	MUT;MUT		Resistant	PTEN oncogenic mutation + BRAF oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:23039341									
PTEN:del;BRAF:.	CNA;MUT		Resistant	PTEN deletion + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:21317224;PMID:21725359									
PTEN:.;BRAF:.	MUT;MUT		Resistant	PTEN oncogenic mutation + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	PTEN;BRAF		CM	PMID:21317224;PMID:21725359									
PTEN:.;ERBB2:amp	MUT;CNA		Responsive	PTEN oncogenic mutation + ERBB2 amplification	RDientsmann	Everolimus;Trastuzumab;Chemotherapy	MTOR inhibitor;ERBB2 mAb inhibitor;Chemotherapy	Everolimus + Trastuzumab + Chemotherapy (MTOR inhibitor + ERBB2 mAb inhibitor + Chemotherapy)		Late trials	PTEN;ERBB2		BRCA	PMID:27091708									
PTPRD:.	MUT		Responsive	PTPRD oncogenic mutation	RDientsmann	[]	[IGF1R inhibitor]	IGF1R inhibitors		Case report	PTPRD		S	PMID:23800680									
RAC1:P29S;BRAF:.	MUT;MUT		Resistant	RAC1 (P29S) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	RAC1;BRAF		CM	PMID:25056119									
RAC1:P29S;BRAF:.	MUT;MUT		Resistant	RAC1 (P29S) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Case report	RAC1;BRAF		CM	PMID:25056119									
RAD50:L1237F;ATM:del	MUT;CNA		Responsive	RAD50 (L1237F) + ATM deletion	RDientsmann	Irinotecan;CHK1/2 inhibitor	TOPO1 inhibitor;CHK1/2 inhibitor	Irinotecan + CHK1/2 inhibitor (TOPO1 inhibitor + CHK1/2 inhibitor)		Case report	RAD50;ATM		CANCER	PMID:24934408									
RAD51C:.	MUT		Responsive	RAD51C oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	RAD51C		OV	ASCO 2015 (abstr 5508)									
RAD51C:.	MUT		Responsive	RAD51C oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Early trials	RAD51C		OV	ASCO 2015 (abstr 5508)									
RAF1__.	FUS	Cell line	Responsive	RAF1 fusion	ARodriguez-Vida	[]	[Pan-RAF inhibitor]	Pan-RAF inhibitors	Pre-clinical	Pre-clinical	RAF1		PRAD	PMID:20526349	Direct								
RAF1__.	FUS	Cell line	Responsive	RAF1 fusion	ARodriguez-Vida	U0126	MEK inhibitor	U0126 (MEK inhibitor)	Approved	Pre-clinical	RAF1		PRAD	PMID:20526349	Indirect								
RAF1:over	EXPR	Cell line	Responsive	RAF1 overexpression	CdeTorres	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	RAF1		OS	PMID:24375110									
RAF1__.	FUS		Responsive	RAF1 fusion	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Pre-clinical	RAF1		PRAD	PMID:20526349									
RAF1:S257P,G361A,P261P;BRAF:.	MUT;MUT		Resistant	RAF1 (S257P,G361A,P261P) + BRAF oncogenic mutation	RDientsmann	[]	[BRAF inhibitor]	BRAF inhibitors		Pre-clinical	RAF1;BRAF		CM	PMID:23737487									
RB1:.	MUT		Responsive	RB1 oncogenic mutation	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	RB1		RB	PMID:18483379									
RB1:del	CNA		Responsive	RB1 deletion	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	RB1		RB	PMID:18483379									
RB1:over	EXPR	Xenograft	Responsive	RB1 overexpression	ARodriguez-Vida	PD-0332991	CDK4/6 inhibitor	PD-0332991 (CDK4/6 inhibitor)	Pre-clinical	Pre-clinical	RB1		PRAD	PMID:23708653	Indirect								
RB1:.	MUT		Responsive	RB1 oncogenic mutation	RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	RB1		RB	PMID:17080083;PMID:21515735									
RB1:del	CNA		Responsive	RB1 deletion	RDientsmann	[]	[MDM2/MDMX inhibitor]	MDM2/MDMX inhibitors		Pre-clinical	RB1		RB	PMID:17080083;PMID:21515735									
RB1:.	MUT		Responsive	RB1 oncogenic mutation	ARodriguez-Vida;RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	RB1	BLCA	BLCA	PMID:26238431	Indirect								
RB1:del	CNA		Responsive	RB1 deletion	ARodriguez-Vida;RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	Early trials	RB1	BLCA	BLCA	PMID:26238431	Indirect								
RET__.	FUS		Responsive	RET fusion	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		LUAD	PMID:22327624;PMID:22327622									
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	PMID:23056499									
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	PMID:23056499		RET:p.C634W	ENST00000355710	RET	+	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	c.1902C>G	chr10:g.43609950C>G
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	[]	[RET inhibitor]	RET inhibitors		Pre-clinical	RET		TH	PMID:23056499		RET:p.M918T	ENST00000355710	RET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	c.2753T>C	chr10:g.43617416T>C
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		TH	PMID:21470995		RET:p.C634W	ENST00000355710	RET	+	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	c.1902C>G	chr10:g.43609950C>G
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		TH	PMID:21470995		RET:p.M918T	ENST00000355710	RET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	c.2753T>C	chr10:g.43617416T>C
RET__.	FUS		Responsive	RET fusion	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Early trials,Case report	RET		LUAD	PMID:23533264;PMID:23584301;PMID:25366691;ASCO 2015 (abstr 8007);ENA 2015 (abstract LB-C17)									
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		TH	PMID:21470995		RET:p.C634W	ENST00000355710	RET	+	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	c.1902C>G	chr10:g.43609950C>G
RET:C634W,M918T	MUT		Responsive	RET (C634W,M918T)	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		TH	PMID:21470995		RET:p.M918T	ENST00000355710	RET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	c.2753T>C	chr10:g.43617416T>C
RET__.	FUS		Responsive	RET fusion	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Early trials,Case report	RET		LUAD	PMID:23533264;PMID:23584301;PMID:25366691;ASCO 2015 (abstr 8007);ENA 2015 (abstract LB-C17)									
RET__.	FUS		Responsive	RET fusion	RDientsmann	Nintedanib	Pan-TK inhibitor	Nintedanib (Pan-TK inhibitor)		Case report	RET		LUAD	PMID:26787234									
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	RET		THCA	PMID:21470995									
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	Sunitinib	Pan-TK inhibitor	Sunitinib (Pan-TK inhibitor)		Pre-clinical	RET		THCA	PMID:21470995									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146									
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146		RET:p.C634W	ENST00000355710	RET	+	inside_[cds_in_exon_11]	CSQN=Missense;reference_codon=TGC;candidate_codons=TGG;aliases=ENSP00000347942;source=Ensembl	c.1902C>G	chr10:g.43609950C>G
RET:.618.,.620.,.634.,.768.,.791.,.891.,.918.,C634W,M918T	MUT		Responsive	RET (618,620,634,768,791,891,918,C634W,M918T)	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)	Approved	FDA guidelines	RET		THCA	PMID:20065189;PMID:22025146		RET:p.M918T	ENST00000355710	RET	+	inside_[cds_in_exon_16]	CSQN=Missense;reference_codon=ATG;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr10:g.43617416_43617417delTGinsCA,chr10:g.43617416_43617417delTGinsCT,chr10:g.43617416_43617417delTGinsCC;aliases=ENSP00000347942;source=Ensembl	c.2753T>C	chr10:g.43617416T>C
RET__TPCN1	FUS		Responsive	RET-TPCN1 fusion	RDientsmann	Vandetanib	Pan-TK inhibitor	Vandetanib (Pan-TK inhibitor)		Pre-clinical	RET		THCA	PMID:21470995									
RICTOR:amp	CNA		Responsive	RICTOR amplification	RDientsmann	[]	[MTORC1/2 inhibitor]	MTORC1/2 inhibitors		Case report	RICTOR		L	PMID:26370156									
RNF43:.	MUT		Responsive	RNF43 oncogenic mutation	RDientsmann	[]	[Porcupine inhibitor]	Porcupine inhibitors		Case report	RNF43		COREAD	ENA 2015 (abstr C45)									
ROS1__.	FUS		Responsive	ROS1 fusion	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	ROS1		LUAD	PMID:23533265									
ROS1:G2032R	MUT		Responsive	ROS1 (G2032R)	RDientsmann	Cabozantinib	Pan-kinase inhibitor	Cabozantinib (Pan-kinase inhibitor)		Pre-clinical	ROS1		LUAD	PMID:25351743		ROS1:p.G2032R	ENST00000368508	ROS1	-	inside_[cds_in_exon_38]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr6:g.117638347C>G;candidate_mnv_variants=chr6:g.117638345_117638347delTCCinsCCT,chr6:g.117638345_117638347delTCCinsGCG,chr6:g.117638345_117638347delTCCinsCCG,chr6:g.117638345_117638347delTCCinsACG;aliases=ENSP00000357494;source=Ensembl	c.6094G>A	chr6:g.117638347C>T
ROS1__.	FUS		Responsive	ROS1 fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Case report	ROS1		IM	PMID:24875859									
ROS1__.	FUS		Responsive	ROS1 fusion	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)		Early trials	ROS1		LUAD	PMID:25264305									
ROS1__.	FUS		Responsive	ROS1 fusion	CRubio-Perez;EArriola	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Clinical trials	FDA guidelines	ROS1		NSCLC	FDA									
ROS1:G2032R	MUT		Resistant	ROS1 (G2032R)	RDientsmann	Crizotinib	ALK inhibitor	Crizotinib (ALK inhibitor)	Approved	Case report	ROS1		LUAD	PMID:23724914;PMID:25688157		ROS1:p.G2032R	ENST00000368508	ROS1	-	inside_[cds_in_exon_38]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr6:g.117638347C>G;candidate_mnv_variants=chr6:g.117638345_117638347delTCCinsCCT,chr6:g.117638345_117638347delTCCinsGCG,chr6:g.117638345_117638347delTCCinsCCG,chr6:g.117638345_117638347delTCCinsACG;aliases=ENSP00000357494;source=Ensembl	c.6094G>A	chr6:g.117638347C>T
SERPINB3:.	MUT		Responsive	SERPINB3 oncogenic mutation	RDientsmann	[]	[CTLA4 inhibitor]	CTLA4 inhibitors		Early trials	SERPINB3		CM	PMID:27668655									
SETD2:del	CNA		Responsive	SETD2 deletion	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	SETD2		CANCER	ENA 2014 (abstr 211)									
SETD2:.	MUT		Responsive	SETD2 oncogenic mutation	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	SETD2		CANCER	ENA 2014 (abstr 211)									
SF3B1:K700E,K666N	MUT		Responsive	SF3B1 (K700E,K666N)	RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SF3B1		CANCER	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858		SF3B1:p.K700E	ENST00000335508	SF3B1	-	inside_[cds_in_exon_15]	CSQN=Missense;reference_codon=AAA;candidate_codons=GAG,GAA;candidate_mnv_variants=chr2:g.198266832_198266834delTTTinsCTC;aliases=ENSP00000335321;source=Ensembl	c.2098A>G	chr2:g.198266834T>C
SF3B1:K700E,K666N	MUT		Responsive	SF3B1 (K700E,K666N)	RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SF3B1		CANCER	ENA 2014 (abstr 456);ENA 2014 (abstr 575);PMID:25424858		SF3B1:p.K666N	ENST00000335508	SF3B1	-	inside_[cds_in_exon_14]	CSQN=Missense;reference_codon=AAG;candidate_codons=AAC,AAT;candidate_snv_variants=chr2:g.198267359C>A;aliases=ENSP00000335321;source=Ensembl	c.1998G>C	chr2:g.198267359C>G
SH2B3:del	CNA		Responsive	SH2B3 deletion	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	SH2B3		MDPS	PMID:20404132									
SH2B3:.	MUT		Responsive	SH2B3 oncogenic mutation	RDientsmann	[]	[JAK inhibitor]	JAK inhibitors		Pre-clinical	SH2B3		MDPS	PMID:20404132									
SLC29A1:.	MUT		Resistant	SLC29A1 oncogenic mutation	ARodriguez-Vida	Gemcitabine	Chemotherapy	Gemcitabine (Chemotherapy)		Pre-clinical	SLC29A1	BLCA	BLCA	PMID:21166756									
SMARCA1:.	MUT		Responsive	SMARCA1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Pre-clinical	SMARCA1		CANCER	PMID:26552009									
SMARCA4:del	CNA		Responsive	SMARCA4 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCA4		OV	ESMO 2015 (abstract 302)									
SMARCA4:.	MUT		Responsive	SMARCA4 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCA4		OV	ESMO 2015 (abstract 302)									
SMARCB1:del	CNA		Responsive	SMARCB1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCB1		MRT	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)									
SMARCB1:.	MUT		Responsive	SMARCB1 oncogenic mutation	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors		Case report	SMARCB1		MRT	ENA 2014 (abstr 6LBA);ESMO 2015 (abstract 302)									
SMARCB1:.	MUT		Responsive	SMARCB1 oncogenic mutation	RDientsmann	[]	[HDAC inhibitor]	HDAC inhibitors		Pre-clinical	SMARCB1		MRT	PMID:26920892									
SMARCB1:del	CNA		Responsive	SMARCB1 deletion	RDientsmann	[]	[EZH2 inhibitor]	EZH2 inhibitors	Clinical Trials	Early trials	SMARCB1		MRT	ESMO 2015 (abstract 302)									
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		SMO:p.D473H	ENST00000249373	SMO	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr7:g.128849189_128849191delGACinsCAT;aliases=ENSP00000249373;source=Ensembl	c.1417G>C	chr7:g.128849189G>C
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		SMO:p.D473G	ENST00000249373	SMO	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAC;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr7:g.128849190_128849191delACinsGT,chr7:g.128849190_128849191delACinsGG,chr7:g.128849190_128849191delACinsGA;aliases=ENSP00000249373;source=Ensembl	c.1418A>G	chr7:g.128849190A>G
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		SMO:p.W535L	ENST00000249373	SMO	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=TGG;candidate_codons=CTT,CTG,CTA,CTC,TTA,TTG;candidate_mnv_variants=chr7:g.128850340_128850341delTGinsCT,chr7:g.128850341_128850342delGGinsTA,chr7:g.128850340_128850342delTGGinsCTT,chr7:g.128850340_128850342delTGGinsCTA,chr7:g.128850340_128850342delTGGinsCTC;aliases=ENSP00000249373;source=Ensembl	c.1604G>T	chr7:g.128850341G>T
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		SMO:p.L412F	ENST00000249373	SMO	+	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=CTC;candidate_codons=TTT,TTC;candidate_mnv_variants=chr7:g.128846398_128846400delCTCinsTTT;aliases=ENSP00000249373;source=Ensembl	c.1234C>T	chr7:g.128846398C>T
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		SMO:p.W281C	ENST00000249373	SMO	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=TGG;candidate_codons=TGT,TGC;candidate_snv_variants=chr7:g.128845546G>C;aliases=ENSP00000249373;source=Ensembl	c.843G>T	chr7:g.128845546G>T
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		SMO:p.Q477E	ENST00000249373	SMO	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=CAG;candidate_codons=GAG,GAA;candidate_mnv_variants=chr7:g.128849201_128849203delCAGinsGAA;aliases=ENSP00000249373;source=Ensembl	c.1429C>G	chr7:g.128849201C>G
SMO:D473H,D473G,W535L,L412F,W281C,Q477E,G497W	MUT		Resistant	SMO (D473H,D473G,W535L,L412F,W281C,Q477E,G497W)	DTamborero;RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		BCC	PMID:25759020;PMID:25306392		SMO:p.G497W	ENST00000249373	SMO	+	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=GGG;candidate_codons=TGG;aliases=ENSP00000249373;source=Ensembl	c.1489G>T	chr7:g.128850226G>T
SMO:L225R,N223D,S391N,D338N,D473H,G457S,E518.	MUT		Resistant	SMO (L225R,N223D,S391N,D338N,D473H,G457S,E518)	DTamborero;RDientsmann	[]	[SMO inhibitor]	SMO inhibitors		Pre-clinical	SMO		MB	PMID:24951114		SMO:p.D473H	ENST00000249373	SMO	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr7:g.128849189_128849191delGACinsCAT;aliases=ENSP00000249373;source=Ensembl	c.1417G>C	chr7:g.128849189G>C
SMO:D473H	MUT		Resistant	SMO (D473H)	RDientsmann	Vismodegib	SHH inhibitor	Vismodegib (SHH inhibitor)		Case report	SMO		MB	PMID:19726788;PMID:25759019		SMO:p.D473H	ENST00000249373	SMO	+	inside_[cds_in_exon_8]	CSQN=Missense;reference_codon=GAC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr7:g.128849189_128849191delGACinsCAT;aliases=ENSP00000249373;source=Ensembl	c.1417G>C	chr7:g.128849189G>C
SRSF2:.	MUT		Responsive	SRSF2 oncogenic mutation	RDientsmann	[]	[Spliceosome inhibitor]	Spliceosome inhibitors		Pre-clinical	SRSF2		AML	PMID:27135740									
STAG2:.	MUT		Responsive	STAG2 oncogenic mutation	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	STAG2		G	PMID:24356817									
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	[]	[SRC inhibitor;PI3K/MEK inhibitor]	SRC inhibitor + PI3K/MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:20541700									
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	[]	[SRC inhibitor;PI3K/MEK inhibitor]	SRC inhibitor + PI3K/MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:20541700									
STK11:D194E	MUT		Responsive	STK11 (D194E)	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	STK11		PA	PMID:21189378		STK11:p.D194E	ENST00000326873	STK11	+	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GAC;candidate_codons=GAG,GAA;candidate_snv_variants=chr19:g.1220489C>A;aliases=ENSP00000324856;source=Ensembl	c.582C>G	chr19:g.1220489C>G
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	Phenformin	Anti-diabetic	Phenformin (Anti-diabetic)		Pre-clinical	STK11		LUAD	PMID:23352126									
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	Phenformin	Anti-diabetic	Phenformin (Anti-diabetic)		Pre-clinical	STK11		LUAD	PMID:23352126									
STK11:.	MUT		Resistant	STK11 oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	STK11		L	PMID:23129625;PMID:24045185									
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:19165201									
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	[]	[MEK inhibitor]	MEK inhibitors		Pre-clinical	STK11		LUAD	PMID:19165201									
STK11:del	CNA		Responsive	STK11 deletion	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	STK11		CANCER	PMID:19541609									
STK11:.	MUT		Responsive	STK11 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Pre-clinical	STK11		CANCER	PMID:19541609									
STK11:del;KRAS:.	CNA;MUT		Resistant	STK11 deletion + KRAS oncogenic mutation	RDientsmann	MEK inhibitor;Docetaxel	MEK inhibitor;Chemotherapy	MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)		Pre-clinical	STK11;KRAS		LUAD	PMID:22425996									
STK11:.;KRAS:.	MUT;MUT		Resistant	STK11 oncogenic mutation + KRAS oncogenic mutation	RDientsmann	MEK inhibitor;Docetaxel	MEK inhibitor;Chemotherapy	MEK inhibitor + Docetaxel (MEK inhibitor + Chemotherapy)		Pre-clinical	STK11;KRAS		LUAD	PMID:22425996									
SUZ12:del	CNA		Responsive	SUZ12 deletion	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	SUZ12		CANCER	PMID:25119042									
SUZ12:.	MUT		Responsive	SUZ12 oncogenic mutation	RDientsmann	[]	[BET inhibitor]	BET inhibitors		Pre-clinical	SUZ12		CANCER	PMID:25119042									
SYK:amp	CNA		Responsive	SYK amplification	RDientsmann	[]	[SYK inhibitor]	SYK inhibitors		Pre-clinical	SYK		MCL;CLL	PMID:16409295;PMID:19549911									
TMPRSS2__.	FUS		Responsive	TMPRSS2 fusion	RDientsmann	[]	[DNA-PKc inhibitor]	DNA-PKc inhibitors		Pre-clinical	TMPRSS2		PRAD	PMID:21575865									
TMPRSS2__.	FUS		Responsive	TMPRSS2 fusion	RDientsmann	[]	[PARP inhibitor]	PARP inhibitors		Pre-clinical	TMPRSS2		PRAD	PMID:21575865									
TOP2A:amp	CNA		Responsive	TOP2A amplification	RDientsmann	Anthracyclines	Chemotherapy	Anthracyclines (Chemotherapy)		Late trials	TOP2A		BRCA	PMID:22864769									
TP53:.	MUT		Resistant	TP53 oncogenic mutation	RDientsmann	[]	[MDM2 inhibitor]	MDM2 inhibitors		Early trials	TP53		LIP	PMID:23084521;ASCO 2015 (abstr 10564)									
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		TP53:p.R248Q	ENST00000269305	TP53	-	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr17:g.7577537_7577538delCCinsTT;aliases=ENSP00000269305;source=Ensembl	c.743G>A	chr17:g.7577538C>T
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		TP53:p.R175H	ENST00000269305	TP53	-	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CGC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.7578405_7578406delGCinsAT;aliases=ENSP00000269305;source=Ensembl	c.524G>A	chr17:g.7578406C>T
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	[]	[WEE1 inhibitor]	WEE1 inhibitors		Pre-clinical	TP53		HNC	PMID:25125259									
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		TP53:p.R248Q	ENST00000269305	TP53	-	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=CGG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr17:g.7577537_7577538delCCinsTT;aliases=ENSP00000269305;source=Ensembl	c.743G>A	chr17:g.7577538C>T
TP53:R248Q,R175H	MUT		Responsive	TP53 (R248Q,R175H)	RDientsmann	[]	[HSP90 inhibitor]	HSP90 inhibitors		Pre-clinical	TP53		CANCER	PMID:26009011		TP53:p.R175H	ENST00000269305	TP53	-	inside_[cds_in_exon_5]	CSQN=Missense;reference_codon=CGC;candidate_codons=CAT,CAC;candidate_mnv_variants=chr17:g.7578405_7578406delGCinsAT;aliases=ENSP00000269305;source=Ensembl	c.524G>A	chr17:g.7578406C>T
TP53:.	MUT		Resistant	TP53 oncogenic mutation	RDientsmann	Abemaciclib	CDK4/CDK6 inhibitor	Abemaciclib (CDK4/CDK6 inhibitor)		Early trials	TP53		BRCA	PMID:27217383									
TP53:del	CNA		Responsive	TP53 deletion	ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	TP53		BCL	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Indirect								
TP53:.	MUT		Responsive	TP53 oncogenic mutation	ECampo	AZD6738	ATR inhibitor	AZD6738 (ATR inhibitor)	Clinical Trials	Early trials	TP53		BCL	NCT01955668;https://ash.confex.com/ash/2014/webprogram/Paper71027.html	Indirect								
TP53:.	MUT		Resistant	TP53 oncogenic mutation	RDientsmann	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)		Early trials	TP53		FGCT;MGCT	PMID:27646943									
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Decitabine	Chemotherapy	Decitabine (Chemotherapy)		Early trials	TP53		AML;MDPS	PMID:27959731									
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Doxorubicin	Anthracycline antitumor antibiotic	Doxorubicin (Anthracycline antitumor antibiotic)		Pre-clinical	TP53		BLCA	PMID:27397505									
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Gemcitabine	Chemotherapy	Gemcitabine (Chemotherapy)		Pre-clinical	TP53		BLCA	PMID:27397505									
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Mitomycin C	Chemotherapy	Mitomycin C (Chemotherapy)		Pre-clinical	TP53		BLCA	PMID:27397505									
TP53:.	MUT		Responsive	TP53 oncogenic mutation	KKarube;RDientsmann	MK-1775	WEE1 inhibitor	MK-1775 (WEE1 inhibitor)	Clinical Trials	Early trials	TP53		OV	NCT01357161;ASCO2015 (abstr 2507)	Indirect								
TP53:.	MUT		Responsive	TP53 oncogenic mutation	RDientsmann	Pramlintide	Amylin analogue	Pramlintide (Amylin analogue)		Pre-clinical	TP53		THYM	PMID:25409149									
TP53:del	CNA		Responsive	TP53 deletion	RDientsmann	Pramlintide	Amylin analogue	Pramlintide (Amylin analogue)		Pre-clinical	TP53		THYM	PMID:25409149									
TPMT:.	BIA		Increased Toxicity (Ototoxicity)	TPMT biallelic inactivation	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA									
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A80P	ENST00000309983	TPMT	-	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	c.238G>C	chr6:g.18143955C>G
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.Y240C	ENST00000309983	TPMT	-	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	c.719A>G	chr6:g.18130918T>C
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A154T	ENST00000309983	TPMT	-	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	c.460G>A	chr6:g.18139228C>T
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Ototoxicity)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Cisplatin	Chemotherapy	Cisplatin (Chemotherapy)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A167G	ENST00000309983	TPMT	-	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	c.500C>G	chr6:g.18134115G>C
TPMT:.	BIA		Increased Toxicity (Myelosupression)	TPMT biallelic inactivation	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA									
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A80P	ENST00000309983	TPMT	-	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	c.238G>C	chr6:g.18143955C>G
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.Y240C	ENST00000309983	TPMT	-	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	c.719A>G	chr6:g.18130918T>C
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A154T	ENST00000309983	TPMT	-	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	c.460G>A	chr6:g.18139228C>T
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Mercaptopurine	Purine analog	Mercaptopurine (Purine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A167G	ENST00000309983	TPMT	-	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	c.500C>G	chr6:g.18134115G>C
TPMT:.	BIA		Increased Toxicity (Myelosupression)	TPMT biallelic inactivation	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA									
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A80P	ENST00000309983	TPMT	-	inside_[cds_in_exon_4]	CSQN=Missense;reference_codon=GCA;candidate_codons=CCT,CCG,CCA,CCC;candidate_mnv_variants=chr6:g.18143953_18143955delTGCinsAGG,chr6:g.18143953_18143955delTGCinsCGG,chr6:g.18143953_18143955delTGCinsGGG;aliases=ENSP00000312304;source=Ensembl	c.238G>C	chr6:g.18143955C>G
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.Y240C	ENST00000309983	TPMT	-	inside_[cds_in_exon_9]	CSQN=Missense;reference_codon=TAT;candidate_codons=TGT,TGC;candidate_mnv_variants=chr6:g.18130917_18130918delATinsGC;aliases=ENSP00000312304;source=Ensembl	c.719A>G	chr6:g.18130918T>C
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A154T	ENST00000309983	TPMT	-	inside_[cds_in_exon_6]	CSQN=Missense;reference_codon=GCA;candidate_codons=ACA,ACG,ACT,ACC;candidate_mnv_variants=chr6:g.18139226_18139228delTGCinsCGT,chr6:g.18139226_18139228delTGCinsAGT,chr6:g.18139226_18139228delTGCinsGGT;aliases=ENSP00000312304;source=Ensembl	c.460G>A	chr6:g.18139228C>T
TPMT:A80P,Y240C,A154T,A167G	MUT		Increased Toxicity (Myelosupression)	TPMT (A80P,Y240C,A154T,A167G)	DTamborero;CRubio-Perez	Thioguanine	Guanine analog	Thioguanine (Guanine analog)	Approved	FDA guidelines	TPMT		CANCER	FDA		TPMT:p.A167G	ENST00000309983	TPMT	-	inside_[cds_in_exon_7]	CSQN=Missense;reference_codon=GCA;candidate_codons=GGT,GGG,GGA,GGC;candidate_mnv_variants=chr6:g.18134114_18134115delTGinsAC,chr6:g.18134114_18134115delTGinsCC,chr6:g.18134114_18134115delTGinsGC;aliases=ENSP00000312304;source=Ensembl	c.500C>G	chr6:g.18134115G>C
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	TSC1		RA	PMID:23312829;PMID:21525172;PMID:20048174									
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Early trials	TSC1		BLCA	PMID:22923433	Indirect								
TSC1:del	CNA		Responsive	TSC1 deletion	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	TSC1		R	PMID:24622468;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)									
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)		Case report	TSC1		R	PMID:24622468;PMID:26859683;ASCO 2015 (abstr 11010);ASCO 2015 (abstr 4519)									
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	DTamborero	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC1		GCA	FDA									
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Case report	TSC1		S;ST	PMID:26859683									
TSC1:.	MUT		Responsive	TSC1 oncogenic mutation	ARodriguez-Vida	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC1	RA	RA	FDA									
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	RDientsmann	[]	[MTOR inhibitor]	MTOR inhibitors		Early trials	TSC2		RA	PMID:23312829;PMID:21525172;PMID:20048174									
TSC2:Q1178*	MUT		Responsive	TSC2 (Q1178*)	CRubio-Perez;RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Case report	TSC2		THCA	PMID:25295501	Indirect	TSC2:p.Q1178*	ENST00000219476	TSC2	+	inside_[cds_in_exon_30]	CSQN=Nonsense;reference_codon=CAG;candidate_codons=TAA,TAG,TGA;candidate_mnv_variants=chr16:g.2130300_2130302delCAGinsTAA,chr16:g.2130300_2130302delCAGinsTGA;aliases=ENSP00000219476;source=Ensembl	c.3532C>T	chr16:g.2130300C>T
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	RDientsmann	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	Early trials	TSC2		BLCA	PMID:22923433	Indirect								
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	ARodriguez-Vida;DTamborero	Everolimus	MTOR inhibitor	Everolimus (MTOR inhibitor)	Approved	FDA guidelines	TSC2	RA	RA;GCA	FDA									
TSC2:del	CNA		Responsive	TSC2 deletion	RDientsmann	[]	[SRC inhibitor]	SRC inhibitors		Pre-clinical	TSC2		LAM	PMID:24691995									
TSC2:.	MUT		Responsive	TSC2 oncogenic mutation	RDientsmann	[]	[SRC inhibitor]	SRC inhibitors		Pre-clinical	TSC2		LAM	PMID:24691995									
TUBB3:over	EXPR		Resistant	TUBB3 overexpression	ARodriguez-Vida	Paclitaxel	Taxane	Paclitaxel (Taxane)		Pre-clinical	TUBB3	BLCA	BLCA	PMID:23184177									
U2AF1:.	MUT		Responsive	U2AF1 oncogenic mutation	RDientsmann	[]	[FLT3 inhibitor]	FLT3 inhibitors		Pre-clinical	U2AF1		CANCER	PMID:27397505									
UGT1A1:.	BIA		Increased Toxicity	UGT1A1 biallelic inactivation	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA									
UGT1A1:G71R,P229Q	MUT		Increased Toxicity	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		UGT1A1:p.G71R	ENST00000305208	UGT1A1	+	inside_[cds_in_exon_1]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.234669144G>C;candidate_mnv_variants=chr2:g.234669144_234669146delGGAinsAGG,chr2:g.234669144_234669146delGGAinsCGC,chr2:g.234669144_234669146delGGAinsCGG,chr2:g.234669144_234669146delGGAinsCGT;aliases=ENSP00000304845;source=Ensembl	c.211G>A	chr2:g.234669144G>A
UGT1A1:G71R,P229Q	MUT		Increased Toxicity	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Irinotecan	TOPO1 inhibitor	Irinotecan (TOPO1 inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		UGT1A1:p.P229Q	ENST00000305208	UGT1A1	+	inside_[cds_in_exon_1]	CSQN=Missense;reference_codon=CCG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.234669619_234669620delCGinsAA;aliases=ENSP00000304845;source=Ensembl	c.686C>A	chr2:g.234669619C>A
UGT1A1:.	BIA		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 biallelic inactivation	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	FDA									
UGT1A1:G71R,P229Q	MUT		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		UGT1A1:p.G71R	ENST00000305208	UGT1A1	+	inside_[cds_in_exon_1]	CSQN=Missense;reference_codon=GGA;candidate_codons=AGG,AGA,CGA,CGC,CGG,CGT;candidate_snv_variants=chr2:g.234669144G>C;candidate_mnv_variants=chr2:g.234669144_234669146delGGAinsAGG,chr2:g.234669144_234669146delGGAinsCGC,chr2:g.234669144_234669146delGGAinsCGG,chr2:g.234669144_234669146delGGAinsCGT;aliases=ENSP00000304845;source=Ensembl	c.211G>A	chr2:g.234669144G>A
UGT1A1:G71R,P229Q	MUT		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 (G71R,P229Q)	DTamborero;CRubio-Perez	Nilotinib	BCR-ABL inhibitor 2nd gen	Nilotinib (BCR-ABL inhibitor 2nd gen)	Approved	FDA guidelines	UGT1A1		CANCER	FDA		UGT1A1:p.P229Q	ENST00000305208	UGT1A1	+	inside_[cds_in_exon_1]	CSQN=Missense;reference_codon=CCG;candidate_codons=CAA,CAG;candidate_mnv_variants=chr2:g.234669619_234669620delCGinsAA;aliases=ENSP00000304845;source=Ensembl	c.686C>A	chr2:g.234669619C>A
UGT1A1:.	BIA		Increased Toxicity (Hyperbilirubinemia)	UGT1A1 biallelic inactivation	DTamborero;CRubio-Perez	Pazopanib	VEGFR inhibitor	Pazopanib (VEGFR inhibitor)	Approved	FDA guidelines	UGT1A1		CANCER	FDA									
VEGFA:amp	CNA		Responsive	VEGFA amplification	RDientsmann	Sorafenib	Pan-TK inhibitor	Sorafenib (Pan-TK inhibitor)		Early trials	VEGFA		HC	PMID:24687604									
VHL:.	MUT	Retrospective analysis	Responsive	VHL oncogenic mutation	ARodriguez-Vida	[Sorafenib,Sunitinib,Bevacizumab,Axitinib]	[VEGFR inhibitor]	VEGFR inhibitors (Sorafenib,Sunitinib,Bevacizumab,Axitinib,etc)	Approved	Pre-clinical	VHL		R	PMID:18635227	Indirect								
ZBTB16:under	EXPR		Resistant	ZBTB16 undexpression	ARodriguez-Vida	[]	[LHRH analogues or antagonist]	LHRH analogues or antagonists		Pre-clinical	ZBTB16	PR	PRAD	PMID:16637071									
ZNRF3:.	MUT		Responsive	ZNRF3 oncogenic mutation	RDientsmann	[]	[Porcupine inhibitor]	Porcupine inhibitors		Pre-clinical	ZNRF3		COREAD	PMID:26023187									
